{
  "studies": [
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00002938",
          "orgStudyIdInfo": {
            "id": "CALGB-9687"
          },
          "secondaryIdInfos": [
            {
              "id": "U10CA031946",
              "type": "NIH",
              "link": "https://reporter.nih.gov/quickSearch/U10CA031946"
            },
            {
              "id": "CALGB-9687"
            },
            {
              "id": "CDR0000065381",
              "type": "REGISTRY",
              "domain": "NCI Physician Data Query"
            }
          ],
          "organization": {
            "fullName": "Alliance for Clinical Trials in Oncology",
            "class": "OTHER"
          },
          "briefTitle": "Surgery in Treating Patients With Prostate Cancer",
          "officialTitle": "The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial"
        },
        "statusModule": {
          "statusVerifiedDate": "2016-07",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "1997-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2005-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2010-01",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "1999-11-01",
          "studyFirstSubmitQcDate": "2003-01-26",
          "studyFirstPostDateStruct": {
            "date": "2003-01-27",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2016-07-01",
          "lastUpdatePostDateStruct": {
            "date": "2016-07-06",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "Alliance for Clinical Trials in Oncology",
            "class": "OTHER"
          },
          "collaborators": [
            {
              "name": "National Cancer Institute (NCI)",
              "class": "NIH"
            }
          ]
        },
        "oversightModule": {
          "oversightHasDmc": false
        },
        "descriptionModule": {
          "briefSummary": "RATIONALE: Prostatectomy may be an effective treatment for prostate cancer that has not responded to radiation therapy.\n\nPURPOSE: This phase II trial is studying how well prostatectomy works in treating patients with recurrent or persistent prostate cancer that has not responded to radiation therapy.",
          "detailedDescription": "OBJECTIVES:\n\n* Determine the characteristics of failure-free survival, disease-free survival, overall survival, surgical morbidity and mortality, and quality of life of patients treated with salvage prostatectomy for the recurrence of persistent disease after treatment with prior radiotherapy for localized prostate cancer.\n* Develop expertise in the use of salvage prostatectomy prior to a possible phase III trial of salvage prostatectomy in this population versus a control arm such as hormonal therapy or cryotherapy.\n* Determine the quality of life measures in these patients.\n* Determine the preliminary data on the quality of life of patients undergoing salvage radical prostatectomy and use the data to design a phase III study.\n* Determine the histologic and morphometric characterization of the carcinoma.\n\nOUTLINE: Patients undergo modified bilateral pelvic lymph node dissection.\n\nPatients with negative nodes undergo salvage prostatectomy via either retropubic or perineal approach. Patients with positive nodes may undergo radical prostatectomy at the discretion of the investigator.\n\nPostoperative hormonal therapy may be given at time of symptomatic disease progression or a newly positive bone scan, or for a consistently rising prostate-specific antigen. Adjuvant hormonal therapy is also allowed.\n\nQuality of life is assessed prior to surgery and at 3, 6, 12, 18, and 24 months after surgery.\n\nPatients are followed at least every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.\n\nPROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years."
        },
        "conditionsModule": {
          "conditions": [
            "Prostate Cancer"
          ],
          "keywords": [
            "recurrent prostate cancer"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 49,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Surgery",
              "type": "OTHER",
              "description": "Salvage prostatectomy",
              "interventionNames": [
                "Procedure: conventional surgery"
              ]
            }
          ],
          "interventions": [
            {
              "type": "PROCEDURE",
              "name": "conventional surgery",
              "description": "Salvage prostatectomy",
              "armGroupLabels": [
                "Surgery"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Survival characteristics",
              "timeFrame": "pre treatment; q 3 mon for 2 years, then q 6 mon for 2 yrs, then q year"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "QOL assessment",
              "description": "Quality of life questionnaire",
              "timeFrame": "pre treatment; 3, 6, 12, 18, and 24 mon post treatment"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically proven recurrent or persistent prostate cancer\n* Prostate-specific antigen (PSA) no greater than 20 ng/mL\n* Must have been previously treated with at least 60 cGy of external beam radiotherapy or brachytherapy for clinical stages T1-2NXM0 with PSA no greater than 30 ng/mL\n* No metastatic disease at time of biopsy\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 75 and under\n\nPerformance status:\n\n* CALGB (Zubrod) 0-1\n\nLife expectancy:\n\n* At least 5-10 years\n\nOther:\n\n* No other \"currently Temporarily closed\" malignancy except nonmelanoma skin cancer\n\n  * Patients are not considered to have a \"currently Temporarily closed\" malignancy if they have completed therapy and are considered to be at less than 30% risk of relapse\n\nPRIOR CONCURRENT THERAPY:\n\nEndocrine therapy:\n\n* At least 3 months since prior adjuvant hormonal therapy\n\nRadiotherapy:\n\n* See Disease Characteristics\n* At least 18 months since prior external beam or interstitial radiotherapy",
          "healthyVolunteers": false,
          "sex": "MALE",
          "maximumAge": "75 Years",
          "stdAges": [
            "CHILD",
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Gary D. Steinberg, MD",
              "affiliation": "University of Chicago",
              "role": "STUDY_CHAIR"
            }
          ],
          "locations": [
            {
              "facility": "Northeast Alabama Regional Medical Center",
              "city": "Anniston",
              "state": "Alabama",
              "zip": "36207",
              "country": "United States",
              "geoPoint": {
                "lat": 33.65983,
                "lon": -85.83163
              }
            },
            {
              "facility": "Rebecca and John Moores UCSD Cancer Center",
              "city": "La Jolla",
              "state": "California",
              "zip": "92093-0658",
              "country": "United States",
              "geoPoint": {
                "lat": 32.84727,
                "lon": -117.2742
              }
            },
            {
              "facility": "Naval Medical Center - San Diego",
              "city": "San Diego",
              "state": "California",
              "zip": "92134-3202",
              "country": "United States",
              "geoPoint": {
                "lat": 32.71533,
                "lon": -117.15726
              }
            },
            {
              "facility": "Veterans Affairs Medical Center - San Diego",
              "city": "San Diego",
              "state": "California",
              "zip": "92161",
              "country": "United States",
              "geoPoint": {
                "lat": 32.71533,
                "lon": -117.15726
              }
            },
            {
              "facility": "UCSF Comprehensive Cancer Center",
              "city": "San Francisco",
              "state": "California",
              "zip": "94115",
              "country": "United States",
              "geoPoint": {
                "lat": 37.77493,
                "lon": -122.41942
              }
            },
            {
              "facility": "CCOP - Christiana Care Health Services",
              "city": "Newark",
              "state": "Delaware",
              "zip": "19713",
              "country": "United States",
              "geoPoint": {
                "lat": 39.68372,
                "lon": -75.74966
              }
            },
            {
              "facility": "Walter Reed Army Medical Center",
              "city": "Washington",
              "state": "District of Columbia",
              "zip": "20307-5001",
              "country": "United States",
              "geoPoint": {
                "lat": 38.89511,
                "lon": -77.03637
              }
            },
            {
              "facility": "Veterans Affairs Medical Center - Washington, DC",
              "city": "Washington",
              "state": "District of Columbia",
              "zip": "20422",
              "country": "United States",
              "geoPoint": {
                "lat": 38.89511,
                "lon": -77.03637
              }
            },
            {
              "facility": "Broward General Medical Center",
              "city": "Fort Lauderdale",
              "state": "Florida",
              "zip": "33316",
              "country": "United States",
              "geoPoint": {
                "lat": 26.12231,
                "lon": -80.14338
              }
            },
            {
              "facility": "Memorial Cancer Institute at Memorial Regional Hospital",
              "city": "Hollywood",
              "state": "Florida",
              "zip": "33021",
              "country": "United States",
              "geoPoint": {
                "lat": 26.0112,
                "lon": -80.14949
              }
            },
            {
              "facility": "CCOP - Mount Sinai Medical Center",
              "city": "Miami Beach",
              "state": "Florida",
              "zip": "33140",
              "country": "United States",
              "geoPoint": {
                "lat": 25.79065,
                "lon": -80.13005
              }
            },
            {
              "facility": "University of Chicago Cancer Research Center",
              "city": "Chicago",
              "state": "Illinois",
              "zip": "60637-1470",
              "country": "United States",
              "geoPoint": {
                "lat": 41.85003,
                "lon": -87.65005
              }
            },
            {
              "facility": "Louis A. Weiss Memorial Hospital",
              "city": "Chicago",
              "state": "Illinois",
              "zip": "60640",
              "country": "United States",
              "geoPoint": {
                "lat": 41.85003,
                "lon": -87.65005
              }
            },
            {
              "facility": "CCOP - Illinois Oncology Research Association",
              "city": "Peoria",
              "state": "Illinois",
              "zip": "61615-7828",
              "country": "United States",
              "geoPoint": {
                "lat": 40.69365,
                "lon": -89.58899
              }
            },
            {
              "facility": "West Suburban Center for Cancer Care",
              "city": "River Forest",
              "state": "Illinois",
              "zip": "60305",
              "country": "United States",
              "geoPoint": {
                "lat": 41.89781,
                "lon": -87.81395
              }
            },
            {
              "facility": "Fort Wayne Medical Oncology and Hematology, Incorporated",
              "city": "Fort Wayne",
              "state": "Indiana",
              "zip": "46885-5099",
              "country": "United States",
              "geoPoint": {
                "lat": 41.1306,
                "lon": -85.12886
              }
            },
            {
              "facility": "Holden Comprehensive Cancer Center at University of Iowa",
              "city": "Iowa City",
              "state": "Iowa",
              "zip": "52242-1009",
              "country": "United States",
              "geoPoint": {
                "lat": 41.66113,
                "lon": -91.53017
              }
            },
            {
              "facility": "Baptist Hospital East - Louisville",
              "city": "Louisville",
              "state": "Kentucky",
              "zip": "40207",
              "country": "United States",
              "geoPoint": {
                "lat": 38.25424,
                "lon": -85.75941
              }
            },
            {
              "facility": "Greenebaum Cancer Center at University of Maryland Medical Center",
              "city": "Baltimore",
              "state": "Maryland",
              "zip": "21201",
              "country": "United States",
              "geoPoint": {
                "lat": 39.29038,
                "lon": -76.61219
              }
            },
            {
              "facility": "Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute",
              "city": "Boston",
              "state": "Massachusetts",
              "zip": "02115",
              "country": "United States",
              "geoPoint": {
                "lat": 42.35843,
                "lon": -71.05977
              }
            },
            {
              "facility": "UMASS Memorial Cancer Center - University Campus",
              "city": "Worcester",
              "state": "Massachusetts",
              "zip": "01655",
              "country": "United States",
              "geoPoint": {
                "lat": 42.26259,
                "lon": -71.80229
              }
            },
            {
              "facility": "Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph",
              "city": "Saint Joseph",
              "state": "Michigan",
              "zip": "49085",
              "country": "United States",
              "geoPoint": {
                "lat": 42.10976,
                "lon": -86.48002
              }
            },
            {
              "facility": "Ellis Fischel Cancer Center at University of Missouri - Columbia",
              "city": "Columbia",
              "state": "Missouri",
              "zip": "65203",
              "country": "United States",
              "geoPoint": {
                "lat": 38.95171,
                "lon": -92.33407
              }
            },
            {
              "facility": "CCOP - Kansas City",
              "city": "Kansas City",
              "state": "Missouri",
              "zip": "64131",
              "country": "United States",
              "geoPoint": {
                "lat": 39.09973,
                "lon": -94.57857
              }
            },
            {
              "facility": "Siteman Cancer Center at Barnes-Jewish Hospital",
              "city": "Saint Louis",
              "state": "Missouri",
              "zip": "63110",
              "country": "United States",
              "geoPoint": {
                "lat": 38.62727,
                "lon": -90.19789
              }
            },
            {
              "facility": "UNMC Eppley Cancer Center at the University of Nebraska Medical Center",
              "city": "Omaha",
              "state": "Nebraska",
              "zip": "68198-7680",
              "country": "United States",
              "geoPoint": {
                "lat": 41.25626,
                "lon": -95.94043
              }
            },
            {
              "facility": "CCOP - Southern Nevada Cancer Research Foundation",
              "city": "Las Vegas",
              "state": "Nevada",
              "zip": "89106",
              "country": "United States",
              "geoPoint": {
                "lat": 36.17497,
                "lon": -115.13722
              }
            },
            {
              "facility": "Veterans Affairs Medical Center - Las Vegas",
              "city": "Las Vegas",
              "state": "Nevada",
              "zip": "89106",
              "country": "United States",
              "geoPoint": {
                "lat": 36.17497,
                "lon": -115.13722
              }
            },
            {
              "facility": "New Hampshire Oncology-Hematology, PA - Hooksett",
              "city": "Hooksett",
              "state": "New Hampshire",
              "zip": "03106",
              "country": "United States",
              "geoPoint": {
                "lat": 43.09675,
                "lon": -71.46507
              }
            },
            {
              "facility": "Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center",
              "city": "Lebanon",
              "state": "New Hampshire",
              "zip": "03756-0002",
              "country": "United States",
              "geoPoint": {
                "lat": 43.64229,
                "lon": -72.25176
              }
            },
            {
              "facility": "Cancer Institute of New Jersey at the Cooper University Hospital",
              "city": "Camden",
              "state": "New Jersey",
              "zip": "08103",
              "country": "United States",
              "geoPoint": {
                "lat": 39.92595,
                "lon": -75.11962
              }
            },
            {
              "facility": "St. Joseph's Hospital and Medical Center",
              "city": "Paterson",
              "state": "New Jersey",
              "zip": "07503",
              "country": "United States",
              "geoPoint": {
                "lat": 40.91677,
                "lon": -74.17181
              }
            },
            {
              "facility": "Roswell Park Cancer Institute",
              "city": "Buffalo",
              "state": "New York",
              "zip": "14263-0001",
              "country": "United States",
              "geoPoint": {
                "lat": 42.88645,
                "lon": -78.87837
              }
            },
            {
              "facility": "CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.",
              "city": "East Syracuse",
              "state": "New York",
              "zip": "13057",
              "country": "United States",
              "geoPoint": {
                "lat": 43.06534,
                "lon": -76.07853
              }
            },
            {
              "facility": "Elmhurst Hospital Center",
              "city": "Elmhurst",
              "state": "New York",
              "zip": "11373",
              "country": "United States",
              "geoPoint": {
                "lat": 40.73649,
                "lon": -73.87791
              }
            },
            {
              "facility": "Queens Cancer Center of Queens Hospital",
              "city": "Jamaica",
              "state": "New York",
              "zip": "11432",
              "country": "United States",
              "geoPoint": {
                "lat": 40.69149,
                "lon": -73.80569
              }
            },
            {
              "facility": "CCOP - North Shore University Hospital",
              "city": "Manhasset",
              "state": "New York",
              "zip": "11030",
              "country": "United States",
              "geoPoint": {
                "lat": 40.79788,
                "lon": -73.69957
              }
            },
            {
              "facility": "North Shore University Hospital",
              "city": "Manhasset",
              "state": "New York",
              "zip": "11030",
              "country": "United States",
              "geoPoint": {
                "lat": 40.79788,
                "lon": -73.69957
              }
            },
            {
              "facility": "Memorial Sloan-Kettering Cancer Center",
              "city": "New York",
              "state": "New York",
              "zip": "10021",
              "country": "United States",
              "geoPoint": {
                "lat": 40.71427,
                "lon": -74.00597
              }
            },
            {
              "facility": "New York Weill Cornell Cancer Center at Cornell University",
              "city": "New York",
              "state": "New York",
              "zip": "10021",
              "country": "United States",
              "geoPoint": {
                "lat": 40.71427,
                "lon": -74.00597
              }
            },
            {
              "facility": "Mount Sinai Medical Center",
              "city": "New York",
              "state": "New York",
              "zip": "10029",
              "country": "United States",
              "geoPoint": {
                "lat": 40.71427,
                "lon": -74.00597
              }
            },
            {
              "facility": "SUNY Upstate Medical University Hospital",
              "city": "Syracuse",
              "state": "New York",
              "zip": "13210",
              "country": "United States",
              "geoPoint": {
                "lat": 43.04812,
                "lon": -76.14742
              }
            },
            {
              "facility": "Veterans Affairs Medical Center - Asheville",
              "city": "Asheville",
              "state": "North Carolina",
              "zip": "28805-9913",
              "country": "United States",
              "geoPoint": {
                "lat": 35.60095,
                "lon": -82.55402
              }
            },
            {
              "facility": "Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill",
              "city": "Chapel Hill",
              "state": "North Carolina",
              "zip": "27599-7295",
              "country": "United States",
              "geoPoint": {
                "lat": 35.9132,
                "lon": -79.05584
              }
            },
            {
              "facility": "NorthEast Oncology Associates - Concord",
              "city": "Concord",
              "state": "North Carolina",
              "zip": "28025",
              "country": "United States",
              "geoPoint": {
                "lat": 35.40888,
                "lon": -80.58158
              }
            },
            {
              "facility": "Duke Comprehensive Cancer Center",
              "city": "Durham",
              "state": "North Carolina",
              "zip": "27710",
              "country": "United States",
              "geoPoint": {
                "lat": 35.99403,
                "lon": -78.89862
              }
            },
            {
              "facility": "Cape Fear Valley Medical Center",
              "city": "Fayetteville",
              "state": "North Carolina",
              "zip": "28302-2000",
              "country": "United States",
              "geoPoint": {
                "lat": 35.05266,
                "lon": -78.87836
              }
            },
            {
              "facility": "CCOP - Southeast Cancer Control Consortium",
              "city": "Goldsboro",
              "state": "North Carolina",
              "zip": "27534-9479",
              "country": "United States",
              "geoPoint": {
                "lat": 35.38488,
                "lon": -77.99277
              }
            },
            {
              "facility": "Lenoir Memorial Cancer Center",
              "city": "Kinston",
              "state": "North Carolina",
              "zip": "28503-1678",
              "country": "United States",
              "geoPoint": {
                "lat": 35.26266,
                "lon": -77.58164
              }
            },
            {
              "facility": "Comprehensive Cancer Center at Moore Regional Hospital",
              "city": "Pinehurst",
              "state": "North Carolina",
              "zip": "28374",
              "country": "United States",
              "geoPoint": {
                "lat": 35.19543,
                "lon": -79.46948
              }
            },
            {
              "facility": "Zimmer Cancer Center at New Hanover Regional Medical Center",
              "city": "Wilmington",
              "state": "North Carolina",
              "zip": "28402-9025",
              "country": "United States",
              "geoPoint": {
                "lat": 34.22573,
                "lon": -77.94471
              }
            },
            {
              "facility": "Comprehensive Cancer Center at Wake Forest University",
              "city": "Winston-Salem",
              "state": "North Carolina",
              "zip": "27157-1082",
              "country": "United States",
              "geoPoint": {
                "lat": 36.09986,
                "lon": -80.24422
              }
            },
            {
              "facility": "Oklahoma University Medical Center",
              "city": "Oklahoma City",
              "state": "Oklahoma",
              "zip": "73104",
              "country": "United States",
              "geoPoint": {
                "lat": 35.46756,
                "lon": -97.51643
              }
            },
            {
              "facility": "Miriam Hospital at Lifespan",
              "city": "Providence",
              "state": "Rhode Island",
              "zip": "02906",
              "country": "United States",
              "geoPoint": {
                "lat": 41.82399,
                "lon": -71.41283
              }
            },
            {
              "facility": "Veterans Affairs Medical Center - Dallas",
              "city": "Dallas",
              "state": "Texas",
              "zip": "75219",
              "country": "United States",
              "geoPoint": {
                "lat": 32.78306,
                "lon": -96.80667
              }
            },
            {
              "facility": "Vermont Cancer Center at University of Vermont",
              "city": "Burlington",
              "state": "Vermont",
              "zip": "05401-3498",
              "country": "United States",
              "geoPoint": {
                "lat": 44.47588,
                "lon": -73.21207
              }
            },
            {
              "facility": "Martha Jefferson Hospital",
              "city": "Charlottesville",
              "state": "Virginia",
              "zip": "22902",
              "country": "United States",
              "geoPoint": {
                "lat": 38.02931,
                "lon": -78.47668
              }
            },
            {
              "facility": "Virginia Oncology Associates - Norfolk",
              "city": "Norfolk",
              "state": "Virginia",
              "zip": "23502",
              "country": "United States",
              "geoPoint": {
                "lat": 36.84681,
                "lon": -76.28522
              }
            },
            {
              "facility": "MBCCOP - Massey Cancer Center",
              "city": "Richmond",
              "state": "Virginia",
              "zip": "23298-0037",
              "country": "United States",
              "geoPoint": {
                "lat": 37.55376,
                "lon": -77.46026
              }
            },
            {
              "facility": "Oncology and Hematology Associates of Southwest Virginia, Incorporated - Roanoke",
              "city": "Roanoke",
              "state": "Virginia",
              "zip": "24014",
              "country": "United States",
              "geoPoint": {
                "lat": 37.27097,
                "lon": -79.94143
              }
            },
            {
              "facility": "St. Mary's Medical Center",
              "city": "Huntington",
              "state": "West Virginia",
              "zip": "25701",
              "country": "United States",
              "geoPoint": {
                "lat": 38.41925,
                "lon": -82.44515
              }
            }
          ]
        },
        "referencesModule": {
          "references": [
            {
              "type": "RESULT",
              "citation": "Sokoloff MH, Halabi S, Sanford B, et al.: Management of recurrent prostate cancer after radiotherapy: preliminary results of CALGB 9687, a contemporary salvage prostatectomy series. [Abstract] American Society of Clinical Oncology 2005 Prostate Cancer Symposium, 17-19 February 2005, Orlando, Florida. A-166, 2005."
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000011471",
              "term": "Prostatic Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000005834",
              "term": "Genital Neoplasms, Male"
            },
            {
              "id": "D000014565",
              "term": "Urogenital Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000005832",
              "term": "Genital Diseases, Male"
            },
            {
              "id": "D000091662",
              "term": "Genital Diseases"
            },
            {
              "id": "D000091642",
              "term": "Urogenital Diseases"
            },
            {
              "id": "D000011469",
              "term": "Prostatic Diseases"
            },
            {
              "id": "D000052801",
              "term": "Male Urogenital Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M5224",
              "name": "Carcinoma",
              "relevance": "LOW"
            },
            {
              "id": "M14540",
              "name": "Recurrence",
              "relevance": "LOW"
            },
            {
              "id": "M14025",
              "name": "Prostatic Neoplasms",
              "asFound": "Prostate Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M8636",
              "name": "Genital Neoplasms, Male",
              "relevance": "LOW"
            },
            {
              "id": "M17005",
              "name": "Urogenital Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M2877",
              "name": "Genital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M8634",
              "name": "Genital Diseases, Male",
              "relevance": "LOW"
            },
            {
              "id": "M2876",
              "name": "Urogenital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M14023",
              "name": "Prostatic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M26785",
              "name": "Male Urogenital Diseases",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC23",
              "name": "Symptoms and General Pathology"
            },
            {
              "abbrev": "BXS",
              "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00673738",
          "orgStudyIdInfo": {
            "id": "MCC-15294"
          },
          "secondaryIdInfos": [
            {
              "id": "106296",
              "type": "OTHER",
              "domain": "USF IRB"
            },
            {
              "id": "CA225286",
              "type": "OTHER",
              "domain": "Bristol-Myers Squibb"
            }
          ],
          "organization": {
            "fullName": "H. Lee Moffitt Cancer Center and Research Institute",
            "class": "OTHER"
          },
          "briefTitle": "Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)",
          "officialTitle": "Safety and Efficacy (Phase II) Study of Concurrent Cetuximab Plus Conformal Thoracic Radiotherapy in (Poor Prognosis) Patients With Inoperable or Unresectable, Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)"
        },
        "statusModule": {
          "statusVerifiedDate": "2015-09",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2008-04"
          },
          "primaryCompletionDateStruct": {
            "date": "2013-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2008-05-05",
          "studyFirstSubmitQcDate": "2008-05-05",
          "studyFirstPostDateStruct": {
            "date": "2008-05-07",
            "type": "ESTIMATED"
          },
          "resultsFirstSubmitDate": "2013-09-18",
          "resultsFirstSubmitQcDate": "2014-01-16",
          "resultsFirstPostDateStruct": {
            "date": "2014-03-04",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2015-09-23",
          "lastUpdatePostDateStruct": {
            "date": "2015-10-08",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "H. Lee Moffitt Cancer Center and Research Institute",
            "class": "OTHER"
          },
          "collaborators": [
            {
              "name": "Bristol-Myers Squibb",
              "class": "INDUSTRY"
            }
          ]
        },
        "oversightModule": {
          "oversightHasDmc": true
        },
        "descriptionModule": {
          "briefSummary": "This research is being done to find out if a treatment consisting of a combination of thoracic radiotherapy with cetuximab, given together, and followed by chemotherapy with docetaxel and cetuximab (also given together) will kill the cancer cells in the patient's body and shrink the size of their tumor without causing unacceptable side effects. This may allow patients to live longer or decrease the frequency and/or severity of the symptoms caused by the cancer without increasing the frequency and/or severity of the symptoms caused by the treatment.",
          "detailedDescription": "Patients will be asked to spend about six months in this study. There will be 4 different phases in this study as follows: (1) Loading Phase: This is the first week (week 1) of the study, when patients receive their first (loading) dose of cetuximab only, in the vein. (2) Concurrent Phase: During this phase patients will be treated simultaneously (concurrently) with radiation therapy to their chest and cetuximab. Radiation is delivered 5 days a week, Monday to Friday for a total of 7 weeks (weeks 2-8). Cetuximab is delivered in the vein, weekly, during the weeks of radiation. (3) Recovery Phase: Patients receive no treatment during these next 3 weeks (weeks 9-11). This phase is designed to allow patients to recover from side effects before they start the last phase. (4) Consolidation Phase: The last phase. Patients will receive 3 doses of chemotherapy with docetaxel during this phase. Docetaxel is given intravenously every 21 days. Patients also receive weekly cetuximab during this phase. Cetuximab is delivered in a similar way as it was during the concurrent (second) phase of this study. In total, this phase lasts 6 weeks (weeks 12-18). Once the therapy treatment is completed, and if the patient's cancer did not get worse, follow up visits will include visits to their physician every three months for 2 years, then every 4 months for 2 years or more, as long as their cancer doesn't get worse (at which time they will be removed from the study)."
        },
        "conditionsModule": {
          "conditions": [
            "Lung Cancer"
          ],
          "keywords": [
            "Lung",
            "Thoracic",
            "Immunotherapy",
            "Radiotherapy",
            "LA - NSCLC",
            "Non-Small Cell Lung Cancer"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Cetuximab Plus Radiotherapy",
              "type": "EXPERIMENTAL",
              "description": "Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT). Patients were treated with definitive radiotherapy (70 Gy in 35 fractions, per our currently-existing institutional standard) with concurrent cetuximab followed by 3 cycles of consolidation docetaxel plus cetuximab.",
              "interventionNames": [
                "Drug: Cetuximab",
                "Radiation: Conformal Thoracic Radiotherapy (CTRT)"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "Cetuximab",
              "description": "* Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.\n* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.",
              "armGroupLabels": [
                "Cetuximab Plus Radiotherapy"
              ],
              "otherNames": [
                "Chemotherapy single agent systemic",
                "docetaxel",
                "immunotherapy"
              ]
            },
            {
              "type": "RADIATION",
              "name": "Conformal Thoracic Radiotherapy (CTRT)",
              "description": "* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.\n* Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC \\>1,000 and platelets \\>75,000) required. Patient may be delayed for a max. of 2 weeks. If \\> 2 week delay occurs, patient will come off study.",
              "armGroupLabels": [
                "Cetuximab Plus Radiotherapy"
              ],
              "otherNames": [
                "CTRT",
                "Radiotherapy"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Median Progression Free Survival (PFS)",
              "description": "Progression Free Survival is defined as the interval between the date of the first cetuximab administration and the date of objective progression of disease. Progression was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.",
              "timeFrame": "Up to 36 months"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Median Overall Survival (OS)",
              "description": "Overall survival is defined as the time from randomization until death from any cause.",
              "timeFrame": "Up to 36 months"
            },
            {
              "measure": "Overall Response Rate (ORR)",
              "description": "ORR = Complete Response (CR) + Partial Response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete Response: Disappearance of all target lesions; Partial Response: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.",
              "timeFrame": "Up to 36 months"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed inoperable or unresectable, LA-NSCLC (adenocarcinoma, squamous cell carcinoma or anaplastic large cell carcinoma or non-small cell otherwise not specified).\n* Eligible Stages: Stages IIA through IIIA disease if it is felt that they are not candidates for possible resection, medically or otherwise. Stage IIIA (multi-station mediastinal lymph nodes) and stage IIIB disease without significant pleural effusion (metastases to contralateral mediastinal or supraclavicular lymph nodes) are also eligible.\n* Age ≥ 70 OR Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 2 at time of registration OR weight loss ≥ 5% in the preceding three months to the time of registration\n* Must have measurable disease by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. When applicable, baseline measurements/evaluations must be obtained within 4 weeks prior to registration.\n* Must have adequate bone marrow reserve as determined by the following laboratory values, obtained within 14 days prior to registration:\n\n  * White blood cell count (WBC) ≥ 4000/ul or absolute neutrophil count (ANC) ≥ 1000/ul\n  * Platelet count ≥ 100,000/ul\n  * Hemoglobin ≥ 8 gms/dl\n* Adequate renal and liver function as determined by the following laboratory values, obtained within 14 days prior to registration:\n\n  * Serum creatinine ≤ 2.0 mg/dl or creatinine clearance ≥ 40 cc/min\n  * Bilirubin \\< 2.0 mg/dl\n  * serum glutamic oxaloacetic transaminase (SGOT) ≤ 2.5 times the upper limit of normal(ULN)\n* Written, informed consent must be obtained prior to registration\n* Women of childbearing potential (WOCBP) must use an accepted, effective method of contraception during the course of the study, in a manner such that risk of failure is minimized. Sexually active males enrolled should understand the risks to any sexual partner of childbearing potential; must also practice an effective method of contraception. WOCBP must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy; have a negative pregnancy test within 7 days prior to first receiving investigational product; be instructed to contact the Investigator immediately if they suspect they might be pregnant at any time during study participation. Investigator must immediately notify Bristol-Myers Squibb (BMS) in the event of a confirmed pregnancy in a patient participating in the study. If the pregnancy test is positive, the patient must not receive investigational product and must not be enrolled in the study.\n\nExclusion Criteria:\n\n* Must not have small cell carcinoma as part of the histological specimen\n* Evidence of distant metastasis.\n* History of a prior or concomitant malignancy in the past 3 years except for surgically cured basal cell carcinoma of the skin or carcinoma in situ of the cervix. Invasive malignancies, properly treated and currently disease-free \\> 3 years are allowed.\n* Prior thoracic radiotherapy or epidermal growth factor receptor (EGFR) pathway targeting therapy. Prior systemic chemotherapy is allowed if received as therapy for an invasive malignancy, currently disease-free \\> 3 years\n* Concomitant life threatening or uncontrolled serious medical illness such as cardiac disease (uncontrolled hypertension, arrhythmia, unstable angina, recent myocardial infarction, end stage congestive heart failure, cardiomyopathy with decreased ejection fraction), liver disease with significant hepatic insufficiency, kidney disease with significant renal insufficiency or organic brain syndrome.",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Alberto Chiappori, M.D.",
              "affiliation": "H. Lee Moffitt Cancer Center and Research Institute",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "H. Lee Moffitt Cancer Center and Research Institute",
              "city": "Tampa",
              "state": "Florida",
              "zip": "33612",
              "country": "United States",
              "geoPoint": {
                "lat": 27.94752,
                "lon": -82.45843
              }
            }
          ]
        }
      },
      "resultsSection": {
        "participantFlowModule": {
          "recruitmentDetails": "Participants were recruited at Moffitt Cancer Center from May, 2008 to November, 2010.",
          "groups": [
            {
              "id": "FG000",
              "title": "Cetuximab Plus Radiotherapy",
              "description": "Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT)"
            }
          ],
          "periods": [
            {
              "title": "Overall Study",
              "milestones": [
                {
                  "type": "STARTED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "27"
                    }
                  ]
                },
                {
                  "type": "COMPLETED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "27"
                    }
                  ]
                },
                {
                  "type": "NOT COMPLETED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        "baselineCharacteristicsModule": {
          "groups": [
            {
              "id": "BG000",
              "title": "Cetuximab Plus Radiotherapy",
              "description": "Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT)"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "BG000",
                  "value": "27"
                }
              ]
            }
          ],
          "measures": [
            {
              "title": "Age, Categorical",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "categories": [
                    {
                      "title": "<=18 years",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Between 18 and 65 years",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "2"
                        }
                      ]
                    },
                    {
                      "title": ">=65 years",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "25"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Age, Continuous",
              "paramType": "MEDIAN",
              "dispersionType": "FULL_RANGE",
              "unitOfMeasure": "years",
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "72",
                          "lowerLimit": "58",
                          "upperLimit": "83"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Sex: Female, Male",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "categories": [
                    {
                      "title": "Female",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "9"
                        }
                      ]
                    },
                    {
                      "title": "Male",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "18"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Region of Enrollment",
              "paramType": "NUMBER",
              "unitOfMeasure": "participants",
              "classes": [
                {
                  "title": "United States",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "27"
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        "outcomeMeasuresModule": {
          "outcomeMeasures": [
            {
              "type": "PRIMARY",
              "title": "Median Progression Free Survival (PFS)",
              "description": "Progression Free Survival is defined as the interval between the date of the first cetuximab administration and the date of objective progression of disease. Progression was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.",
              "populationDescription": "All participants",
              "reportingStatus": "POSTED",
              "paramType": "MEDIAN",
              "dispersionType": "95% Confidence Interval",
              "unitOfMeasure": "months",
              "timeFrame": "Up to 36 months",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Cetuximab Plus Radiotherapy",
                  "description": "Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT). Patients were treated with definitive radiotherapy (70 Gy in 35 fractions, per our currently-existing institutional standard) with concurrent cetuximab followed by 3 cycles of consolidation docetaxel plus cetuximab."
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "27"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "7.5",
                          "lowerLimit": "4.0",
                          "upperLimit": "10.7"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Median Overall Survival (OS)",
              "description": "Overall survival is defined as the time from randomization until death from any cause.",
              "populationDescription": "All participants",
              "reportingStatus": "POSTED",
              "paramType": "MEDIAN",
              "dispersionType": "95% Confidence Interval",
              "unitOfMeasure": "months",
              "timeFrame": "Up to 36 months",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Cetuximab Plus Radiotherapy",
                  "description": "Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT). Patients were treated with definitive radiotherapy (70 Gy in 35 fractions, per our currently-existing institutional standard) with concurrent cetuximab followed by 3 cycles of consolidation docetaxel plus cetuximab."
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "27"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "10.5",
                          "lowerLimit": "4.3",
                          "upperLimit": "20.5"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Overall Response Rate (ORR)",
              "description": "ORR = Complete Response (CR) + Partial Response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete Response: Disappearance of all target lesions; Partial Response: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.",
              "populationDescription": "All participants",
              "reportingStatus": "POSTED",
              "paramType": "NUMBER",
              "dispersionType": "95% Confidence Interval",
              "unitOfMeasure": "percentage of participants",
              "timeFrame": "Up to 36 months",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Cetuximab Plus Radiotherapy",
                  "description": "Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT). Patients were treated with definitive radiotherapy (70 Gy in 35 fractions, per our currently-existing institutional standard) with concurrent cetuximab followed by 3 cycles of consolidation docetaxel plus cetuximab."
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "27"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "title": "Partial Response",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "59.3",
                          "lowerLimit": "38.8",
                          "upperLimit": "77.6"
                        }
                      ]
                    }
                  ]
                },
                {
                  "title": "Complete Response",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "0",
                          "lowerLimit": "NA",
                          "upperLimit": "NA",
                          "comment": "There was no occurrence of Complete Response."
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        "adverseEventsModule": {
          "frequencyThreshold": "5",
          "timeFrame": "3 years",
          "eventGroups": [
            {
              "id": "EG000",
              "title": "Cetuximab Plus Radiotherapy",
              "description": "Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT)",
              "seriousNumAffected": 20,
              "seriousNumAtRisk": 27,
              "otherNumAffected": 27,
              "otherNumAtRisk": 27
            }
          ],
          "seriousEvents": [
            {
              "term": "Allergic reaction/hypersensitivity (including drug fever)",
              "organSystem": "Immune system disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Low Neutrophils/granulocytes (ANC/AGC)",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Supraventricular and nodal arrhythmia - Atrial fibrillation",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Hypotension",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Sweating (diaphoresis)",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Death not associated with CTCAE term - Death",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Death not associated with CTCAE term - Sudden death",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Anorexia",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Constipation",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Dehydration",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 3,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Diarrhea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Dysphagia (difficulty swallowing)",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 3,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Esophagitis",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Mucositis/stomatitis (functional/symptomatic) - Oral cavity",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Nausea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Stricture/stenosis (including anastomotic), GI - Esophagus",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Vomiting",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Hemorrhage, pulmonary/upper respiratory - Respiratory tract NOS",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Febrile neutropenia",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Lung",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils - Urinary Tract",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Infection with normal ANC or Grade 1 or 2 neutrophils - Esophagus",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Infection with normal ANC or Grade 1 or 2 neutrophils - Lung (pneumonia)",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Infection with normal ANC or Grade 1 or 2 neutrophils - Skin (cellulitis)",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Edema: limb",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Potassium, serum-high (hyperkalemia)",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Potassium, serum-low (hypokalemia)",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Sodium, serum-low (hyponatremia)",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Muscle weakness, generalized or specific area (not due to neuropathy) - Whole body/generalized",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Musculoskeletal/Soft Tissue - Other",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Mood alteration - Agitation",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pain - Abdomen NOS",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pain - Throat/pharynx/larynx",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Dyspnea (shortness of breath)",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 5,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Hiccoughs (hiccups, singultus)",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Hypoxia",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 3,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pneumonitis/pulmonary infiltrates",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pneumothorax",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Urinary retention (including neurogenic bladder)",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Thrombosis/thrombus/embolism",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 3,
                  "numAtRisk": 27
                }
              ]
            }
          ],
          "otherEvents": [
            {
              "term": "Dysphagia (difficulty swallowing)",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 19,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Esophagitis",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 19,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Constipation",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 15,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Nausea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 14,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Anorexia",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 11,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Vomiting",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 9,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Diarrhea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 6,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Dehydration",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 5,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Stricture/stenosis (including anastomotic), GI - Esophagus",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Taste alteration (dysgeusia)",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Heartburn/dyspepsia",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Mucositis/stomatitis clinical exam) - Oral cavity",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Fatigue (asthenia, lethargy, malaise)",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 22,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Weight loss",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 5,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Constitutional Symptoms - Other",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Insomnia",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Fever (in the absence of neutropenia)",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Sweating (diaphoresis)",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Rash: dermatitis associated with radiation - Radiation",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 20,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pruritus/itching",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 19,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Rash: acne/acneiform",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 18,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Dry skin",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 9,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Hair loss/alopecia (scalp or body)",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 5,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Hyperpigmentation",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Nail changes",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Rash/desquamation",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Dyspnea (shortness of breath)",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 17,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Cough",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 14,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pneumonitis/pulmonary infiltrates",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Hypoxia",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 3,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Hiccoughs",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pulmonary/Upper Respiratory - Other",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pain - Head/headache",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 6,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pain - Back",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pain - Chest/thorax NOS",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pain - Throat/pharynx/larynx",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pain - Abdomen NOS",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 3,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pain - Esophagus",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Pain - Other",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Infection with normal ANC or Grade 1 or 2 neutrophils - Lung (pneumonia)",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Febrile neutropenia (fever of unknown origin)",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 3,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Infection with normal ANC or Grade 1 or 2 neutrophils - Bronchus",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Infection with unknown ANC - Oral cavity-gums (gingivitis)",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Dizziness",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 6,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Confusion",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Musculoskeletal/Soft Tissue - Other",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 5,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Muscle weakness generalized or specific area (not due to neuropathy) whole body/generalized",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Magnesium, serum-low (hypomagnesemia)",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Potassium, serum-high (hyperkalemia)",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Sodium, serum-low (hyponatremia)",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Edema: limb",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Edema: head and neck",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Allergic reaction/hypersensitivity (including drug fever)",
              "organSystem": "Immune system disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Hypotension",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Ocular/Visual - Other",
              "organSystem": "Eye disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Thrombosis/thrombus/embolism",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            },
            {
              "term": "Low Neutrophils/granulocytes (ANC/AGC)",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "CTC V3",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 27
                }
              ]
            }
          ]
        },
        "moreInfoModule": {
          "limitationsAndCaveats": {
            "description": "Accrual, and therefore treatment ended earlier than planned due to pulmonary toxicity. Three participants remain on follow-up."
          },
          "certainAgreement": {
            "piSponsorEmployee": true
          },
          "pointOfContact": {
            "title": "Alberto Chiappori, M.D.",
            "organization": "H. Lee Moffitt Cancer Center and Research Institute",
            "email": "alberto.chiappori@moffitt.org",
            "phone": "813-745-3050"
          }
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000008175",
              "term": "Lung Neoplasms"
            },
            {
              "id": "D000002289",
              "term": "Carcinoma, Non-Small-Cell Lung"
            }
          ],
          "ancestors": [
            {
              "id": "D000012142",
              "term": "Respiratory Tract Neoplasms"
            },
            {
              "id": "D000013899",
              "term": "Thoracic Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000008171",
              "term": "Lung Diseases"
            },
            {
              "id": "D000012140",
              "term": "Respiratory Tract Diseases"
            },
            {
              "id": "D000002283",
              "term": "Carcinoma, Bronchogenic"
            },
            {
              "id": "D000001984",
              "term": "Bronchial Neoplasms"
            }
          ],
          "browseLeaves": [
            {
              "id": "M10862",
              "name": "Lung Neoplasms",
              "asFound": "Lung Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M5236",
              "name": "Carcinoma, Non-Small-Cell Lung",
              "asFound": "Non-Small Cell Lung Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M5224",
              "name": "Carcinoma",
              "relevance": "LOW"
            },
            {
              "id": "M14669",
              "name": "Respiratory Tract Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M16348",
              "name": "Thoracic Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M10858",
              "name": "Lung Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M14667",
              "name": "Respiratory Tract Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M5230",
              "name": "Carcinoma, Bronchogenic",
              "relevance": "LOW"
            },
            {
              "id": "M4950",
              "name": "Bronchial Neoplasms",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC08",
              "name": "Respiratory Tract (Lung and Bronchial) Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000077143",
              "term": "Docetaxel"
            },
            {
              "id": "D000068818",
              "term": "Cetuximab"
            }
          ],
          "ancestors": [
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000050257",
              "term": "Tubulin Modulators"
            },
            {
              "id": "D000050256",
              "term": "Antimitotic Agents"
            },
            {
              "id": "D000050258",
              "term": "Mitosis Modulators"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            },
            {
              "id": "D000074322",
              "term": "Antineoplastic Agents, Immunological"
            }
          ],
          "browseLeaves": [
            {
              "id": "M1668",
              "name": "Docetaxel",
              "asFound": "Following",
              "relevance": "HIGH"
            },
            {
              "id": "M2854",
              "name": "Immunomodulating Agents",
              "relevance": "LOW"
            },
            {
              "id": "M315",
              "name": "Cetuximab",
              "asFound": "Per week",
              "relevance": "HIGH"
            },
            {
              "id": "M1804",
              "name": "Carbamide Peroxide",
              "relevance": "LOW"
            },
            {
              "id": "M25887",
              "name": "Tubulin Modulators",
              "relevance": "LOW"
            },
            {
              "id": "M25886",
              "name": "Antimitotic Agents",
              "relevance": "LOW"
            },
            {
              "id": "M1346",
              "name": "Antineoplastic Agents, Immunological",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            },
            {
              "abbrev": "Infe",
              "name": "Anti-Infective Agents"
            }
          ]
        }
      },
      "hasResults": true
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01061138",
          "orgStudyIdInfo": {
            "id": "#03"
          },
          "organization": {
            "fullName": "Konica Minolta Medical Imaging, USA",
            "class": "INDUSTRY"
          },
          "briefTitle": "Xpress Digital Mammography System Images for Computer Aided Detection Development",
          "officialTitle": "A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development"
        },
        "statusModule": {
          "statusVerifiedDate": "2012-12",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2010-02"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2010-02-01",
          "studyFirstSubmitQcDate": "2010-02-01",
          "studyFirstPostDateStruct": {
            "date": "2010-02-02",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2012-12-03",
          "lastUpdatePostDateStruct": {
            "date": "2012-12-04",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "Konica Minolta Medical Imaging, USA",
            "class": "INDUSTRY"
          }
        },
        "oversightModule": {
          "oversightHasDmc": false
        },
        "descriptionModule": {
          "briefSummary": "The primary objective of this study is to acquire digital mammography images produced by the Xpress Digital Mammography System in order to develop Computer Aided Detection software and systems.",
          "detailedDescription": "The proposed study is an image acquisition study of mammograms produced by the investigational digital system. Women who meet the selection criteria and who agree to participate in the study will be imaged with the Xpress Digital Mammography System at the clinical sites. These images will be provided to CAD development companies to conduct their own development and testing. The CAD development companies will be responsible for submitting their results to the FDA for marketing approval of their CAD systems.\n\nPatients will be drawn primarily from those women scheduled for breast biopsy since this population has an enhanced probability of cancer. The intent is to enroll patients until at least 107 women with biopsy proven cancers, and at least 330 women who have negative mammograms are enrolled. All cancers found will be used in the study. It is anticipated that approximately 720 patients undergoing diagnostic mammography will need to be enrolled to yield 107 proven cancer cases. In addition, approximately 330 cases will be drawn from a screening population. The negative status of the screening cases will be established by selecting only cases classified as BIRADS 1 or 2, and have a negative mammogram at one year follow-up. All images collected will be utilized to develop and test the CAD systems, and may be used for further product development."
        },
        "conditionsModule": {
          "conditions": [
            "Breast Cancer"
          ],
          "keywords": [
            "breast cancer",
            "screening mammograms",
            "breast biopsy"
          ]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "designInfo": {
            "observationalModel": "COHORT",
            "timePerspective": "PROSPECTIVE"
          },
          "enrollmentInfo": {
            "count": 597,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Screening Patients",
              "description": "Female patients scheduled for routine annual screening mammograms"
            },
            {
              "label": "Biopsy Patients",
              "description": "Female patients scheduled for routine breast biopsy procedures"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria\n\nCases selected for the study must meet all of the following criteria:\n\n* Female\n* Scheduled for a routine screening mammography or routine breast biopsy for non-palpable findings\n* Any ethnic origin\n\nExclusion Criteria\n\nPatients meeting any of the following criteria will be excluded from the study:\n\n* Any contraindication to mammography\n* Pregnant or suspicion of being pregnant, or nursing\n* Patients with palpable lesions\n* Patients with internal breast markers in the region of interest\n* Breast implants, without displaced views\n* Significant recent breast trauma/acute mastitis\n* Patient has previously undergone an excisional breast biopsy\n* Patients with a history of breast cancer\n* Unable or unwilling to give consent",
          "healthyVolunteers": true,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ],
          "studyPopulation": "To achieve the goal of 107 cases with biopsy-proven cancer, it is expected that approximatley 720 patients undergoing breast biopsy will need to be enrolled in the study. In addition, we will enroll up to 330 patients from a screening population.",
          "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Etta Pisano, MD",
              "affiliation": "Medical University of South Carolina",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Waterbury Hospital",
              "city": "Waterbury",
              "state": "Connecticut",
              "country": "United States",
              "geoPoint": {
                "lat": 41.55815,
                "lon": -73.0515
              }
            },
            {
              "facility": "Jackson Memorial Hospital",
              "city": "Miami",
              "state": "Florida",
              "country": "United States",
              "geoPoint": {
                "lat": 25.77427,
                "lon": -80.19366
              }
            },
            {
              "facility": "University of Iowa",
              "city": "Iowa City",
              "state": "Iowa",
              "country": "United States",
              "geoPoint": {
                "lat": 41.66113,
                "lon": -91.53017
              }
            },
            {
              "facility": "Greenville Hospital Systems",
              "city": "Greenville",
              "state": "South Carolina",
              "country": "United States",
              "geoPoint": {
                "lat": 34.85262,
                "lon": -82.39401
              }
            },
            {
              "facility": "University of Texas San Antonio",
              "city": "San Antonio",
              "state": "Texas",
              "country": "United States",
              "geoPoint": {
                "lat": 29.42412,
                "lon": -98.49363
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000001943",
              "term": "Breast Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000001941",
              "term": "Breast Diseases"
            },
            {
              "id": "D000012871",
              "term": "Skin Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M4910",
              "name": "Breast Neoplasms",
              "asFound": "Breast Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M4908",
              "name": "Breast Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M15364",
              "name": "Skin Diseases",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC17",
              "name": "Skin and Connective Tissue Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01786538",
          "orgStudyIdInfo": {
            "id": "Regorafenib/FOLFOX"
          },
          "organization": {
            "fullName": "Asan Medical Center",
            "class": "OTHER"
          },
          "briefTitle": "Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines",
          "officialTitle": "Randomized Phase III Study of Oxaliplatin, Fluorouracil and Leucovorin (FOLFOX) With or Without Regorafenib in Patients With Metastatic Colorectal Cancer Progressed After First-line Irinotecan Plus Fluoropyrimidines"
        },
        "statusModule": {
          "statusVerifiedDate": "2013-03",
          "overallStatus": "WITHDRAWN",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2013-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2016-05",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2017-05",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2013-02-04",
          "studyFirstSubmitQcDate": "2013-02-06",
          "studyFirstPostDateStruct": {
            "date": "2013-02-08",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2013-03-12",
          "lastUpdatePostDateStruct": {
            "date": "2013-03-13",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "PRINCIPAL_INVESTIGATOR",
            "investigatorFullName": "Tae Won Kim",
            "investigatorTitle": "Professor",
            "investigatorAffiliation": "Asan Medical Center"
          },
          "leadSponsor": {
            "name": "Asan Medical Center",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": true
        },
        "descriptionModule": {
          "briefSummary": "Regorafenib has been proved to improved survival in patients with metastatic colorectal cancer who have been failed to all of known standard chemotherapy (The CORRECT study). The phase Ib study of regorafenib plus FOLFOX or FOLFIRI was performed and the dose of regorafenib was fixed; 160 mg/day on days 4 to 10 (7 days per cycle when combined with FOLFOX or FOLFIRI). Regorafenib plus FOLFOX as second-line chemotherapy in mCRC patients who progressed after first-line irinotecan-based chemotherapy has not been studied yet, and because there have been unmet needs for the discovery of valid targeted agent combination for the second-line FOLFOX as above reasons, the investigators planned this study of regorafenib plus FOLFOX as second-line chemotherapy in mCRC patients who progressed after first-line irinotecan-based chemotherapy.",
          "detailedDescription": "Limited active drugs are available for the treatment of patients with metastatic colorectal cancer (mCRC) at present and upfront doublet combination of fluoropyrimidines plus either oxaliplatin or irinotecan is regarded as reference strategy for patients appropriate for intensive therapy. Before the era of targeted agents, the treatment strategies in terms of either combination or sequence of cytotoxic agents were rather simple; survival outcomes did not differ according to either the administration sequence of oxaliplatin or irinotecan, or the sequential versus combination chemotherapy in the treatment continuum. However, the treatment strategies have become more complicated in the era of targeted agents.\n\nIn case of failure to first-line oxaliplatin plus fluoropyrimidines (FOLFOX or CapeOX) with or without bevacizumab, second-line chemotherapy with FOLFIRI would be administered for treatment continuum, and more various targeted agents can be combined in these setting; bevacizumab beyond progression only in patients who have been treated with first-line bevacizumab plus FOLFOX or CapeOX (TML and BRiTE), cetuximab (only for patients with wild-type KRAS), panitumumab (only for patients with wild-type KRAS), and aflibercept (VELOUR). However, there have been a few valid targeted agents which could be combined in the second line FOLFOX or CapeOX in those progressed after first-line FOLFIRI with or without targeted agents; bevacizumab beyond progression could be a valid treatment strategy only in those received first-line bevacizumab plus FOLFIRI. Higher dose of bevacizumab (10 mg/kg/2-week) could be combined to FOLFOX as second-line chemotherapy; however, it is not recommended at present in terms of cost effectiveness and higher adverse events, and cetuximab plus oxaliplatin-based chemotherapy is neither recommended by current consensus. Thus, there have been unmet needs for the discovery of valid targeted agent combination for the second-line FOLFOX as above reasons."
        },
        "conditionsModule": {
          "conditions": [
            "Metastatic Colorectal Cancer"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE3"
          ],
          "designInfo": {
            "allocation": "RANDOMIZED",
            "interventionModel": "PARALLEL",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "TRIPLE",
              "whoMasked": [
                "PARTICIPANT",
                "CARE_PROVIDER",
                "INVESTIGATOR"
              ]
            }
          },
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Regorafenib/FOLFOX",
              "type": "EXPERIMENTAL",
              "interventionNames": [
                "Drug: Regorafenib/FOLFOX"
              ]
            },
            {
              "label": "Placebo/FOLFOX",
              "type": "ACTIVE_COMPARATOR",
              "interventionNames": [
                "Drug: Placebo/FOLFOX"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "Regorafenib/FOLFOX",
              "description": "FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Regorafenib will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.",
              "armGroupLabels": [
                "Regorafenib/FOLFOX"
              ]
            },
            {
              "type": "DRUG",
              "name": "Placebo/FOLFOX",
              "description": "FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Placebo will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.",
              "armGroupLabels": [
                "Placebo/FOLFOX"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Progression-free survival",
              "timeFrame": "time from randomization to disease-progression or any event (up to 1 year from the end of study treatment)"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Overall survival",
              "timeFrame": "Time from randomization to death (up to 1 year from the end of study treatment)"
            },
            {
              "measure": "Response rate",
              "timeFrame": "every 6 weeks, up to disease progression from study treatment"
            },
            {
              "measure": "Disease-control rate",
              "description": "partial response + stable disease",
              "timeFrame": "every 6 weeks, up to disease progression from study treatment"
            },
            {
              "measure": "Number of participants with adverse events",
              "description": "Adverse events will be monitored according to the NCI-CTCAE version 4.0.",
              "timeFrame": "Every cycle (every 2 weeks) till the end of study treatment (because of disease progression or any event, up to 1 year)"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histologically or cytologically confirmed adenocarcinoma of the colon or the rectum.\n2. Progressed during or within 6 months of first-line irinotecan plus fluoropyrimidines with or without targeted agents (bevacizumab or cetuximab).\n3. Measurable or evaluable lesion(s) by RECIST 1.1.\n4. Unresectable metastatic disease.\n5. Age over 20 years old.\n6. ECOG performance status of 1 or lower.\n7. Adequate organ functions. A. Bone marrow function: ANC ≥ 1,500/mm3, platelet ≥ 100,000/mm3 B. Hepatic functions: bilirubin ≤ 1.5 X ULN, AST/ALT ≤ 2.5 X ULN (≤ 5 X ULN in cases of liver metastasis) C. Renal functions: serum Cr ≤ 1.5 X ULN or calculated CCr (Cockroft) ≥ 60 ml/min\n8. Be willing and able to comply with the protocol for the duration of the study.\n9. Give written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw the study at any time, without prejudice.\n10. Women of childbearing potential and men must agree to use adequate contraception since signing of the IC form until at least 8 weeks after the last study drug administration.\n\nExclusion Criteria:\n\n1. Prior treatment of regorafenib.\n2. Prior exposure to oxaliplatin as metastatic setting is not allowed in any case; however, prior exposure to oxaliplatin as (neo)adjuvant chemo(radio)therapy is allowed if progressed after 12 months from the date of completion of oxaliplatin-containing (neo)adjuvant treatment.\n3. Concurrent or previous history of another primary cancer within 3 years prior to randomisation except for curatively treated cervical cancer in situ, non-melanomatous skin cancer, superficial bladder cancer (pTis and pT1) and curatively treated thyroid cancer of any stage. Concurrent, histologically confirmed, unresected thyroid cancer without distant metastasis could be allowed with the agreement of the chief principal investigator.\n4. Uncontrolled CNS metastases.\n5. Prior radiation therapy would be permitted, but non-radiated evaluable lesions should be present at study entry.\n6. Radiation therapy during chemotherapy is not permitted, but if the local investigator decides that radiation therapy should be given during study treatments, he should be convinced that there is no evidence of disease progression with agreement of the chief principal investigator. Radiation therapy during the chemotherapy-free interval between 1st and 2nd line chemotherapy is permitted.\n7. Uncontrolled hypertension (\\>150/100 mmHg) despite of optimal management; anti-hypertensive drugs for BP lowering before study entry would be permitted.\n8. Congestive heart failure ≥ New York Heart Association (NYHA) class 2.\n9. Unstable angina, new-onset angina within 3 months, or history of myocardial infarction within 6 months before the study entry.\n10. Arterial or venous thromboembolism within 6 months.\n11. Serious concurrent infections or non-malignant illness.\n12. Liver cirrhosis ≥ Child-Pugh class B.\n13. Prior unanticipated severe toxicity to fluoropyrimidines, or known dihydropyrimidine dehydrogenase (DPD) deficiency.\n14. Prior hypersensitivity to oxaliplatin (grade ≥ 2).\n15. Peripheral neuropathy of grade ≥ 2.\n16. Major surgery or significant traumatic injury within 28 days prior to study treatment.\n17. Non-healing wound, ulcer, or bone fracture.\n18. Current evidence of significant gastrointestinal bleeding or (impending) obstruction.\n19. Proteinuria ≥ 3+ in the routine urinalysis; in this case, the total protein in the 24-hour urine collection should be measured, and the accrual is permitted if total protein \\< 3.5 g/day.\n20. Concomitant participation in another clinical trial.\n21. Pregnant of breast-feeding subjects. Women of child-bearing potential must have pregnancy test within 7 days and a negative result must be documented before start of study treatment.\n22. Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results.",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "locations": [
            {
              "facility": "Asan Medical Center",
              "city": "Seoul",
              "state": "Songpa-gu",
              "zip": "138736",
              "country": "Korea, Republic of",
              "geoPoint": {
                "lat": 37.566,
                "lon": 126.9784
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000015179",
              "term": "Colorectal Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000007414",
              "term": "Intestinal Neoplasms"
            },
            {
              "id": "D000005770",
              "term": "Gastrointestinal Neoplasms"
            },
            {
              "id": "D000004067",
              "term": "Digestive System Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000004066",
              "term": "Digestive System Diseases"
            },
            {
              "id": "D000005767",
              "term": "Gastrointestinal Diseases"
            },
            {
              "id": "D000003108",
              "term": "Colonic Diseases"
            },
            {
              "id": "D000007410",
              "term": "Intestinal Diseases"
            },
            {
              "id": "D000012002",
              "term": "Rectal Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M17580",
              "name": "Colorectal Neoplasms",
              "asFound": "Colorectal Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M10138",
              "name": "Intestinal Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M8576",
              "name": "Gastrointestinal Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M6946",
              "name": "Digestive System Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M8573",
              "name": "Gastrointestinal Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M6945",
              "name": "Digestive System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M6026",
              "name": "Colonic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M10134",
              "name": "Intestinal Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M14534",
              "name": "Rectal Diseases",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC06",
              "name": "Digestive System Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000002955",
              "term": "Leucovorin"
            },
            {
              "id": "D000005472",
              "term": "Fluorouracil"
            },
            {
              "id": "D000077150",
              "term": "Oxaliplatin"
            }
          ],
          "ancestors": [
            {
              "id": "D000000963",
              "term": "Antimetabolites"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            },
            {
              "id": "D000000964",
              "term": "Antimetabolites, Antineoplastic"
            },
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000007166",
              "term": "Immunosuppressive Agents"
            },
            {
              "id": "D000007155",
              "term": "Immunologic Factors"
            },
            {
              "id": "D000045505",
              "term": "Physiological Effects of Drugs"
            },
            {
              "id": "D000000931",
              "term": "Antidotes"
            },
            {
              "id": "D000020011",
              "term": "Protective Agents"
            },
            {
              "id": "D000014803",
              "term": "Vitamin B Complex"
            },
            {
              "id": "D000014815",
              "term": "Vitamins"
            },
            {
              "id": "D000018977",
              "term": "Micronutrients"
            }
          ],
          "browseLeaves": [
            {
              "id": "M1671",
              "name": "Irinotecan",
              "relevance": "LOW"
            },
            {
              "id": "M5881",
              "name": "Leucovorin",
              "asFound": "Gastrointestinal",
              "relevance": "HIGH"
            },
            {
              "id": "M8290",
              "name": "Fluorouracil",
              "asFound": "Gastrointestinal",
              "relevance": "HIGH"
            },
            {
              "id": "M1674",
              "name": "Oxaliplatin",
              "asFound": "Gastrointestinal",
              "relevance": "HIGH"
            },
            {
              "id": "M3971",
              "name": "Antimetabolites",
              "relevance": "LOW"
            },
            {
              "id": "M9902",
              "name": "Immunosuppressive Agents",
              "relevance": "LOW"
            },
            {
              "id": "M9891",
              "name": "Immunologic Factors",
              "relevance": "LOW"
            },
            {
              "id": "M3940",
              "name": "Antidotes",
              "relevance": "LOW"
            },
            {
              "id": "M21559",
              "name": "Protective Agents",
              "relevance": "LOW"
            },
            {
              "id": "M17248",
              "name": "Vitamins",
              "relevance": "LOW"
            },
            {
              "id": "M8308",
              "name": "Folic Acid",
              "relevance": "LOW"
            },
            {
              "id": "M17236",
              "name": "Vitamin B Complex",
              "relevance": "LOW"
            },
            {
              "id": "M20699",
              "name": "Micronutrients",
              "relevance": "LOW"
            },
            {
              "id": "M16575",
              "name": "Trace Elements",
              "relevance": "LOW"
            },
            {
              "id": "T446",
              "name": "Folic Acid",
              "relevance": "LOW"
            },
            {
              "id": "T448",
              "name": "Folate",
              "relevance": "LOW"
            },
            {
              "id": "T475",
              "name": "Vitamin B9",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            },
            {
              "abbrev": "Micro",
              "name": "Micronutrients"
            },
            {
              "abbrev": "Hemat",
              "name": "Hematinics"
            },
            {
              "abbrev": "Vi",
              "name": "Vitamins"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02232438",
          "orgStudyIdInfo": {
            "id": "6797"
          },
          "organization": {
            "fullName": "New York State Psychiatric Institute",
            "class": "OTHER"
          },
          "briefTitle": "Psychotherapy for Depressed or Anxious Adolescents With Cancer",
          "officialTitle": "Open Trial of Behavioral Activation Therapy for Depressed or Anxious Adolescents With Cancer"
        },
        "statusModule": {
          "statusVerifiedDate": "2015-10",
          "overallStatus": "WITHDRAWN",
          "whyStopped": "No participants enrolled.",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2015-01"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2017-12",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2014-09-02",
          "studyFirstSubmitQcDate": "2014-09-02",
          "studyFirstPostDateStruct": {
            "date": "2014-09-05",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2015-10-05",
          "lastUpdatePostDateStruct": {
            "date": "2015-10-07",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "New York State Psychiatric Institute",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": true
        },
        "descriptionModule": {
          "briefSummary": "At present, there are no established treatments for depression or anxiety in adolescents with cancer, creating an important clinical and research gap. Fortunately, there is now substantial evidence documenting the efficacy of psychotherapy in the treatment of depressed and anxious adolescents in the general population.",
          "detailedDescription": "Despite the high prevalence of depression and anxiety in cancer patients, little is known about the efficacy of psychotherapy in depressed and anxious adolescents with cancer.\n\nBehavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients, including adult cancer patients. The goal of this open label clinical trial is to obtain preliminary evidence of the efficacy of BAT(6 sessions) in a group of adolescent cancer patients with MDD, GAD or adjustment disorder with mood or anxiety features.\n\nWe will test the efficacy of BAT using the Multidimensional Anxiety Scale for Children at several time points of the treatment."
        },
        "conditionsModule": {
          "conditions": [
            "Depression",
            "Anxiety",
            "Cancer"
          ],
          "keywords": [
            "Depression",
            "Psychotherapy",
            "Anxiety",
            "Cancer"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "NA"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "SINGLE",
              "whoMasked": [
                "OUTCOMES_ASSESSOR"
              ]
            }
          },
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Behavioral activation therapy",
              "type": "EXPERIMENTAL",
              "description": "Patients treated with Behavioral activation therapy will improve in mood and anxiety symptoms and psychosocial functioning at the end of the 6 weeks of treatment.",
              "interventionNames": [
                "Behavioral: Behavioral activation therapy"
              ]
            }
          ],
          "interventions": [
            {
              "type": "BEHAVIORAL",
              "name": "Behavioral activation therapy",
              "description": "Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).",
              "armGroupLabels": [
                "Behavioral activation therapy"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Change in Multidimensional Anxiety Scale for Children (MASC 2)",
              "description": "10 to 15 minutes of mood assessment.",
              "timeFrame": "baseline, and every two weeks till week 10"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* A primary psychiatric diagnosis of Major Depressive Disorder, Generalized Anxiety Disorder or Adjustment Disorder with Mood or Anxiety features as defined by DSM-IV.\n* Cancer patients.\n* Parent consent and child assent to participate for patients younger than 18. Patient consent for subjects 18-21.\n* Diagnosis of cancer (stage 1-4), but healthy enough to complete study procedures.\n\nExclusion Criteria:\n\n* Lifetime history of psychosis or bipolar disorder.\n* Current suicide risk.\n* History of substance abuse or dependence in the three months prior to the study.\n* Patients who have ever failed BAT in the context of cancer.\n* Receiving other concurrent therapy for same disorder and patients who are receiving effective medication for depression.\n* Mental retardation.\n* CNS tumors.\n* Patients undergoing Stem Cell Transplantation.",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years",
          "maximumAge": "21 Years",
          "stdAges": [
            "CHILD",
            "ADULT"
          ]
        },
        "contactsLocationsModule": {
          "locations": [
            {
              "facility": "New York State Psychiatric Institute",
              "city": "New York",
              "state": "New York",
              "zip": "10032",
              "country": "United States",
              "geoPoint": {
                "lat": 40.71427,
                "lon": -74.00597
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000003863",
              "term": "Depression"
            }
          ],
          "ancestors": [
            {
              "id": "D000001526",
              "term": "Behavioral Symptoms"
            }
          ],
          "browseLeaves": [
            {
              "id": "M4014",
              "name": "Anxiety Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M6748",
              "name": "Depression",
              "asFound": "Depression",
              "relevance": "HIGH"
            },
            {
              "id": "M6751",
              "name": "Depressive Disorder",
              "relevance": "LOW"
            },
            {
              "id": "M4508",
              "name": "Behavioral Symptoms",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BXM",
              "name": "Behaviors and Mental Disorders"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00171938",
          "orgStudyIdInfo": {
            "id": "CSTI571BBR03"
          },
          "organization": {
            "fullName": "Novartis",
            "class": "INDUSTRY"
          },
          "briefTitle": "Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)",
          "officialTitle": "Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)"
        },
        "statusModule": {
          "statusVerifiedDate": "2009-11",
          "overallStatus": "TERMINATED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2004-04",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2006-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2006-06",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2005-09-13",
          "studyFirstSubmitQcDate": "2005-09-13",
          "studyFirstPostDateStruct": {
            "date": "2005-09-15",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2017-02-23",
          "lastUpdatePostDateStruct": {
            "date": "2017-02-24",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "leadSponsor": {
            "name": "Novartis",
            "class": "INDUSTRY"
          }
        },
        "descriptionModule": {
          "briefSummary": "This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months"
        },
        "conditionsModule": {
          "conditions": [
            "Glioblastoma"
          ],
          "keywords": [
            "Glioblastoma",
            "Brain tumors",
            "Imatinib",
            "PDGFR"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NON_RANDOMIZED",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "type": "DRUG",
              "name": "imatinib mesylate"
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 months"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Objective Tumoral Response defined by RECISt criteria performed by MRI"
            },
            {
              "measure": "OS (overall survival)"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histologically documented diagnosis of GBM.\n2. Immunohistochemical documentation of expression of PDGFR.\n3. Unresectable, recurrent disease by MRI and spectroscopy\n\nExclusion Criteria:\n\n1. Treatment with any other investigational agents within 28 days of first day of study drug dosing.\n2. Concurrent chemotherapy.\n3. Concurrent radiotherapy.\n\nOther protocol-defined exclusion criteria may apply.",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Novartis",
              "affiliation": "Novartis",
              "role": "STUDY_CHAIR"
            }
          ],
          "locations": [
            {
              "city": "Rio Grande",
              "country": "Brazil",
              "geoPoint": {
                "lat": -32.035,
                "lon": -52.09861
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000005909",
              "term": "Glioblastoma"
            }
          ],
          "ancestors": [
            {
              "id": "D000001254",
              "term": "Astrocytoma"
            },
            {
              "id": "D000005910",
              "term": "Glioma"
            },
            {
              "id": "D000018302",
              "term": "Neoplasms, Neuroepithelial"
            },
            {
              "id": "D000017599",
              "term": "Neuroectodermal Tumors"
            },
            {
              "id": "D000009373",
              "term": "Neoplasms, Germ Cell and Embryonal"
            },
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000009375",
              "term": "Neoplasms, Glandular and Epithelial"
            },
            {
              "id": "D000009380",
              "term": "Neoplasms, Nerve Tissue"
            }
          ],
          "browseLeaves": [
            {
              "id": "M4899",
              "name": "Brain Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M14540",
              "name": "Recurrence",
              "relevance": "LOW"
            },
            {
              "id": "M8709",
              "name": "Glioblastoma",
              "asFound": "Glioblastoma",
              "relevance": "HIGH"
            },
            {
              "id": "M4251",
              "name": "Astrocytoma",
              "relevance": "LOW"
            },
            {
              "id": "M8710",
              "name": "Glioma",
              "relevance": "LOW"
            },
            {
              "id": "M20136",
              "name": "Neoplasms, Neuroepithelial",
              "relevance": "LOW"
            },
            {
              "id": "M19535",
              "name": "Neuroectodermal Tumors",
              "relevance": "LOW"
            },
            {
              "id": "M20078",
              "name": "Neuroectodermal Tumors, Primitive",
              "relevance": "LOW"
            },
            {
              "id": "M12008",
              "name": "Neoplasms, Germ Cell and Embryonal",
              "relevance": "LOW"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M12010",
              "name": "Neoplasms, Glandular and Epithelial",
              "relevance": "LOW"
            },
            {
              "id": "M12015",
              "name": "Neoplasms, Nerve Tissue",
              "relevance": "LOW"
            },
            {
              "id": "T2518",
              "name": "Glioblastoma",
              "asFound": "Glioblastoma",
              "relevance": "HIGH"
            },
            {
              "id": "T2519",
              "name": "Glioma",
              "relevance": "LOW"
            },
            {
              "id": "T4092",
              "name": "Neuroepithelioma",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC10",
              "name": "Nervous System Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC23",
              "name": "Symptoms and General Pathology"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000068877",
              "term": "Imatinib Mesylate"
            }
          ],
          "ancestors": [
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000047428",
              "term": "Protein Kinase Inhibitors"
            },
            {
              "id": "D000004791",
              "term": "Enzyme Inhibitors"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            }
          ],
          "browseLeaves": [
            {
              "id": "M324",
              "name": "Imatinib Mesylate",
              "asFound": "Inspiratory",
              "relevance": "HIGH"
            },
            {
              "id": "M11590",
              "name": "Mitogens",
              "relevance": "LOW"
            },
            {
              "id": "M25510",
              "name": "Protein Kinase Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M7641",
              "name": "Enzyme Inhibitors",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05049538",
          "orgStudyIdInfo": {
            "id": "PA19-0309"
          },
          "secondaryIdInfos": [
            {
              "id": "NCI-2021-08621",
              "type": "REGISTRY",
              "domain": "CTRP (Clinical Trial Reporting Program)"
            }
          ],
          "organization": {
            "fullName": "M.D. Anderson Cancer Center",
            "class": "OTHER"
          },
          "briefTitle": "Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers",
          "officialTitle": "A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers"
        },
        "statusModule": {
          "statusVerifiedDate": "2023-11",
          "overallStatus": "RECRUITING",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2019-06-18",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-06-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2024-06-30",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2021-09-07",
          "studyFirstSubmitQcDate": "2021-09-16",
          "studyFirstPostDateStruct": {
            "date": "2021-09-20",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2023-11-06",
          "lastUpdatePostDateStruct": {
            "date": "2023-11-07",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "M.D. Anderson Cancer Center",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": false,
          "isFdaRegulatedDrug": false,
          "isFdaRegulatedDevice": false,
          "isUsExport": false
        },
        "descriptionModule": {
          "briefSummary": "This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in patients with high-risk endometrial cancer. A liquid biopsy is a blood test that may be able to find cancer cells. Collecting and storing samples of blood and tissue from patients with endometrial cancer to study in the laboratory may help doctors learn how the cells in the blood may change during treatment for uterine cancer.",
          "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. Compare TP53, FBXW7, and other mutated gene variant allele frequencies (VAF) in serial circulating cell free deoxyribonucleic acid (ccfDNA) samples obtained from patients with high-risk endometrial cancer subtypes during the primary treatment course, which may include pretreatment, post-surgical removal, post adjuvant treatment, and at time of recurrence.\n\nII. Compare the findings from the liquid biopsy mutational analysis to next generation sequencing from the primary tumor.\n\nEXPLORATORY OBJECTIVES:\n\nI. To estimate the presence of malignant cells in the vagina before and after minimally invasive hysterectomy among patients with high-risk endometrial cancer.\n\nII. Characterize the immune profile and single cell ribonucleic acid (RNA) sequencing (scRNAseq) profile of high-risk endometrial cancer subtypes.\n\nIII. Estimate time to progression (TTP), and investigate potential correlations between mutated gene variant allele frequency (VAF) ccfDNA samples and progression.\n\nIV. Compare the efficacy of experimental ccfDNA assays to approved ccfDNA assay using the same samples.\n\nOUTLINE:\n\nPatients undergo collection of blood samples for liquid biopsy during pre-treatment consultation before hysterectomy, after hysterectomy but before starting any chemotherapy, and at the end of last chemotherapy cycle. Patients also undergo collection of tissue samples during hysterectomy. Patients may also undergo Pap smears before and after hysterectomy."
        },
        "conditionsModule": {
          "conditions": [
            "Endometrial Clear Cell Adenocarcinoma",
            "Endometrial Dedifferentiated Carcinoma",
            "Endometrial Mucinous Adenocarcinoma",
            "Endometrial Serous Adenocarcinoma",
            "Malignant Uterine Neoplasm",
            "Uterine Corpus Carcinosarcoma"
          ]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "designInfo": {
            "observationalModel": "COHORT",
            "timePerspective": "PROSPECTIVE"
          },
          "bioSpec": {
            "retention": "SAMPLES_WITH_DNA",
            "description": "Blood, tissue"
          },
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Observational (biospecimen collection, Pap smear)",
              "description": "Patients undergo collection of blood samples for liquid biopsy during pre-treatment consultation before hysterectomy, after hysterectomy but before starting any chemotherapy, and at the end of last chemotherapy cycle. Patients also undergo collection of tissue samples during hysterectomy. Patients may also undergo Pap smears before and after hysterectomy.",
              "interventionNames": [
                "Procedure: Biospecimen Collection",
                "Procedure: Liquid Biopsy",
                "Other: Pap Smear"
              ]
            }
          ],
          "interventions": [
            {
              "type": "PROCEDURE",
              "name": "Biospecimen Collection",
              "description": "Undergo collection of blood and tissue samples",
              "armGroupLabels": [
                "Observational (biospecimen collection, Pap smear)"
              ],
              "otherNames": [
                "Biological Sample Collection"
              ]
            },
            {
              "type": "PROCEDURE",
              "name": "Liquid Biopsy",
              "description": "Undergo liquid biopsy",
              "armGroupLabels": [
                "Observational (biospecimen collection, Pap smear)"
              ],
              "otherNames": [
                "Plasma Biopsy"
              ]
            },
            {
              "type": "OTHER",
              "name": "Pap Smear",
              "description": "Undergo Pap smear",
              "armGroupLabels": [
                "Observational (biospecimen collection, Pap smear)"
              ],
              "otherNames": [
                "Cervical Smear Preparation",
                "Cervical Smear Procedure",
                "Pap Smear Procedure",
                "Pap Test",
                "Papanicolaou Smear Procedure",
                "Papanicolaou Test",
                "Vaginal Smears"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Proportion of circulating cell free deoxyribonucleic acid (ccfDNA) mutations",
              "description": "The proportion of ccfDNA mutations determined by liquid biopsy will be calculated along with 95% confidence intervals, and comparison between treatment time points will be performed.",
              "timeFrame": "through study completion, an average of 1 year"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Women age 18 years and older\n* Diagnosis of high-risk uterine cancer, including carcinosarcoma, clear cell, mucinous, serous, and dedifferentiated tumors\n* Candidate for primary surgical treatment\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Patients who have received prior treatment including surgery, chemotherapy or radiation therapy for endometrial cancer. Note: patients with a history of other cancers may be enrolled after discussion with the principal investigator (PI) if it is determined that they are at low risk for recurrence or metastasis",
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ],
          "studyPopulation": "Patients with diagnosis of high-risk uterine cancer",
          "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Pamela T Soliman",
              "affiliation": "M.D. Anderson Cancer Center",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "M D Anderson Cancer Center",
              "status": "RECRUITING",
              "city": "Houston",
              "state": "Texas",
              "zip": "77030",
              "country": "United States",
              "contacts": [
                {
                  "name": "Pamela T. Soliman",
                  "role": "CONTACT",
                  "phone": "713-745-2352",
                  "email": "psoliman@mdanderson.org"
                },
                {
                  "name": "Pamela T. Soliman",
                  "role": "PRINCIPAL_INVESTIGATOR"
                }
              ],
              "geoPoint": {
                "lat": 29.76328,
                "lon": -95.36327
              }
            }
          ]
        },
        "referencesModule": {
          "seeAlsoLinks": [
            {
              "label": "M D Anderson Cancer Center",
              "url": "http://www.mdanderson.org"
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000000230",
              "term": "Adenocarcinoma"
            },
            {
              "id": "D000016889",
              "term": "Endometrial Neoplasms"
            },
            {
              "id": "D000018284",
              "term": "Cystadenocarcinoma, Serous"
            },
            {
              "id": "D000002296",
              "term": "Carcinosarcoma"
            },
            {
              "id": "D000018262",
              "term": "Adenocarcinoma, Clear Cell"
            },
            {
              "id": "D000002288",
              "term": "Adenocarcinoma, Mucinous"
            },
            {
              "id": "D000003536",
              "term": "Cystadenocarcinoma"
            },
            {
              "id": "D000014594",
              "term": "Uterine Neoplasms"
            },
            {
              "id": "D000012008",
              "term": "Recurrence"
            }
          ],
          "ancestors": [
            {
              "id": "D000002277",
              "term": "Carcinoma"
            },
            {
              "id": "D000009375",
              "term": "Neoplasms, Glandular and Epithelial"
            },
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000020969",
              "term": "Disease Attributes"
            },
            {
              "id": "D000010335",
              "term": "Pathologic Processes"
            },
            {
              "id": "D000005833",
              "term": "Genital Neoplasms, Female"
            },
            {
              "id": "D000014565",
              "term": "Urogenital Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000014591",
              "term": "Uterine Diseases"
            },
            {
              "id": "D000005831",
              "term": "Genital Diseases, Female"
            },
            {
              "id": "D000052776",
              "term": "Female Urogenital Diseases"
            },
            {
              "id": "D000005261",
              "term": "Female Urogenital Diseases and Pregnancy Complications"
            },
            {
              "id": "D000091642",
              "term": "Urogenital Diseases"
            },
            {
              "id": "D000091662",
              "term": "Genital Diseases"
            },
            {
              "id": "D000018297",
              "term": "Neoplasms, Cystic, Mucinous, and Serous"
            },
            {
              "id": "D000018193",
              "term": "Neoplasms, Complex and Mixed"
            },
            {
              "id": "D000012509",
              "term": "Sarcoma"
            },
            {
              "id": "D000018204",
              "term": "Neoplasms, Connective and Soft Tissue"
            }
          ],
          "browseLeaves": [
            {
              "id": "M5224",
              "name": "Carcinoma",
              "relevance": "LOW"
            },
            {
              "id": "M20098",
              "name": "Adenocarcinoma, Clear Cell",
              "asFound": "Clear Cell Adenocarcinoma",
              "relevance": "HIGH"
            },
            {
              "id": "M14540",
              "name": "Recurrence",
              "asFound": "Recurrence",
              "relevance": "HIGH"
            },
            {
              "id": "M3275",
              "name": "Adenocarcinoma",
              "asFound": "Adenocarcinoma",
              "relevance": "HIGH"
            },
            {
              "id": "M17032",
              "name": "Uterine Neoplasms",
              "asFound": "Uterine Neoplasms",
              "relevance": "HIGH"
            },
            {
              "id": "M5235",
              "name": "Adenocarcinoma, Mucinous",
              "asFound": "Mucinous Adenocarcinoma",
              "relevance": "HIGH"
            },
            {
              "id": "M6431",
              "name": "Cystadenocarcinoma",
              "asFound": "Mucinous Adenocarcinoma",
              "relevance": "HIGH"
            },
            {
              "id": "M20119",
              "name": "Cystadenocarcinoma, Serous",
              "asFound": "Serous Adenocarcinoma",
              "relevance": "HIGH"
            },
            {
              "id": "M5242",
              "name": "Carcinosarcoma",
              "asFound": "Carcinosarcoma",
              "relevance": "HIGH"
            },
            {
              "id": "M20036",
              "name": "Mixed Tumor, Mullerian",
              "relevance": "LOW"
            },
            {
              "id": "M18925",
              "name": "Endometrial Neoplasms",
              "asFound": "Endometrial Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M12010",
              "name": "Neoplasms, Glandular and Epithelial",
              "relevance": "LOW"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M22390",
              "name": "Disease Attributes",
              "relevance": "LOW"
            },
            {
              "id": "M8635",
              "name": "Genital Neoplasms, Female",
              "relevance": "LOW"
            },
            {
              "id": "M17005",
              "name": "Urogenital Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M17029",
              "name": "Uterine Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M2877",
              "name": "Genital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M8633",
              "name": "Genital Diseases, Female",
              "relevance": "LOW"
            },
            {
              "id": "M2876",
              "name": "Urogenital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M26783",
              "name": "Female Urogenital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M13817",
              "name": "Pregnancy Complications",
              "relevance": "LOW"
            },
            {
              "id": "M8089",
              "name": "Female Urogenital Diseases and Pregnancy Complications",
              "relevance": "LOW"
            },
            {
              "id": "M20131",
              "name": "Neoplasms, Cystic, Mucinous, and Serous",
              "relevance": "LOW"
            },
            {
              "id": "M15017",
              "name": "Sarcoma",
              "relevance": "LOW"
            },
            {
              "id": "M20040",
              "name": "Neoplasms, Connective and Soft Tissue",
              "relevance": "LOW"
            },
            {
              "id": "T200",
              "name": "Adenocarcinoma of the Appendix",
              "asFound": "Mucinous Adenocarcinoma",
              "relevance": "HIGH"
            },
            {
              "id": "T3586",
              "name": "Malignant Mixed Mullerian Tumor",
              "relevance": "LOW"
            },
            {
              "id": "T5820",
              "name": "Uterine Carcinosarcoma",
              "asFound": "Uterine Corpus Carcinosarcoma",
              "relevance": "HIGH"
            },
            {
              "id": "T5284",
              "name": "Soft Tissue Sarcoma",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC23",
              "name": "Symptoms and General Pathology"
            },
            {
              "abbrev": "BXS",
              "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03650738",
          "orgStudyIdInfo": {
            "id": "BL2014084"
          },
          "organization": {
            "fullName": "The First Affiliated Hospital with Nanjing Medical University",
            "class": "OTHER"
          },
          "briefTitle": "This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment",
          "officialTitle": "A Prospective, One-arm Open Clinical Trial of Apatinib Combined With Albumin Paclitaxel and Carboplatin as a Neoadjuvant Therapy for the Safety and Efficacy of Triple-negative Breast Cancer"
        },
        "statusModule": {
          "statusVerifiedDate": "2018-08",
          "overallStatus": "UNKNOWN",
          "lastKnownStatus": "RECRUITING",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2018-09-01",
            "type": "ESTIMATED"
          },
          "primaryCompletionDateStruct": {
            "date": "2019-12-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2019-12-31",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2018-08-27",
          "studyFirstSubmitQcDate": "2018-08-28",
          "studyFirstPostDateStruct": {
            "date": "2018-08-29",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2018-08-28",
          "lastUpdatePostDateStruct": {
            "date": "2018-08-29",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "The First Affiliated Hospital with Nanjing Medical University",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "isFdaRegulatedDrug": true,
          "isFdaRegulatedDevice": false,
          "isUsExport": true
        },
        "descriptionModule": {
          "briefSummary": "This study was a prospective, one-arm open phase II clinical trial. A systematic review of the pCR of apatinib in combination with the albumin paclitaxel and carboplatin regimens for the neoadjuvant therapy of triple-negative breast cancer, as well as the safety of treatment, at the same time, relevant exploratory biomarker research is conducted.",
          "detailedDescription": "Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated. If there is still no PD after 6 cycles, the surgical approach is based on the tumor condition and the patient's wishes. If the condition progresses to terminate the treatment regimen, the patient may receive subsequent local or systemic treatment. The follow-up period was followed up to assess safety and effectiveness.\n\nMAIN OBJECTIVE: To systematically evaluate the pCR rate of apatinib combined with albumin paclitaxel and carboplatin regimen for neoadjuvant therapy of triple-negative breast cancer Secondary objective: To evaluate the safety of apatinib combined with albumin paclitaxel and carboplatin in neoadjuvant therapy for triple-negative breast cancer, an exploratory biomarker study"
        },
        "conditionsModule": {
          "conditions": [
            "Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Study group",
              "type": "EXPERIMENTAL",
              "description": "apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.",
              "interventionNames": [
                "Drug: Apatinib"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "Apatinib",
              "description": "Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.",
              "armGroupLabels": [
                "Study group"
              ],
              "otherNames": [
                "Carboplatin",
                "albumin paclitaxel"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "pCR rate",
              "description": "The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.",
              "timeFrame": "4 months"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* 1. The patient volunteers and signs an informed consent form. 2.age ≥18 years old, female; 3.Diagnosed as triple negative breast cancer by histopathology; 4.Did not receive systemic anti-tumor treatment; 5. The clinical stage is stage II-III; 6.There must be at least one measurable lesion (according to RECIST v1.1); 7.Physical condition ECOG PS: 0-1; 8.Expected survival time ≥ 3 months; 9.Laboratory tests meet the following criteria: Bone marrow function: absolute count of blood neutrophils (ANC) ≥1.5×109/L; platelet (PLT)≥100×109/L; hemoglobin (HB)≥90g/L; Liver function: serum total bilirubin (STB), combined bilirubin (CB) ≤ upper limit of normal (ULN) \\*1.5; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ULN\\*2.5; Renal function: serum creatinine (Cr) ≤ ULN; endogenous creatinine clearance (Ccr) ≥ 60 ml / min (calculated using the Cockcroft-Gault formula);\n\nExclusion Criteria:\n\n* 1.Major surgery within 4 weeks prior to enrollment, or surgical wounds have not healed; 2.Embolization and bleeding occurred within 4 weeks before enrollment; 3.Malignant tumors of other histological origins in the past 5 years, except for cured cervical carcinoma in situ and basal cell carcinoma or squamous cell carcinoma; 4.Severe cardiovascular disease, including hypertension (BP≥160/95mmHg) uncontrolled by medical treatment, unstable angina, history of myocardial infarction in the past 6 months, congestive heart failure\\>NYHA II, severe heart rhythm Abnormalities and pericardial effusions; 5.Severe infection requires intravenous antibiotic, antifungal or antiviral treatment; 6.Suffering from mental illness, poor compliance; 7.Researchers believe that it is not suitable for inclusion.",
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "centralContacts": [
            {
              "name": "Li Wei",
              "role": "CONTACT",
              "phone": "13851603656",
              "email": "real.lw@163.com"
            },
            {
              "name": "Yin Yongmei",
              "role": "CONTACT",
              "phone": "13951842727"
            }
          ],
          "locations": [
            {
              "facility": "Jiangsu Provincial Hospital",
              "status": "RECRUITING",
              "city": "Nanjing",
              "state": "Jiangsu",
              "zip": "210000",
              "country": "China",
              "contacts": [
                {
                  "name": "Tang Jinhai",
                  "role": "CONTACT"
                }
              ],
              "geoPoint": {
                "lat": 32.06167,
                "lon": 118.77778
              }
            }
          ]
        },
        "ipdSharingStatementModule": {
          "ipdSharing": "NO"
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000001943",
              "term": "Breast Neoplasms"
            },
            {
              "id": "D000064726",
              "term": "Triple Negative Breast Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000001941",
              "term": "Breast Diseases"
            },
            {
              "id": "D000012871",
              "term": "Skin Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M4910",
              "name": "Breast Neoplasms",
              "asFound": "Breast Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M30063",
              "name": "Triple Negative Breast Neoplasms",
              "asFound": "Triple Negative Breast Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M4908",
              "name": "Breast Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M15364",
              "name": "Skin Diseases",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC17",
              "name": "Skin and Connective Tissue Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000017239",
              "term": "Paclitaxel"
            },
            {
              "id": "D000016190",
              "term": "Carboplatin"
            },
            {
              "id": "C000553458",
              "term": "Apatinib"
            }
          ],
          "ancestors": [
            {
              "id": "D000000972",
              "term": "Antineoplastic Agents, Phytogenic"
            },
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000050257",
              "term": "Tubulin Modulators"
            },
            {
              "id": "D000050256",
              "term": "Antimitotic Agents"
            },
            {
              "id": "D000050258",
              "term": "Mitosis Modulators"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            },
            {
              "id": "D000047428",
              "term": "Protein Kinase Inhibitors"
            },
            {
              "id": "D000004791",
              "term": "Enzyme Inhibitors"
            }
          ],
          "browseLeaves": [
            {
              "id": "M18340",
              "name": "Carboplatin",
              "asFound": "Level",
              "relevance": "HIGH"
            },
            {
              "id": "M19227",
              "name": "Paclitaxel",
              "asFound": "In Patients",
              "relevance": "HIGH"
            },
            {
              "id": "M231",
              "name": "Albumin-Bound Paclitaxel",
              "relevance": "LOW"
            },
            {
              "id": "M288146",
              "name": "Apatinib",
              "asFound": "Size",
              "relevance": "HIGH"
            },
            {
              "id": "M25887",
              "name": "Tubulin Modulators",
              "relevance": "LOW"
            },
            {
              "id": "M25886",
              "name": "Antimitotic Agents",
              "relevance": "LOW"
            },
            {
              "id": "M25510",
              "name": "Protein Kinase Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M7641",
              "name": "Enzyme Inhibitors",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06132438",
          "orgStudyIdInfo": {
            "id": "INTERROGATE-GBM"
          },
          "organization": {
            "fullName": "The University of New South Wales",
            "class": "OTHER"
          },
          "briefTitle": "Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma",
          "officialTitle": "Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma (INTERROGATE-GBM)"
        },
        "statusModule": {
          "statusVerifiedDate": "2023-11",
          "overallStatus": "NOT_YET_RECRUITING",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2023-11",
            "type": "ESTIMATED"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-09",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2023-11-02",
          "studyFirstSubmitQcDate": "2023-11-09",
          "studyFirstPostDateStruct": {
            "date": "2023-11-15",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2023-11-09",
          "lastUpdatePostDateStruct": {
            "date": "2023-11-15",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR_INVESTIGATOR",
            "investigatorFullName": "Charlotte Lemech",
            "investigatorTitle": "Principal Investigator",
            "investigatorAffiliation": "The University of New South Wales"
          },
          "leadSponsor": {
            "name": "Charlotte Lemech",
            "class": "OTHER"
          },
          "collaborators": [
            {
              "name": "The University of New South Wales",
              "class": "OTHER"
            }
          ]
        },
        "oversightModule": {
          "isFdaRegulatedDrug": false,
          "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
          "briefSummary": "In Australia, glioblastoma (GBM) has a higher annual fatality rate than a variety of other cancers, such as melanoma, bladder, and kidney tumors. While the 5-year survival rate for other cancers, such as breast and prostate cancer, has increased, there have been no notable advancements in GBM during the past ten years, and the incidence and mortality patterns have barely changed between 1982 and 2011. In particular, GBM poses a challenging therapeutic dilemma for patients and physicians due to its aggressive biology and resistance to available treatments. Recent studies showed that cytomegalovirus (CMV) is expressed in GBM tumors, making it a good target for immunotherapy trials. This phase I trial aims to determine the safety and tolerability of the PEP-CMV vaccine in patients with newly diagnosed MGMT-unmethylated GBM in combination with one cycle of adjuvant temozolomide."
        },
        "conditionsModule": {
          "conditions": [
            "Glioblastoma"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE1"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 26,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Glioblastoma",
              "type": "EXPERIMENTAL",
              "interventionNames": [
                "Drug: PEP-CMV vaccine"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "PEP-CMV vaccine",
              "description": "The PEP-CMV vaccine is a long synthetic peptide (PEP) made up of 26 amino acids that is derived from the human cytomegalovirus (CMV) matrix protein pp65 and has both MHC class I and II epitopes. A vaccine platform that initially consists of TMZ-induced lymphopenia and Td pre-conditioning will be used, with serial vaccinations of up to 12 times (maximum 20) being applied. To ensure the effectiveness of the future Td pre-conditioning, which is given right before the initial PEP-CMV vaccine, a Td booster is required at enrollment.",
              "armGroupLabels": [
                "Glioblastoma"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Percentage of participants with treatment-related adverse events according to NCI CTCAE V5.0.",
              "description": "To assess the safety of PEP-CMV vaccination in combination with adjuvant TMZ, the percentage of patients with unacceptable toxicity will be estimated within each arm. All patients who receive any PEP-CMV vaccine will be included in these analyses.",
              "timeFrame": "2 weeks after the 3rd vaccine, which is approximately 12 weeks after consent."
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Immunologic response as measured by peak number of T cells that secrete IFNy by ELISPOT in response to component A of PEP-CMV.",
              "timeFrame": "Through study completion, an average of 1.5 years."
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histopathologically proven newly diagnosed primary glioblastoma.\n3. Patients must have tumours which are MGMT-unmethylated.\n4. Patients must be CMV-seropositive.\n5. The tumour must be supratentorial.\n6. Received debulking surgery. This includes complete or partial surgical resection. Biopsy alone is not acceptable.\n7. Will have undergone standard concurrent radiotherapy (XRT) and temozolomide (TMZ) by the time of stage 2 participation consent.\n8. Patients who are being treated with stable or decreasing doses of dexamethasone (\\>/= 4 mg/day) or other steroid equivalent, at the time of post-XRT adjuvant TMZ initiation.\n9. Brain MRI (gadolinium-enhanced) within 31 days prior to the adjuvant TMZ.\n10. Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to stage 2 participant consent and should remain stable prior to the commencement of adjuvant TMZ.\n11. ECOG 0-2 if \\>/= 70 years. ECOG 0-1 if aged \\> 70 years.\n12. Life expectancy of \\> 12 weeks.\n13. Adequate bone marrow function:\n\n    * platelet count ≥ 100 x 109/L\n    * absolute neutrophil count (ANC) ≥ 1.5 x 109/L\n    * Haemoglobin ≥ 10g/dl.\n14. Adequate liver function:\n\n    * (alanine transaminase (ALT)/aspartate transaminase (AST) ≤ 3.0 times the upper limit of normal (ULN)).\n    * Total bilirubin ≤ 1.5 x ULN (Exception: Patient has known Gilbert's Syndrome or is suspected of having it, for which additional lab testing of direct and/or indirect bilirubin supports this diagnosis. In these instances, a total bilirubin of ≤ 3.0 x ULN is acceptable).\n15. Adequate renal function:\n\n    • creatinine ≤ 1.5 x ULN\n16. Willing to comply with all study requirements, including treatment, timing and/or nature of required assessments\n17. Signed, written informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or need to breastfeed during the study period (Negative serum pregnancy test required for women of childbearing potential). Not adhering to pregnancy prevention recommendations.\n2. Active infection requiring treatment or an unexplained febrile (\\> 39 C) illness within a week of starting the trial.\n3. Patients with previous inguinal lymph node dissection, radiosurgery, brachytherapy, or radiolabelled monoclonal antibodies.\n4. Prior allogeneic solid organ transplant. Currently receiving or ever received immunosuppressive therapy for an organ transplant.\n5. Active or prior documented autoimmune or immunosuppressive disease that has required systemic treatment (i.e. with the use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy such as thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is allowed. Use of non-systemic topical steroids is allowed.\n6. Patients receiving immunosuppressive medication or prior use within 14 days before the first dose of investigational product are excluded, except for systemic steroids up to 4 mg dexamethasone per day for the management of CNS symptoms.\n7. Patients on bevacizumab or who have received prior bevacizumab as management for their GBM\n8. Known human immunodeficiency virus infection and/or hepatitis B or C infections OR known to be positive for hepatitis B antigen (HBsAg)/Hepatitis B virus (HBV) DNA or Hepatitis C antibody or RNA.\n9. Patients with poorly controlled, unstable or severe intercurrent medical conditions such as renal, cardiac (congestive cardiac failure, myocardial infarction within 6 months, myocarditis), or pulmonary disease or other condition, therapy or laboratory abnormality that might confound the results of the study, interfere with the patient's participation, make administration of the study drug hazardous or make it difficult to monitor adverse effects, in the opinion of the treating physician.\n10. Prior conventional antitumour therapy, other than steroids, RT or TMZ therapy given for glioblastoma.\n11. Allergic or unable to tolerate TMZ for any reason. Any patient that successfully completed at least 5 weeks of TMZ during standard of care XRT/TMZ and whose blood counts meet the eligibility requirements (inclusion #13) within 6 weeks post XRT/TMZ is eligible.\n12. Patients receiving any other investigational drug therapy or having participated in an investigational drug/device study within 4 weeks prior to the first dose of study treatment.\n13. Specific comorbidities or conditions (e.g. psychiatric) or concomitant medications which may impact the administration of study-related treatments or procedures.\n14. Radiographic or cytologic evidence of leptomeningeal or multifocal disease at any time prior to treatment.\n15. History of another malignancy within 2 years prior to registration. Patients with a history of adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or superficial transitional cell carcinoma of the bladder are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease-free for at least 2 years after definitive primary treatment.\n16. Receipt of other live and attenuated vaccines within 30 days of treatment product will be excluded.\n17. Unresolved toxicities from prior anticancer therapy, defined as not having resolved to NCI CTCAE grade 0 or 1, with the exception of alopecia.\n18. Patients with a prior severe hypersensitivity reaction to treatment with any monoclonal antibody and/or components of the study vaccine.\n19. Patients with any known severe allergies to gadolinium contrast agents.",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000005909",
              "term": "Glioblastoma"
            }
          ],
          "ancestors": [
            {
              "id": "D000001254",
              "term": "Astrocytoma"
            },
            {
              "id": "D000005910",
              "term": "Glioma"
            },
            {
              "id": "D000018302",
              "term": "Neoplasms, Neuroepithelial"
            },
            {
              "id": "D000017599",
              "term": "Neuroectodermal Tumors"
            },
            {
              "id": "D000009373",
              "term": "Neoplasms, Germ Cell and Embryonal"
            },
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000009375",
              "term": "Neoplasms, Glandular and Epithelial"
            },
            {
              "id": "D000009380",
              "term": "Neoplasms, Nerve Tissue"
            }
          ],
          "browseLeaves": [
            {
              "id": "M8709",
              "name": "Glioblastoma",
              "asFound": "Glioblastoma",
              "relevance": "HIGH"
            },
            {
              "id": "M4251",
              "name": "Astrocytoma",
              "relevance": "LOW"
            },
            {
              "id": "M8710",
              "name": "Glioma",
              "relevance": "LOW"
            },
            {
              "id": "M20136",
              "name": "Neoplasms, Neuroepithelial",
              "relevance": "LOW"
            },
            {
              "id": "M19535",
              "name": "Neuroectodermal Tumors",
              "relevance": "LOW"
            },
            {
              "id": "M20078",
              "name": "Neuroectodermal Tumors, Primitive",
              "relevance": "LOW"
            },
            {
              "id": "M12008",
              "name": "Neoplasms, Germ Cell and Embryonal",
              "relevance": "LOW"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M12010",
              "name": "Neoplasms, Glandular and Epithelial",
              "relevance": "LOW"
            },
            {
              "id": "M12015",
              "name": "Neoplasms, Nerve Tissue",
              "relevance": "LOW"
            },
            {
              "id": "T2518",
              "name": "Glioblastoma",
              "asFound": "Glioblastoma",
              "relevance": "HIGH"
            },
            {
              "id": "T2519",
              "name": "Glioma",
              "relevance": "LOW"
            },
            {
              "id": "T4092",
              "name": "Neuroepithelioma",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "browseLeaves": [
            {
              "id": "M17050",
              "name": "Vaccines",
              "relevance": "LOW"
            },
            {
              "id": "M2854",
              "name": "Immunomodulating Agents",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05225038",
          "orgStudyIdInfo": {
            "id": "CASE8221"
          },
          "organization": {
            "fullName": "Case Comprehensive Cancer Center",
            "class": "OTHER"
          },
          "briefTitle": "Multidimensional Prehabilitation in Pancreatic Surgery for Pancreatic and Periampullary Neoplasms",
          "officialTitle": "Randomized Clinical Trial Investigating Multidimensional Prehabilitation in Pancreatic Surgery for Patients With Pancreatic and Periampullary Neoplasms"
        },
        "statusModule": {
          "statusVerifiedDate": "2024-01",
          "overallStatus": "ENROLLING_BY_INVITATION",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2022-06-13",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-06-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2022-01-10",
          "studyFirstSubmitQcDate": "2022-01-25",
          "studyFirstPostDateStruct": {
            "date": "2022-02-04",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2024-01-05",
          "lastUpdatePostDateStruct": {
            "date": "2024-01-08",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "Case Comprehensive Cancer Center",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": true,
          "isFdaRegulatedDrug": false,
          "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
          "briefSummary": "Randomized Clinical Trial Investigating Multidimensional Prehabilitation in Pancreatic Surgery for participants with Pancreatic and Periampullary Neoplasms",
          "detailedDescription": "Frailty is independently associated with an increased risk of adverse outcomes after major surgery, including pancreatic resection. Prehabilitation aims to optimize modifiable risk factors to improve participants' baseline health prior to surgery. Multiple studies with participants undergoing pancreatic surgery have investigated the impact of prehabilitation on preoperative health metrics as well as postoperative outcomes. The majority of these studies focused only on exercise; if nutritional and/or psychological status were assessed, these dimensions were not intervened upon in prehabilitation regimens or reassessed postoperatively. This randomized controlled trial (RCT) is designed to assess the impact of physical and nutritional prehabilitation on participants' perioperative condition for those undergoing pancreatic resection for diagnosed or suspected pancreatic and periampullary neoplasms."
        },
        "conditionsModule": {
          "conditions": [
            "Pancreatic Neoplasms",
            "Periampullary Carcinoma"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "NA"
          ],
          "designInfo": {
            "allocation": "RANDOMIZED",
            "interventionModel": "PARALLEL",
            "primaryPurpose": "SUPPORTIVE_CARE",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Control Arm (Standard of Care)",
              "type": "ACTIVE_COMPARATOR",
              "description": "Participants will receive the current standard preoperative education and counseling. Participants will receive information regarding exercise and nutrition from a member of the surgical team. Participants will meet with a behavioral medicine specialist for additional education regarding factors affecting postoperative stress and relaxation techniques. Participants who are actively smoking will be counseled regarding smoking cessation and offered a referral to smoking cessation resources.",
              "interventionNames": [
                "Behavioral: Behavioral Medicine",
                "Behavioral: Smoking Cessation"
              ]
            },
            {
              "label": "Intervention Arm (Prehabilitation)",
              "type": "EXPERIMENTAL",
              "description": "Participants in the intervention arm will receive all of the standard of care, as listed above, as well as individualized exercise and nutritional prehabilitation regimens.\n\nDuring the data analysis, participants will be subdivided into treatment groups, upfront surgical resection versus neoadjuvant chemotherapy, in order to determine whether length of prehabilitation affected outcomes and distinguish any possible effect of chemotherapy toxicity.",
              "interventionNames": [
                "Other: Exercise",
                "Dietary Supplement: Nutritional",
                "Behavioral: Behavioral Medicine",
                "Behavioral: Smoking Cessation"
              ]
            }
          ],
          "interventions": [
            {
              "type": "OTHER",
              "name": "Exercise",
              "description": "Participants will meet with an exercise physiologist to undergo evaluation and develop individualized regimens for prehabilitation.",
              "armGroupLabels": [
                "Intervention Arm (Prehabilitation)"
              ]
            },
            {
              "type": "DIETARY_SUPPLEMENT",
              "name": "Nutritional",
              "description": "Participants will meet with a nutritionist to undergo evaluation and develop individualized regimens for prehabilitation.",
              "armGroupLabels": [
                "Intervention Arm (Prehabilitation)"
              ]
            },
            {
              "type": "BEHAVIORAL",
              "name": "Behavioral Medicine",
              "description": "Participants will have 1 appointment with behavioral medicine - all participants will meet with the same behavioral medicine specialist to ensure consistency. Participants will receive education regarding factors that affect postoperative recovery and relaxation techniques.\n\nParticipants will also have the option to request faith support.",
              "armGroupLabels": [
                "Control Arm (Standard of Care)",
                "Intervention Arm (Prehabilitation)"
              ]
            },
            {
              "type": "BEHAVIORAL",
              "name": "Smoking Cessation",
              "description": "Participants who are actively smoking will be counseled regarding smoking cessation during their preoperative appointment with a member of the surgical team. They will also be offered a referral to smoking cessation resources.",
              "armGroupLabels": [
                "Control Arm (Standard of Care)",
                "Intervention Arm (Prehabilitation)"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Change in participants physical capacity, as represented by hand grip strength",
              "description": "Previous studies have demonstrated that grip strength is a predictor of surgical outcomes and mortality in cancer participants. Grip strength will be measured utilizing the Jamar Dynamometer.",
              "timeFrame": "3 weeks after the surgery"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Mortality Rate",
              "description": "Death due to any cause postoperatively.",
              "timeFrame": "Up to 90 days after the surgery"
            },
            {
              "measure": "Morbidity rate",
              "description": "Classified according to the Clavien-Dindo Classification of postoperative complications.",
              "timeFrame": "Up to 90 days after the surgery"
            },
            {
              "measure": "Physical capacity as represented by 30s CST (Chair Stand Test )",
              "description": "Participants rise to full standing position from sitting in a chair as many times as possible within 30 seconds. The 30s CST has been utilized as a reliable test of lower extremity strength.",
              "timeFrame": "3 weeks after the surgery"
            },
            {
              "measure": "Physical capacity as represented by 6-Minute Walk Test",
              "description": "Participants will walk as far as possible in 6 min at a comfortable pace but do not run or jog. If participants cannot complete the full 6 min walk, then record the time and distance walked and the reason for stopping early.",
              "timeFrame": "3 weeks after the surgery"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants \\> 18 years old with ECOG performance status 0-2 and ASA score ≤3\n* Requiring pancreatic resection for diagnosed or suspected pancreatic and periampullary neoplasms\n* Surgery scheduled at least 2 weeks after the initial surgical evaluation\n* Fluency in English\n\n  * Willingness to answer questionnaires, complete daily exercise \\& nutrition log, as well as participate in follow-up telephone calls\n* Screening: Physical Activity Readiness - Questionnaire (PAR-Q+)\n\n  * PAR-Q+ assesses participants comorbidities and symptoms with current activities. If participants answer \"yes\" to any of the screening questions, they will need to complete additional questions regarding their chronic medical conditions including, but not limited to, heart disease, stroke, diabetes, depression/anxiety, and COPD/asthma, to determine their ability to participate in physical activity.\n\nExclusion Criteria:\n\n* Screening: Physical Activity Readiness - Questionnaire (PAR-Q+)\n\n  * Participants with concurrent medical conditions that prohibit exercise, such as those who indicate on the questionnaire that they experience chest pain, dizziness, or loss of consciousness with physical activity; those with chest pain at rest; or those with bone/joint/soft tissue conditions that could worsen with physical activity. Participants with specific comorbidities, such as coronary artery disease. congestive heart failure, or uncontrolled asthma/COPD, that may prevent participation will also be excluded.\n* Inability to provide own informed consent\n* Inability to read or verbally understand questionnaires in English\n* Impaired hearing that creates a barrier for telephone follow-up\n* Visual deficit that would cause exercise to be hazardous\n* Emergent or urgent surgeries",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "locations": [
            {
              "facility": "Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center",
              "city": "Cleveland",
              "state": "Ohio",
              "zip": "44195",
              "country": "United States",
              "geoPoint": {
                "lat": 41.4995,
                "lon": -81.69541
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000010190",
              "term": "Pancreatic Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000004067",
              "term": "Digestive System Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000004701",
              "term": "Endocrine Gland Neoplasms"
            },
            {
              "id": "D000004066",
              "term": "Digestive System Diseases"
            },
            {
              "id": "D000010182",
              "term": "Pancreatic Diseases"
            },
            {
              "id": "D000004700",
              "term": "Endocrine System Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M12800",
              "name": "Pancreatic Neoplasms",
              "asFound": "Pancreatic Neoplasms",
              "relevance": "HIGH"
            },
            {
              "id": "M5224",
              "name": "Carcinoma",
              "relevance": "LOW"
            },
            {
              "id": "M8576",
              "name": "Gastrointestinal Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M6946",
              "name": "Digestive System Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M7553",
              "name": "Endocrine Gland Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M8573",
              "name": "Gastrointestinal Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M6945",
              "name": "Digestive System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M12792",
              "name": "Pancreatic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M7552",
              "name": "Endocrine System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "T4387",
              "name": "Pancreatic Cancer",
              "asFound": "Pancreatic Neoplasms",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC06",
              "name": "Digestive System Diseases"
            },
            {
              "abbrev": "BC19",
              "name": "Gland and Hormone Related Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00238238",
          "orgStudyIdInfo": {
            "id": "CALGB-50401"
          },
          "secondaryIdInfos": [
            {
              "id": "CALGB-50401"
            },
            {
              "id": "U10CA031946",
              "type": "NIH",
              "link": "https://reporter.nih.gov/quickSearch/U10CA031946"
            },
            {
              "id": "CDR0000442872",
              "type": "REGISTRY",
              "domain": "NCI Physician Data Query"
            }
          ],
          "organization": {
            "fullName": "Alliance for Clinical Trials in Oncology",
            "class": "OTHER"
          },
          "briefTitle": "Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab",
          "officialTitle": "A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory"
        },
        "statusModule": {
          "statusVerifiedDate": "2017-02",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2006-03"
          },
          "primaryCompletionDateStruct": {
            "date": "2012-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2005-10-12",
          "studyFirstSubmitQcDate": "2005-10-12",
          "studyFirstPostDateStruct": {
            "date": "2005-10-13",
            "type": "ESTIMATED"
          },
          "resultsFirstSubmitDate": "2016-12-15",
          "resultsFirstSubmitQcDate": "2016-12-15",
          "resultsFirstPostDateStruct": {
            "date": "2017-02-07",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2017-02-06",
          "lastUpdatePostDateStruct": {
            "date": "2017-03-15",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "Alliance for Clinical Trials in Oncology",
            "class": "OTHER"
          },
          "collaborators": [
            {
              "name": "National Cancer Institute (NCI)",
              "class": "NIH"
            }
          ]
        },
        "oversightModule": {
          "oversightHasDmc": false
        },
        "descriptionModule": {
          "briefSummary": "Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide may also stop the growth of non-Hodgkin's lymphoma by blocking blood flow to the cancer. Giving rituximab together with lenalidomide may kill more cancer cells. This randomized phase II trial is studying how well rituximab and/or lenalidomide work in treating patients with follicular non-Hodgkin's lymphoma that is not refractory to rituximab.",
          "detailedDescription": "Outline:\n\nThis is a randomized, multicenter study. Patients are randomized to 1 of 3 treatment arms. Please see the \"Arms\" section for a description of each treatment arm. The primary and secondary objectives of the study are provided below.\n\nPrimary Objectives:\n\n* To determine the response rate (overall and complete) after lenalidomide therapy and rituximab + lenalidomide in follicular NHL patients who have relapsed.\n* To determine time to progression after lenalidomide therapy and rituximab and lenalidomide in follicular NHL patients who have relapsed.\n\nSecondary Objectives:\n\n* To compare the time to progression of the previous rituximab regimen to that obtained subsequently to lenalidomide therapy and rituximab + lenalidomide.\n* To determine the toxicity profile of lenalidomide therapy and of rituximab and lenalidomide in follicular NHL patients who have received a previous rituximab regimen.\n* To correlate Fc receptor polymorphism profiling with response to lenalidomide or rituximab + lenalidomide in previously treated patients with follicular NHL who have relapsed.\n* To evaluate changes in Natural Killer (NK) cells, activated NK cells, activated T-cells and several plasma cytokines followed by rituximab therapy and correlation of observed changes to objective response rates.\n\nAfter completion of study treatment, patients are followed for up to 10 years from study entry."
        },
        "conditionsModule": {
          "conditions": [
            "Lymphoma"
          ],
          "keywords": [
            "recurrent grade 1 follicular lymphoma",
            "recurrent grade 2 follicular lymphoma",
            "recurrent grade 3 follicular lymphoma"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "RANDOMIZED",
            "interventionModel": "PARALLEL",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 97,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Arm I - rituximab",
              "type": "ACTIVE_COMPARATOR",
              "description": "Patients receive rituximab IV on days 1, 8, 15, and 22.",
              "interventionNames": [
                "Biological: rituximab"
              ]
            },
            {
              "label": "Arm II - lenalidomide",
              "type": "EXPERIMENTAL",
              "description": "Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.",
              "interventionNames": [
                "Drug: lenalidomide"
              ]
            },
            {
              "label": "Arm III - lenalidomide and rituximab",
              "type": "EXPERIMENTAL",
              "description": "Patients receive lenalidomide as in arm II. Patients also receive rituximab IV on days 8, 15, 22 and 29.",
              "interventionNames": [
                "Biological: rituximab",
                "Drug: lenalidomide"
              ]
            }
          ],
          "interventions": [
            {
              "type": "BIOLOGICAL",
              "name": "rituximab",
              "description": "Given IV",
              "armGroupLabels": [
                "Arm I - rituximab",
                "Arm III - lenalidomide and rituximab"
              ]
            },
            {
              "type": "DRUG",
              "name": "lenalidomide",
              "description": "Given orally",
              "armGroupLabels": [
                "Arm II - lenalidomide",
                "Arm III - lenalidomide and rituximab"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Overall Response Rate",
              "description": "Response is assessed by investigator according to International Working Group (IWG) criteria. A complete response requires disappearance of all evidence of disease. A partial response is a \\>/= 50% decrease in the sum of products of 6 largest dominant nodes or nodal masses as well as for splenic and hepatic nodules. No increase in size of nodes, liver or spleen and no new sites of disease.",
              "timeFrame": "Duration of treatment (12 cycles)"
            },
            {
              "measure": "Time to Progression",
              "description": "Time to progression (TTP) is defined as the time from study entry until progression or death without progression. The median TTP with 95% CI was estimated using the Kaplan-Meier method.",
              "timeFrame": "Up to 10 years"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "* Documentation of Disease\n\n  * Previously treated, histologically confirmed follicle center cell lymphoma, World Health Organization (WHO) classification, grade 1, 2, or 3a\n  * Institutional flow cytometry or immunohistochemistry must confirm Cluster of Differentiation 20 (CD20) antigen expression.\n* Prior Treatment\n\n  * Patient must have been treated with rituximab either alone or in combination with chemotherapy.\n  * Patient must have a time to progression of ≥ 6 months from last rituximab dose.\n  * No corticosteroids within two weeks prior to study, except for maintenance therapy for a non-malignant disease. Maintenance therapy dose may not exceed 20 mg/day prednisone or equivalent.\n  * No prior radioimmunotherapy within 12 months of study entry.\n* Age ≥ 18 years.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.\n* Measurable disease must be present either on physical examination or imaging studies. Non-measurable disease alone is not acceptable. Any tumor mass \\>1 cm is acceptable.Lesions that are considered non-measurable include the following:\n\n  * Bone lesions\n  * Ascites\n  * Pleural/pericardial effusion\n  * Lymphangitis cutis/pulmonis\n  * Bone marrow\n* No known Central Nervous System (CNS) involvement by lymphoma.\n* No known Human Immunodeficiency Virus (HIV) infection.\n* Non-pregnant and non-nursing.\n* Patients with a \"currently active\" second malignancy, other than non-melanoma skin cancers, are not eligible.\n* Patients with a recent history (within 3 months of study entry) of Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) are not eligible.\n* Required Initial Laboratory Values:\n\n  * Absolute Neutrophil Count (ANC) ≥ 1000/µL\n  * Platelet count ≥ 75,000/µL\n  * Creatinine \\< 1.5 x Upper Limit of Normal (ULN) unless attributed to lymphoma or calculated clearance \\> 50 mL/min (patients on dialysis are not eligible)\n  * Total Bilirubin ≤ 2 x ULN unless attributed to lymphoma or Gilbert's disease",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "John P. Leonard, MD",
              "affiliation": "Weill Medical College of Cornell University",
              "role": "STUDY_CHAIR"
            }
          ],
          "locations": [
            {
              "facility": "Rebecca and John Moores UCSD Cancer Center",
              "city": "La Jolla",
              "state": "California",
              "zip": "92093-0658",
              "country": "United States",
              "geoPoint": {
                "lat": 32.84727,
                "lon": -117.2742
              }
            },
            {
              "facility": "Kaiser Permanente Medical Office -Vandever Medical Office",
              "city": "San Diego",
              "state": "California",
              "zip": "92120",
              "country": "United States",
              "geoPoint": {
                "lat": 32.71533,
                "lon": -117.15726
              }
            },
            {
              "facility": "Walter Reed Army Medical Center",
              "city": "Washington",
              "state": "District of Columbia",
              "zip": "20307-5001",
              "country": "United States",
              "geoPoint": {
                "lat": 38.89511,
                "lon": -77.03637
              }
            },
            {
              "facility": "Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital",
              "city": "Fort Lauderdale",
              "state": "Florida",
              "zip": "33308",
              "country": "United States",
              "geoPoint": {
                "lat": 26.12231,
                "lon": -80.14338
              }
            },
            {
              "facility": "Ella Milbank Foshay Cancer Center at Jupiter Medical Center",
              "city": "Jupiter",
              "state": "Florida",
              "zip": "33458",
              "country": "United States",
              "geoPoint": {
                "lat": 26.93422,
                "lon": -80.09421
              }
            },
            {
              "facility": "CCOP - Mount Sinai Medical Center",
              "city": "Miami Beach",
              "state": "Florida",
              "zip": "33140",
              "country": "United States",
              "geoPoint": {
                "lat": 25.79065,
                "lon": -80.13005
              }
            },
            {
              "facility": "Illinois CancerCare - Bloomington",
              "city": "Bloomington%",
              "state": "Illinois",
              "zip": "61701",
              "country": "United States",
              "geoPoint": {
                "lat": 40.4842,
                "lon": -88.99369
              }
            },
            {
              "facility": "Graham Hospital",
              "city": "Canton",
              "state": "Illinois",
              "zip": "61520",
              "country": "United States",
              "geoPoint": {
                "lat": 40.55809,
                "lon": -90.03512
              }
            },
            {
              "facility": "Illinois CancerCare - Canton",
              "city": "Canton",
              "state": "Illinois",
              "zip": "61520",
              "country": "United States",
              "geoPoint": {
                "lat": 40.55809,
                "lon": -90.03512
              }
            },
            {
              "facility": "Illinois CancerCare - Carthage",
              "city": "Carthage",
              "state": "Illinois",
              "zip": "62321",
              "country": "United States",
              "geoPoint": {
                "lat": 41.91892,
                "lon": -89.31371
              }
            },
            {
              "facility": "Memorial Hospital",
              "city": "Carthage",
              "state": "Illinois",
              "zip": "62321",
              "country": "United States",
              "geoPoint": {
                "lat": 41.91892,
                "lon": -89.31371
              }
            },
            {
              "facility": "University of Chicago Cancer Research Center",
              "city": "Chicago",
              "state": "Illinois",
              "zip": "60637-1470",
              "country": "United States",
              "geoPoint": {
                "lat": 41.85003,
                "lon": -87.65005
              }
            },
            {
              "facility": "Eureka Community Hospital",
              "city": "Eureka",
              "state": "Illinois",
              "zip": "61530",
              "country": "United States",
              "geoPoint": {
                "lat": 40.72143,
                "lon": -89.27286
              }
            },
            {
              "facility": "Illinois CancerCare - Eureka",
              "city": "Eureka",
              "state": "Illinois",
              "zip": "61530",
              "country": "United States",
              "geoPoint": {
                "lat": 40.72143,
                "lon": -89.27286
              }
            },
            {
              "facility": "Galesburg Clinic, PC",
              "city": "Galesburg",
              "state": "Illinois",
              "zip": "61401",
              "country": "United States",
              "geoPoint": {
                "lat": 40.94782,
                "lon": -90.37124
              }
            },
            {
              "facility": "Galesburg Cottage Hospital",
              "city": "Galesburg",
              "state": "Illinois",
              "zip": "61401",
              "country": "United States",
              "geoPoint": {
                "lat": 40.94782,
                "lon": -90.37124
              }
            },
            {
              "facility": "Illinois CancerCare - Galesburg",
              "city": "Galesburg",
              "state": "Illinois",
              "zip": "61401",
              "country": "United States",
              "geoPoint": {
                "lat": 40.94782,
                "lon": -90.37124
              }
            },
            {
              "facility": "Illinois CancerCare - Havana",
              "city": "Havana",
              "state": "Illinois",
              "zip": "62644",
              "country": "United States",
              "geoPoint": {
                "lat": 40.30004,
                "lon": -90.06095
              }
            },
            {
              "facility": "Mason District Hospital",
              "city": "Havana",
              "state": "Illinois",
              "zip": "62644",
              "country": "United States",
              "geoPoint": {
                "lat": 40.30004,
                "lon": -90.06095
              }
            },
            {
              "facility": "Illinois CancerCare - Kewanee Clinic",
              "city": "Kewanee",
              "state": "Illinois",
              "zip": "61443",
              "country": "United States",
              "geoPoint": {
                "lat": 41.24559,
                "lon": -89.92483
              }
            },
            {
              "facility": "Illinois CancerCare - Macomb",
              "city": "Macomb",
              "state": "Illinois",
              "zip": "61455",
              "country": "United States",
              "geoPoint": {
                "lat": 40.45921,
                "lon": -90.6718
              }
            },
            {
              "facility": "McDonough District Hospital",
              "city": "Macomb",
              "state": "Illinois",
              "zip": "61455",
              "country": "United States",
              "geoPoint": {
                "lat": 40.45921,
                "lon": -90.6718
              }
            },
            {
              "facility": "Illinois CancerCare - Monmouth",
              "city": "Monmouth",
              "state": "Illinois",
              "zip": "61462",
              "country": "United States",
              "geoPoint": {
                "lat": 40.91143,
                "lon": -90.64736
              }
            },
            {
              "facility": "BroMenn Regional Medical Center",
              "city": "Normal",
              "state": "Illinois",
              "zip": "61761",
              "country": "United States",
              "geoPoint": {
                "lat": 40.5142,
                "lon": -88.99063
              }
            },
            {
              "facility": "Community Cancer Center",
              "city": "Normal",
              "state": "Illinois",
              "zip": "61761",
              "country": "United States",
              "geoPoint": {
                "lat": 40.5142,
                "lon": -88.99063
              }
            },
            {
              "facility": "Illinois CancerCare - Community Cancer Center",
              "city": "Normal",
              "state": "Illinois",
              "zip": "61761",
              "country": "United States",
              "geoPoint": {
                "lat": 40.5142,
                "lon": -88.99063
              }
            },
            {
              "facility": "Community Hospital of Ottawa",
              "city": "Ottawa",
              "state": "Illinois",
              "zip": "61350",
              "country": "United States",
              "geoPoint": {
                "lat": 41.34559,
                "lon": -88.84258
              }
            },
            {
              "facility": "Oncology Hematology Associates of Central Illinois, PC - Ottawa",
              "city": "Ottawa",
              "state": "Illinois",
              "zip": "61350",
              "country": "United States",
              "geoPoint": {
                "lat": 41.34559,
                "lon": -88.84258
              }
            },
            {
              "facility": "Cancer Treatment Center at Pekin Hospital",
              "city": "Pekin",
              "state": "Illinois",
              "zip": "61554",
              "country": "United States",
              "geoPoint": {
                "lat": 40.56754,
                "lon": -89.64066
              }
            },
            {
              "facility": "Illinois CancerCare - Pekin",
              "city": "Pekin",
              "state": "Illinois",
              "zip": "61603",
              "country": "United States",
              "geoPoint": {
                "lat": 40.56754,
                "lon": -89.64066
              }
            },
            {
              "facility": "Proctor Hospital",
              "city": "Peoria",
              "state": "Illinois",
              "zip": "61614",
              "country": "United States",
              "geoPoint": {
                "lat": 40.69365,
                "lon": -89.58899
              }
            },
            {
              "facility": "CCOP - Illinois Oncology Research Association",
              "city": "Peoria",
              "state": "Illinois",
              "zip": "61615",
              "country": "United States",
              "geoPoint": {
                "lat": 40.69365,
                "lon": -89.58899
              }
            },
            {
              "facility": "Oncology Hematology Associates of Central Illinois, PC - Peoria",
              "city": "Peoria",
              "state": "Illinois",
              "zip": "61615",
              "country": "United States",
              "geoPoint": {
                "lat": 40.69365,
                "lon": -89.58899
              }
            },
            {
              "facility": "Methodist Medical Center of Illinois",
              "city": "Peoria",
              "state": "Illinois",
              "zip": "61636",
              "country": "United States",
              "geoPoint": {
                "lat": 40.69365,
                "lon": -89.58899
              }
            },
            {
              "facility": "Illinois CancerCare - Peru",
              "city": "Peru",
              "state": "Illinois",
              "zip": "61354",
              "country": "United States",
              "geoPoint": {
                "lat": 41.32753,
                "lon": -89.12897
              }
            },
            {
              "facility": "Illinois Valley Community Hospital",
              "city": "Peru",
              "state": "Illinois",
              "zip": "61354",
              "country": "United States",
              "geoPoint": {
                "lat": 41.32753,
                "lon": -89.12897
              }
            },
            {
              "facility": "Illinois CancerCare - Princeton",
              "city": "Princeton",
              "state": "Illinois",
              "zip": "61356",
              "country": "United States",
              "geoPoint": {
                "lat": 41.36809,
                "lon": -89.46481
              }
            },
            {
              "facility": "Perry Memorial Hospital",
              "city": "Princeton",
              "state": "Illinois",
              "zip": "61356",
              "country": "United States",
              "geoPoint": {
                "lat": 41.36809,
                "lon": -89.46481
              }
            },
            {
              "facility": "Illinois CancerCare - Spring Valley",
              "city": "Spring Valley",
              "state": "Illinois",
              "zip": "61362",
              "country": "United States",
              "geoPoint": {
                "lat": 41.32754,
                "lon": -89.19981
              }
            },
            {
              "facility": "Fort Wayne Medical Oncology and Hematology",
              "city": "Fort Wayne",
              "state": "Indiana",
              "zip": "46845",
              "country": "United States",
              "geoPoint": {
                "lat": 41.1306,
                "lon": -85.12886
              }
            },
            {
              "facility": "Menorah Medical Center",
              "city": "Overland Park",
              "state": "Kansas",
              "zip": "66209",
              "country": "United States",
              "geoPoint": {
                "lat": 38.98223,
                "lon": -94.67079
              }
            },
            {
              "facility": "Saint Luke's Hospital - South",
              "city": "Overland Park",
              "state": "Kansas",
              "zip": "66213",
              "country": "United States",
              "geoPoint": {
                "lat": 38.98223,
                "lon": -94.67079
              }
            },
            {
              "facility": "Veterans Affairs Medical Center - Minneapolis",
              "city": "Minneapolis",
              "state": "Minnesota",
              "zip": "55417",
              "country": "United States",
              "geoPoint": {
                "lat": 44.97997,
                "lon": -93.26384
              }
            },
            {
              "facility": "Saint Luke's Cancer Institute at Saint Luke's Hospital",
              "city": "Kansas City",
              "state": "Missouri",
              "zip": "64111",
              "country": "United States",
              "geoPoint": {
                "lat": 39.09973,
                "lon": -94.57857
              }
            },
            {
              "facility": "St. Joseph Medical Center",
              "city": "Kansas City",
              "state": "Missouri",
              "zip": "64114",
              "country": "United States",
              "geoPoint": {
                "lat": 39.09973,
                "lon": -94.57857
              }
            },
            {
              "facility": "North Kansas City Hospital",
              "city": "Kansas City",
              "state": "Missouri",
              "zip": "64116",
              "country": "United States",
              "geoPoint": {
                "lat": 39.09973,
                "lon": -94.57857
              }
            },
            {
              "facility": "Heartland Hematology Oncology Associates, Incorporated",
              "city": "Kansas City",
              "state": "Missouri",
              "zip": "64118",
              "country": "United States",
              "geoPoint": {
                "lat": 39.09973,
                "lon": -94.57857
              }
            },
            {
              "facility": "CCOP - Kansas City",
              "city": "Kansas City",
              "state": "Missouri",
              "zip": "64131",
              "country": "United States",
              "geoPoint": {
                "lat": 39.09973,
                "lon": -94.57857
              }
            },
            {
              "facility": "Research Medical Center",
              "city": "Kansas City",
              "state": "Missouri",
              "zip": "64132",
              "country": "United States",
              "geoPoint": {
                "lat": 39.09973,
                "lon": -94.57857
              }
            },
            {
              "facility": "Saint Luke's East - Lee's Summit",
              "city": "Lee's Summit",
              "state": "Missouri",
              "zip": "64086",
              "country": "United States",
              "geoPoint": {
                "lat": 38.91084,
                "lon": -94.38217
              }
            },
            {
              "facility": "Liberty Hospital",
              "city": "Liberty",
              "state": "Missouri",
              "zip": "64068",
              "country": "United States",
              "geoPoint": {
                "lat": 39.24611,
                "lon": -94.41912
              }
            },
            {
              "facility": "Heartland Regional Medical Center",
              "city": "Saint Joseph",
              "state": "Missouri",
              "zip": "64506",
              "country": "United States",
              "geoPoint": {
                "lat": 39.76861,
                "lon": -94.84663
              }
            },
            {
              "facility": "Saint Joseph Oncology, Incorporated",
              "city": "Saint Joseph",
              "state": "Missouri",
              "zip": "64507",
              "country": "United States",
              "geoPoint": {
                "lat": 39.76861,
                "lon": -94.84663
              }
            },
            {
              "facility": "Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis",
              "city": "Saint Louis",
              "state": "Missouri",
              "zip": "63110",
              "country": "United States",
              "geoPoint": {
                "lat": 38.62727,
                "lon": -90.19789
              }
            },
            {
              "facility": "Methodist Estabrook Cancer Center",
              "city": "Omaha",
              "state": "Nebraska",
              "zip": "68114",
              "country": "United States",
              "geoPoint": {
                "lat": 41.25626,
                "lon": -95.94043
              }
            },
            {
              "facility": "University Medical Center of Southern Nevada",
              "city": "Las Vegas",
              "state": "Nevada",
              "zip": "89102",
              "country": "United States",
              "geoPoint": {
                "lat": 36.17497,
                "lon": -115.13722
              }
            },
            {
              "facility": "CCOP - Nevada Cancer Research Foundation",
              "city": "Las Vegas",
              "state": "Nevada",
              "zip": "89106",
              "country": "United States",
              "geoPoint": {
                "lat": 36.17497,
                "lon": -115.13722
              }
            },
            {
              "facility": "New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care",
              "city": "Concord",
              "state": "New Hampshire",
              "zip": "03301",
              "country": "United States",
              "geoPoint": {
                "lat": 43.20814,
                "lon": -71.53757
              }
            },
            {
              "facility": "New Hampshire Oncology - Hematology, PA - Hooksett",
              "city": "Hooksett",
              "state": "New Hampshire",
              "zip": "03106",
              "country": "United States",
              "geoPoint": {
                "lat": 43.09675,
                "lon": -71.46507
              }
            },
            {
              "facility": "Lakes Region General Hospital",
              "city": "Laconia",
              "state": "New Hampshire",
              "zip": "03246",
              "country": "United States",
              "geoPoint": {
                "lat": 43.52785,
                "lon": -71.47035
              }
            },
            {
              "facility": "Roswell Park Cancer Institute",
              "city": "Buffalo",
              "state": "New York",
              "zip": "14263-0001",
              "country": "United States",
              "geoPoint": {
                "lat": 42.88645,
                "lon": -78.87837
              }
            },
            {
              "facility": "CCOP - Hematology-Oncology Associates of Central New York",
              "city": "East Syracuse",
              "state": "New York",
              "zip": "13057",
              "country": "United States",
              "geoPoint": {
                "lat": 43.06534,
                "lon": -76.07853
              }
            },
            {
              "facility": "New York Weill Cornell Cancer Center at Cornell University",
              "city": "New York",
              "state": "New York",
              "zip": "10021",
              "country": "United States",
              "geoPoint": {
                "lat": 40.71427,
                "lon": -74.00597
              }
            },
            {
              "facility": "Kinston Medical Specialists",
              "city": "Kinston",
              "state": "North Carolina",
              "zip": "28501",
              "country": "United States",
              "geoPoint": {
                "lat": 35.26266,
                "lon": -77.58164
              }
            },
            {
              "facility": "Wake Forest University Comprehensive Cancer Center",
              "city": "Winston-Salem",
              "state": "North Carolina",
              "zip": "27157-1096",
              "country": "United States",
              "geoPoint": {
                "lat": 36.09986,
                "lon": -80.24422
              }
            },
            {
              "facility": "Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center",
              "city": "Columbus",
              "state": "Ohio",
              "zip": "43210-1240",
              "country": "United States",
              "geoPoint": {
                "lat": 39.96118,
                "lon": -82.99879
              }
            },
            {
              "facility": "Cancer Centers of the Carolinas - Easley",
              "city": "Easley",
              "state": "South Carolina",
              "zip": "29640",
              "country": "United States",
              "geoPoint": {
                "lat": 34.82984,
                "lon": -82.60152
              }
            },
            {
              "facility": "Bon Secours St. Francis Health System",
              "city": "Greenville",
              "state": "South Carolina",
              "zip": "29601",
              "country": "United States",
              "geoPoint": {
                "lat": 34.85262,
                "lon": -82.39401
              }
            },
            {
              "facility": "Cancer Centers of the Carolinas - Faris Road",
              "city": "Greenville",
              "state": "South Carolina",
              "zip": "29605",
              "country": "United States",
              "geoPoint": {
                "lat": 34.85262,
                "lon": -82.39401
              }
            },
            {
              "facility": "Cancer Centers of the Carolinas - Grove Commons",
              "city": "Greenville",
              "state": "South Carolina",
              "zip": "29605",
              "country": "United States",
              "geoPoint": {
                "lat": 34.85262,
                "lon": -82.39401
              }
            },
            {
              "facility": "Greenville Hospital Cancer Center",
              "city": "Greenville",
              "state": "South Carolina",
              "zip": "29605",
              "country": "United States",
              "geoPoint": {
                "lat": 34.85262,
                "lon": -82.39401
              }
            },
            {
              "facility": "CCOP - Greenville",
              "city": "Greenville",
              "state": "South Carolina",
              "zip": "29615",
              "country": "United States",
              "geoPoint": {
                "lat": 34.85262,
                "lon": -82.39401
              }
            },
            {
              "facility": "Self Regional Cancer Center at Self Regional Medical Center",
              "city": "Greenwood",
              "state": "South Carolina",
              "zip": "29646",
              "country": "United States",
              "geoPoint": {
                "lat": 34.1954,
                "lon": -82.16179
              }
            },
            {
              "facility": "Cancer Centers of the Carolinas - Greer Medical Oncology",
              "city": "Greer",
              "state": "South Carolina",
              "zip": "29650",
              "country": "United States",
              "geoPoint": {
                "lat": 34.93873,
                "lon": -82.22706
              }
            },
            {
              "facility": "Cancer Centers of the Carolinas - Seneca",
              "city": "Seneca",
              "state": "South Carolina",
              "zip": "29672",
              "country": "United States",
              "geoPoint": {
                "lat": 34.68566,
                "lon": -82.9532
              }
            },
            {
              "facility": "Cancer Centers of the Carolinas - Spartanburg",
              "city": "Spartanburg",
              "state": "South Carolina",
              "zip": "29307",
              "country": "United States",
              "geoPoint": {
                "lat": 34.94957,
                "lon": -81.93205
              }
            },
            {
              "facility": "Mountainview Medical",
              "city": "Berlin",
              "state": "Vermont",
              "zip": "05602",
              "country": "United States",
              "geoPoint": {
                "lat": 44.21006,
                "lon": -72.57594
              }
            },
            {
              "facility": "Fletcher Allen Health Care - University Health Center Campus",
              "city": "Burlington",
              "state": "Vermont",
              "zip": "05401",
              "country": "United States",
              "geoPoint": {
                "lat": 44.47588,
                "lon": -73.21207
              }
            },
            {
              "facility": "Danville Regional Medical Center",
              "city": "Danville",
              "state": "Virginia",
              "zip": "24541",
              "country": "United States",
              "geoPoint": {
                "lat": 36.58597,
                "lon": -79.39502
              }
            }
          ]
        },
        "referencesModule": {
          "references": [
            {
              "pmid": "26304886",
              "type": "RESULT",
              "citation": "Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, Czuczman M, Giguere JK, Cheson BD. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015 Nov 1;33(31):3635-40. doi: 10.1200/JCO.2014.59.9258. Epub 2015 Aug 24."
            }
          ]
        }
      },
      "resultsSection": {
        "participantFlowModule": {
          "preAssignmentDetails": "Three participants assigned to the lenalidomide arm alone arm never began treatment, and the rituximab arm was discontinued early.",
          "recruitmentDetails": "Between October 2006 and April 2011, 97 participants were accrued to the study.",
          "groups": [
            {
              "id": "FG000",
              "title": "Arm I - Rituximab",
              "description": "Patients receive rituximab 375 mg/m\\^2 IV on days 1, 8, 15, and 22."
            },
            {
              "id": "FG001",
              "title": "Arm II - Lenalidomide",
              "description": "Patients receive oral lenalidomide 15 mg once daily on days 1-21 in cycle 1, then 20 mg once daily on days 1-21 cycle 2-12. Treatment repeats every 28 days."
            },
            {
              "id": "FG002",
              "title": "Arm III - Lenalidomide and Rituximab",
              "description": "Patients receive oral lenalidomide 15 mg once daily on days 1-21 in cycle 1, then 20 mg once daily on days 1-21 cycle 2-12 Patients also receive rituximab 375 mg/m\\^2 IV on days 8, 15, 22 and 29."
            }
          ],
          "periods": [
            {
              "title": "Overall Study",
              "milestones": [
                {
                  "type": "STARTED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "3"
                    },
                    {
                      "groupId": "FG001",
                      "numSubjects": "48"
                    },
                    {
                      "groupId": "FG002",
                      "numSubjects": "46"
                    }
                  ]
                },
                {
                  "type": "COMPLETED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "3"
                    },
                    {
                      "groupId": "FG001",
                      "numSubjects": "45"
                    },
                    {
                      "groupId": "FG002",
                      "numSubjects": "46"
                    }
                  ]
                },
                {
                  "type": "NOT COMPLETED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "0"
                    },
                    {
                      "groupId": "FG001",
                      "numSubjects": "3"
                    },
                    {
                      "groupId": "FG002",
                      "numSubjects": "0"
                    }
                  ]
                }
              ],
              "dropWithdraws": [
                {
                  "type": "Withdrawal by Subject",
                  "reasons": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "0"
                    },
                    {
                      "groupId": "FG001",
                      "numSubjects": "3"
                    },
                    {
                      "groupId": "FG002",
                      "numSubjects": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        "baselineCharacteristicsModule": {
          "populationDescription": "Three participants assigned to the lenalidomide arm alone arm never began treatment. Participants on the rituximab arm was discontinued early; in order to avoid potential identification of patients, no results will be entered for this arm.",
          "groups": [
            {
              "id": "BG000",
              "title": "Arm I - Rituximab",
              "description": "Patients receive rituximab 375 mg/m\\^2 IV on days 1, 8, 15, and 22."
            },
            {
              "id": "BG001",
              "title": "Arm II - Lenalidomide",
              "description": "Patients receive oral lenalidomide 15 mg once daily on days 1-21 in cycle 1, then 20 mg once daily on days 1-21 cycle 2-12. Treatment repeats every 28 days."
            },
            {
              "id": "BG002",
              "title": "Arm III - Lenalidomide and Rituximab",
              "description": "Patients receive oral lenalidomide 15 mg once daily on days 1-21 in cycle 1, then 20 mg once daily on days 1-21 cycle 2-12 Patients also receive rituximab 375 mg/m\\^2 IV on days 8, 15, 22 and 29."
            },
            {
              "id": "BG003",
              "title": "Total",
              "description": "Total of all reporting groups"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "BG000",
                  "value": "0"
                },
                {
                  "groupId": "BG001",
                  "value": "45"
                },
                {
                  "groupId": "BG002",
                  "value": "46"
                },
                {
                  "groupId": "BG003",
                  "value": "91"
                }
              ]
            }
          ],
          "measures": [
            {
              "title": "Age, Continuous",
              "paramType": "MEDIAN",
              "dispersionType": "FULL_RANGE",
              "unitOfMeasure": "years",
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "BG001",
                          "value": "63",
                          "lowerLimit": "34",
                          "upperLimit": "85"
                        },
                        {
                          "groupId": "BG002",
                          "value": "64",
                          "lowerLimit": "36",
                          "upperLimit": "89"
                        },
                        {
                          "groupId": "BG003",
                          "value": "63",
                          "lowerLimit": "34",
                          "upperLimit": "89"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Sex: Female, Male",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "categories": [
                    {
                      "title": "Female",
                      "measurements": [
                        {
                          "groupId": "BG001",
                          "value": "18"
                        },
                        {
                          "groupId": "BG002",
                          "value": "19"
                        },
                        {
                          "groupId": "BG003",
                          "value": "37"
                        }
                      ]
                    },
                    {
                      "title": "Male",
                      "measurements": [
                        {
                          "groupId": "BG001",
                          "value": "27"
                        },
                        {
                          "groupId": "BG002",
                          "value": "27"
                        },
                        {
                          "groupId": "BG003",
                          "value": "54"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Race (NIH/OMB)",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "categories": [
                    {
                      "title": "American Indian or Alaska Native",
                      "measurements": [
                        {
                          "groupId": "BG001",
                          "value": "0"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        },
                        {
                          "groupId": "BG003",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Asian",
                      "measurements": [
                        {
                          "groupId": "BG001",
                          "value": "0"
                        },
                        {
                          "groupId": "BG002",
                          "value": "1"
                        },
                        {
                          "groupId": "BG003",
                          "value": "1"
                        }
                      ]
                    },
                    {
                      "title": "Native Hawaiian or Other Pacific Islander",
                      "measurements": [
                        {
                          "groupId": "BG001",
                          "value": "1"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        },
                        {
                          "groupId": "BG003",
                          "value": "1"
                        }
                      ]
                    },
                    {
                      "title": "Black or African American",
                      "measurements": [
                        {
                          "groupId": "BG001",
                          "value": "3"
                        },
                        {
                          "groupId": "BG002",
                          "value": "1"
                        },
                        {
                          "groupId": "BG003",
                          "value": "4"
                        }
                      ]
                    },
                    {
                      "title": "White",
                      "measurements": [
                        {
                          "groupId": "BG001",
                          "value": "37"
                        },
                        {
                          "groupId": "BG002",
                          "value": "44"
                        },
                        {
                          "groupId": "BG003",
                          "value": "81"
                        }
                      ]
                    },
                    {
                      "title": "More than one race",
                      "measurements": [
                        {
                          "groupId": "BG001",
                          "value": "0"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        },
                        {
                          "groupId": "BG003",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Unknown or Not Reported",
                      "measurements": [
                        {
                          "groupId": "BG001",
                          "value": "4"
                        },
                        {
                          "groupId": "BG002",
                          "value": "0"
                        },
                        {
                          "groupId": "BG003",
                          "value": "4"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Region of Enrollment",
              "paramType": "NUMBER",
              "unitOfMeasure": "participants",
              "classes": [
                {
                  "title": "United States",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "BG001",
                          "value": "45"
                        },
                        {
                          "groupId": "BG002",
                          "value": "46"
                        },
                        {
                          "groupId": "BG003",
                          "value": "91"
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        "outcomeMeasuresModule": {
          "outcomeMeasures": [
            {
              "type": "PRIMARY",
              "title": "Overall Response Rate",
              "description": "Response is assessed by investigator according to International Working Group (IWG) criteria. A complete response requires disappearance of all evidence of disease. A partial response is a \\>/= 50% decrease in the sum of products of 6 largest dominant nodes or nodal masses as well as for splenic and hepatic nodules. No increase in size of nodes, liver or spleen and no new sites of disease.",
              "populationDescription": "Three participants assigned to the lenalidomide arm alone arm never began treatment, and the rituximab arm was discontinued early.",
              "reportingStatus": "POSTED",
              "paramType": "NUMBER",
              "dispersionType": "95% Confidence Interval",
              "unitOfMeasure": "percentage of participants",
              "timeFrame": "Duration of treatment (12 cycles)",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Arm I - Rituximab",
                  "description": "Patients receive rituximab 375 mg/m\\^2 IV on days 1, 8, 15, and 22."
                },
                {
                  "id": "OG001",
                  "title": "Arm II - Lenalidomide",
                  "description": "Patients receive oral lenalidomide 15 mg once daily on days 1-21 in cycle 1, then 20 mg once daily on days 1-21 cycle 2-12. Treatment repeats every 28 days."
                },
                {
                  "id": "OG002",
                  "title": "Arm III - Lenalidomide and Rituximab",
                  "description": "Patients receive oral lenalidomide 15 mg once daily on days 1-21 in cycle 1, then 20 mg once daily on days 1-21 cycle 2-12 Patients also receive rituximab 375 mg/m\\^2 IV on days 8, 15, 22 and 29."
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "45"
                    },
                    {
                      "groupId": "OG002",
                      "value": "46"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG001",
                          "value": "53.3",
                          "lowerLimit": "37.9",
                          "upperLimit": "68.3"
                        },
                        {
                          "groupId": "OG002",
                          "value": "76.1",
                          "lowerLimit": "61.2",
                          "upperLimit": "87.4"
                        }
                      ]
                    }
                  ]
                }
              ],
              "analyses": [
                {
                  "groupIds": [
                    "OG001",
                    "OG002"
                  ],
                  "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                  "pValue": "0.29",
                  "statisticalMethod": "Fisher Exact"
                }
              ]
            },
            {
              "type": "PRIMARY",
              "title": "Time to Progression",
              "description": "Time to progression (TTP) is defined as the time from study entry until progression or death without progression. The median TTP with 95% CI was estimated using the Kaplan-Meier method.",
              "populationDescription": "Three participants assigned to the lenalidomide arm alone arm never began treatment, and the rituximab arm was discontinued early.",
              "reportingStatus": "POSTED",
              "paramType": "MEDIAN",
              "dispersionType": "95% Confidence Interval",
              "unitOfMeasure": "years",
              "timeFrame": "Up to 10 years",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Arm I - Rituximab",
                  "description": "Patients receive rituximab 375 mg/m\\^2 IV on days 1, 8, 15, and 22."
                },
                {
                  "id": "OG001",
                  "title": "Arm II - Lenalidomide",
                  "description": "Patients receive oral lenalidomide 15 mg once daily on days 1-21 in cycle 1, then 20 mg once daily on days 1-21 cycle 2-12. Treatment repeats every 28 days."
                },
                {
                  "id": "OG002",
                  "title": "Arm III - Lenalidomide and Rituximab",
                  "description": "Patients receive oral lenalidomide 15 mg once daily on days 1-21 in cycle 1, then 20 mg once daily on days 1-21 cycle 2-12 Patients also receive rituximab 375 mg/m\\^2 IV on days 8, 15, 22 and 29."
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "45"
                    },
                    {
                      "groupId": "OG002",
                      "value": "46"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG001",
                          "value": "1.1",
                          "lowerLimit": "0.8",
                          "upperLimit": "1.2"
                        },
                        {
                          "groupId": "OG002",
                          "value": "2",
                          "lowerLimit": "1.7",
                          "upperLimit": "3.0"
                        }
                      ]
                    }
                  ]
                }
              ],
              "analyses": [
                {
                  "groupIds": [
                    "OG001",
                    "OG002"
                  ],
                  "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                  "pValue": "0.002",
                  "statisticalMethod": "Log Rank"
                }
              ]
            }
          ]
        },
        "adverseEventsModule": {
          "frequencyThreshold": "0",
          "description": "90 participants, on Arms II and III, were evaluable for adverse events.",
          "eventGroups": [
            {
              "id": "EG000",
              "title": "Arm I - Rituximab",
              "description": "Patients receive rituximab 375 mg/m\\^2 IV on days 1, 8, 15, and 22.",
              "seriousNumAffected": 0,
              "seriousNumAtRisk": 0,
              "otherNumAffected": 0,
              "otherNumAtRisk": 0
            },
            {
              "id": "EG001",
              "title": "Arm II - Lenalidomide",
              "description": "Patients receive oral lenalidomide 15 mg once daily on days 1-21 in cycle 1, then 20 mg once daily on days 1-21 cycle 2-12. Treatment repeats every 28 days.",
              "seriousNumAffected": 8,
              "seriousNumAtRisk": 45,
              "otherNumAffected": 44,
              "otherNumAtRisk": 45
            },
            {
              "id": "EG002",
              "title": "Arm III - Lenalidomide and Rituximab",
              "description": "Patients receive oral lenalidomide 15 mg once daily on days 1-21 in cycle 1, then 20 mg once daily on days 1-21 cycle 2-12 Patients also receive rituximab 375 mg/m\\^2 IV on days 8, 15, 22 and 29.",
              "seriousNumAffected": 12,
              "seriousNumAtRisk": 45,
              "otherNumAffected": 41,
              "otherNumAtRisk": 45
            }
          ],
          "seriousEvents": [
            {
              "term": "Febrile neutropenia",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hemoglobin decreased",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 4,
                  "numAffected": 4,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Sinus arrhythmia",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Sinus tachycardia",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hypothyroidism",
              "organSystem": "Endocrine disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dry eye syndrome",
              "organSystem": "Eye disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Vision blurred",
              "organSystem": "Eye disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Abdominal distension",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Abdominal pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Colitis",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Constipation",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 8,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Diarrhea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dyspepsia",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dysphagia",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Ear, nose and throat examination abnormal",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Esophageal pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hemorrhoids",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Nausea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 3,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Obstruction gastric",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Oral pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Vomiting",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Chest pain",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Chills",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Death NOS",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Disease progression",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Edema limbs",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Fatigue",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 6,
                  "numAffected": 5,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 11,
                  "numAffected": 7,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Fever",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Gait abnormal",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pain",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Cytokine release syndrome",
              "organSystem": "Immune system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Bronchitis",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Opportunistic infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pneumonia",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Sepsis",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Skin infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Vaginal infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Intraoperative musculoskeletal injury",
              "organSystem": "Injury, poisoning and procedural complications",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Alanine aminotransferase increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Alkaline phosphatase increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Aspartate aminotransferase increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Blood bilirubin increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Creatinine increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Electrocardiogram QTc interval prolonged",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "INR increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Leukocyte count decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 4,
                  "numAffected": 4,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 6,
                  "numAffected": 5,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Lymphocyte count decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 3,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Neutrophil count decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 6,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Platelet count decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 7,
                  "numAffected": 6,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 6,
                  "numAffected": 5,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Weight loss",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Alkalosis",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Anorexia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Blood glucose increased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 4,
                  "numAffected": 4,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 7,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dehydration",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum albumin decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 5,
                  "numAffected": 5,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum calcium decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum glucose decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum magnesium increased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum phosphate decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum potassium decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum sodium decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 5,
                  "numAffected": 5,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Arthralgia",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Back pain",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Bone pain",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Muscle weakness lower limb",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Myalgia",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Neck pain",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pain in extremity",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Tumor flare",
              "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dysgeusia",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Ischemia cerebrovascular",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Mini mental status examination abnormal",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Neuralgia",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Peripheral sensory neuropathy",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Seizure",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Speech disorder",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Depression",
              "organSystem": "Psychiatric disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Insomnia",
              "organSystem": "Psychiatric disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Kidney pain",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Proteinuria",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Renal failure",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Ureteric obstruction",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Adult respiratory distress syndrome",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Allergic rhinitis",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Bronchospasm",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Cough",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dyspnea",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 5,
                  "numAffected": 3,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hypoxia",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pleural effusion",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dry skin",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 5,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Erythema multiforme",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pruritus",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Sweating",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Flushing",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hot flashes",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hypotension",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Thrombosis",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 3,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            }
          ],
          "otherEvents": [
            {
              "term": "Febrile neutropenia",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hemoglobin decreased",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 89,
                  "numAffected": 19,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 86,
                  "numAffected": 17,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Lymph node pain",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Cardiac disorder",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Cardiac pain",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Left ventricular dysfunction",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Sinus bradycardia",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Ventricular arrhythmia",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Ear pain",
              "organSystem": "Ear and labyrinth disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "External ear pain",
              "organSystem": "Ear and labyrinth disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hearing impaired",
              "organSystem": "Ear and labyrinth disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hypothyroidism",
              "organSystem": "Endocrine disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 24,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dry eye syndrome",
              "organSystem": "Eye disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 5,
                  "numAffected": 3,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Eye disorder",
              "organSystem": "Eye disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Glaucoma",
              "organSystem": "Eye disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Watering eyes",
              "organSystem": "Eye disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 3,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Abdominal distension",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 7,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Abdominal pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 6,
                  "numAffected": 3,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 9,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Anal hemorrhage",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Constipation",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 40,
                  "numAffected": 21,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 45,
                  "numAffected": 16,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Diarrhea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 46,
                  "numAffected": 14,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 34,
                  "numAffected": 14,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dry mouth",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 12,
                  "numAffected": 3,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 6,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dyspepsia",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 7,
                  "numAffected": 6,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Ear, nose and throat examination abnormal",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 3,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Esophageal pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Esophagitis",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Gastrointestinal disorder",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 4,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Gastroscopy abnormal",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hemorrhoids",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Nausea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 40,
                  "numAffected": 16,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 32,
                  "numAffected": 12,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Oral pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Rectal hemorrhage",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Stomach pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Toothache",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Vomiting",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 9,
                  "numAffected": 4,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 7,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Chest pain",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 7,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Chills",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 7,
                  "numAffected": 7,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Edema limbs",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 28,
                  "numAffected": 9,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 11,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Fatigue",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 138,
                  "numAffected": 35,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 166,
                  "numAffected": 33,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Fever",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 7,
                  "numAffected": 7,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Flu-like symptoms",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "General symptom",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Localized edema",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pain",
              "organSystem": "General disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 5,
                  "numAffected": 4,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 16,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Gallbladder pain",
              "organSystem": "Hepatobiliary disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Cytokine release syndrome",
              "organSystem": "Immune system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 12,
                  "numAffected": 12,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hypersensitivity",
              "organSystem": "Immune system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 4,
                  "numAffected": 3,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 3,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Immune system disorder",
              "organSystem": "Immune system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Bronchitis",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Catheter related infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Gastric infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Gingival infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Otitis media",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pharyngitis",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Rhinitis infective",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Sinusitis",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 3,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 15,
                  "numAffected": 8,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Skin infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Tooth infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Tracheitis",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Upper respiratory infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 7,
                  "numAffected": 5,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Urinary tract infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 11,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Vaginal infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Bruising",
              "organSystem": "Injury, poisoning and procedural complications",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 5,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Thermal burn",
              "organSystem": "Injury, poisoning and procedural complications",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Vascular access complication",
              "organSystem": "Injury, poisoning and procedural complications",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Alanine aminotransferase increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 27,
                  "numAffected": 8,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 35,
                  "numAffected": 9,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Alkaline phosphatase increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 14,
                  "numAffected": 5,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Aspartate aminotransferase increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 21,
                  "numAffected": 8,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 33,
                  "numAffected": 10,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Blood bilirubin increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 6,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 31,
                  "numAffected": 8,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Creatinine increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 10,
                  "numAffected": 6,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 14,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "INR increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Laboratory test abnormal",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 15,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Leukocyte count decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 86,
                  "numAffected": 21,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 131,
                  "numAffected": 16,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Lymphocyte count decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 21,
                  "numAffected": 9,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 80,
                  "numAffected": 13,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Neutrophil count decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 94,
                  "numAffected": 19,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 123,
                  "numAffected": 25,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Platelet count decreased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 96,
                  "numAffected": 25,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 114,
                  "numAffected": 23,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum cholesterol increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Weight gain",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Weight loss",
              "organSystem": "Investigations",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Anorexia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 12,
                  "numAffected": 6,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 8,
                  "numAffected": 5,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Blood glucose increased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 50,
                  "numAffected": 15,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 55,
                  "numAffected": 14,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Blood uric acid increased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 5,
                  "numAffected": 3,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Glucose intolerance",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 4,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum albumin decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 12,
                  "numAffected": 7,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 18,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum calcium decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 24,
                  "numAffected": 8,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 38,
                  "numAffected": 10,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum calcium increased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 11,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum glucose decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 6,
                  "numAffected": 4,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 14,
                  "numAffected": 7,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum magnesium decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum phosphate decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 10,
                  "numAffected": 6,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 23,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum potassium decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 13,
                  "numAffected": 7,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 27,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum potassium increased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum sodium decreased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 20,
                  "numAffected": 6,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 16,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum sodium increased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Serum triglycerides increased",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Arthralgia",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 13,
                  "numAffected": 7,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Arthritis",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 8,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Back pain",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 9,
                  "numAffected": 6,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 14,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Bone pain",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 5,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Chest wall pain",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Muscle weakness",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Muscle weakness upper limb",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Musculoskeletal disorder",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 5,
                  "numAffected": 3,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 15,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Myalgia",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 16,
                  "numAffected": 7,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 20,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Myositis",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Neck pain",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 3,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pain in extremity",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 6,
                  "numAffected": 4,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 9,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Tumor flare",
              "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Tumor pain",
              "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Ataxia",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 4,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Depressed level of consciousness",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dizziness",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 11,
                  "numAffected": 8,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 16,
                  "numAffected": 10,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dysgeusia",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 18,
                  "numAffected": 5,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 7,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Headache",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 16,
                  "numAffected": 5,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 10,
                  "numAffected": 5,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Memory impairment",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Neuralgia",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Neurological disorder NOS",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Olfactory nerve disorder",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 4,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Peripheral motor neuropathy",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Peripheral sensory neuropathy",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 32,
                  "numAffected": 15,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 51,
                  "numAffected": 17,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Syncope",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Tremor",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Trigeminal nerve disorder",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Anxiety",
              "organSystem": "Psychiatric disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Depression",
              "organSystem": "Psychiatric disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 15,
                  "numAffected": 4,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Insomnia",
              "organSystem": "Psychiatric disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 6,
                  "numAffected": 4,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 10,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Libido decreased",
              "organSystem": "Psychiatric disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Bladder spasm",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Proteinuria",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Urinary frequency",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Urinary incontinence",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Urinary retention",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 7,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pelvic pain",
              "organSystem": "Reproductive system and breast disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 5,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Allergic rhinitis",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 20,
                  "numAffected": 9,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 12,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Bronchospasm",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Cough",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 15,
                  "numAffected": 8,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 30,
                  "numAffected": 11,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dyspnea",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 13,
                  "numAffected": 6,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 14,
                  "numAffected": 8,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Nasal congestion",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pharyngolaryngeal pain",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 6,
                  "numAffected": 4,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pleural effusion",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pneumonitis",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 7,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pulmonary hemorrhage",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Respiratory disorder",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 4,
                  "numAffected": 4,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 8,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Alopecia",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 3,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Dry skin",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 12,
                  "numAffected": 7,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Erythema multiforme",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 15,
                  "numAffected": 10,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 22,
                  "numAffected": 8,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Petechiae",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 2,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Pruritus",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 17,
                  "numAffected": 9,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 16,
                  "numAffected": 6,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Rash acneiform",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Rash desquamating",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 16,
                  "numAffected": 11,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 13,
                  "numAffected": 10,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Skin disorder",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 9,
                  "numAffected": 6,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 11,
                  "numAffected": 8,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Skin hypopigmentation",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 5,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Skin ulceration",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Sweating",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 8,
                  "numAffected": 6,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 4,
                  "numAffected": 3,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hot flashes",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 8,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Hypotension",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 5,
                  "numAffected": 3,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Peripheral ischemia",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 2,
                  "numAffected": 1,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 45
                }
              ]
            },
            {
              "term": "Thrombosis",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "MedDRA 6",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numEvents": 0,
                  "numAffected": 0,
                  "numAtRisk": 0
                },
                {
                  "groupId": "EG001",
                  "numEvents": 7,
                  "numAffected": 4,
                  "numAtRisk": 45
                },
                {
                  "groupId": "EG002",
                  "numEvents": 1,
                  "numAffected": 1,
                  "numAtRisk": 45
                }
              ]
            }
          ]
        },
        "moreInfoModule": {
          "certainAgreement": {
            "piSponsorEmployee": false,
            "restrictionType": "LTE60",
            "restrictiveAgreement": true
          },
          "pointOfContact": {
            "title": "John P Leonard, M.D.",
            "organization": "Meyer Cancer Center, Weill Cornell Medical College",
            "email": "jpleonar@med.cornell.edu"
          }
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000008223",
              "term": "Lymphoma"
            },
            {
              "id": "D000008228",
              "term": "Lymphoma, Non-Hodgkin"
            },
            {
              "id": "D000008224",
              "term": "Lymphoma, Follicular"
            }
          ],
          "ancestors": [
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000008232",
              "term": "Lymphoproliferative Disorders"
            },
            {
              "id": "D000008206",
              "term": "Lymphatic Diseases"
            },
            {
              "id": "D000007160",
              "term": "Immunoproliferative Disorders"
            },
            {
              "id": "D000007154",
              "term": "Immune System Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M10910",
              "name": "Lymphoma",
              "asFound": "Lymphoma",
              "relevance": "HIGH"
            },
            {
              "id": "M14540",
              "name": "Recurrence",
              "relevance": "LOW"
            },
            {
              "id": "M10911",
              "name": "Lymphoma, Follicular",
              "asFound": "Follicular Non-Hodgkin's Lymphoma",
              "relevance": "HIGH"
            },
            {
              "id": "M10912",
              "name": "Lymphoma, Non-Hodgkin",
              "asFound": "Non-Hodgkin's Lymphoma",
              "relevance": "HIGH"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M10915",
              "name": "Lymphoproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M10893",
              "name": "Lymphatic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M9896",
              "name": "Immunoproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M9890",
              "name": "Immune System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "T3543",
              "name": "Lymphosarcoma",
              "asFound": "Lymphoma",
              "relevance": "HIGH"
            },
            {
              "id": "T2361",
              "name": "Follicular Lymphoma",
              "asFound": "Follicular Non-Hodgkin's Lymphoma",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC15",
              "name": "Blood and Lymph Conditions"
            },
            {
              "abbrev": "BC20",
              "name": "Immune System Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC23",
              "name": "Symptoms and General Pathology"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000069283",
              "term": "Rituximab"
            },
            {
              "id": "D000077269",
              "term": "Lenalidomide"
            }
          ],
          "ancestors": [
            {
              "id": "D000074322",
              "term": "Antineoplastic Agents, Immunological"
            },
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000007155",
              "term": "Immunologic Factors"
            },
            {
              "id": "D000045505",
              "term": "Physiological Effects of Drugs"
            },
            {
              "id": "D000018501",
              "term": "Antirheumatic Agents"
            },
            {
              "id": "D000020533",
              "term": "Angiogenesis Inhibitors"
            },
            {
              "id": "D000043924",
              "term": "Angiogenesis Modulating Agents"
            },
            {
              "id": "D000006133",
              "term": "Growth Substances"
            },
            {
              "id": "D000006131",
              "term": "Growth Inhibitors"
            }
          ],
          "browseLeaves": [
            {
              "id": "M373",
              "name": "Rituximab",
              "asFound": "Adults",
              "relevance": "HIGH"
            },
            {
              "id": "M1725",
              "name": "Lenalidomide",
              "asFound": "Pediatric",
              "relevance": "HIGH"
            },
            {
              "id": "M1346",
              "name": "Antineoplastic Agents, Immunological",
              "relevance": "LOW"
            },
            {
              "id": "M9891",
              "name": "Immunologic Factors",
              "relevance": "LOW"
            },
            {
              "id": "M20294",
              "name": "Antirheumatic Agents",
              "relevance": "LOW"
            },
            {
              "id": "M22008",
              "name": "Angiogenesis Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M8921",
              "name": "Growth Inhibitors",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "ARhu",
              "name": "Antirheumatic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            }
          ]
        }
      },
      "hasResults": true
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00548938",
          "orgStudyIdInfo": {
            "id": "MHIRB #2007-040"
          },
          "organization": {
            "fullName": "Methodist Healthcare",
            "class": "OTHER"
          },
          "briefTitle": "Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM",
          "officialTitle": "A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed by Metronomic Therapy With Temozolomide for Newly Diagnosed Malignant High Grade Glioma"
        },
        "statusModule": {
          "statusVerifiedDate": "2009-09",
          "overallStatus": "TERMINATED",
          "whyStopped": "Principal Investigator has left the institution",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2007-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2009-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2010-10",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2007-10-23",
          "studyFirstSubmitQcDate": "2007-10-23",
          "studyFirstPostDateStruct": {
            "date": "2007-10-24",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2009-09-17",
          "lastUpdatePostDateStruct": {
            "date": "2009-09-18",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "oldNameTitle": "Allen Sills, MD",
            "oldOrganization": "Methodist Healthcare"
          },
          "leadSponsor": {
            "name": "Methodist Healthcare",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": true
        },
        "descriptionModule": {
          "briefSummary": "The purpose of this study is to determine the safety and efficacy of the combination of Gliadel wafers plus surgery and limited field radiation therapy with concomitant temozolomide followed by temozolomide given at an extended dose schedule (metronomic schedule) in patients undergoing initial surgery for newly-diagnosed high grade glioma.",
          "detailedDescription": "The patient population in this Phase II clinical trial will be patients with newly diagnosed high-grade glioma undergoing initial surgery. Patients will receive Surgery + Gliadel® wafer implantation + Limited Field Radiation Therapy with concomitant daily temozolomide (75 mg/m2) followed by monthly temozolomide given at the same dose (75 mg/m2 per day for 21 days each month.\n\nPatients will have up to 8 wafers implanted into the tumor resection cavity (depending upon its size) after maximal tumor resection. Between Study Days 14 and 45 all patients will begin a standard course of post-operative limited field radiation therapy to the tumor site and a surrounding margin. Temozolomide will be administered concomitantly with radiation at a daily dose of 75 mg/m2 daily (7 days/week) and then beginning no later than 30 days following completion of radiation therapy on a 75 mg/m2 daily dose given 21 days out of each month for a total of up to 18 cycles."
        },
        "conditionsModule": {
          "conditions": [
            "Glioblastoma Multiforme",
            "High-Grade Glioma"
          ],
          "keywords": [
            "Brain Tumor",
            "GBM",
            "Glioblastoma Multiforme",
            "Giladel",
            "Temozolomide"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "type": "DRUG",
              "name": "Gliadel wafer",
              "description": "Implanted at surgery"
            },
            {
              "type": "DRUG",
              "name": "Temozolomide",
              "description": "During External Beam Radiation"
            },
            {
              "type": "RADIATION",
              "name": "External Beam Radiation Therapy",
              "description": "60 Gy"
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "To determine the efficacy of Gliadel wafer + radiation + temozolomide in patients with newly diagnosed high grade glioma undergoing surgery as determined by time to disease progression.",
              "timeFrame": "2 years"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Median, one year and overall survival rate.",
              "timeFrame": "2 years"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Men and women, must be between ages 18-72\n* Patients must have radiographic evidence on cranial magnetic resonance imaging (MRI) of a single, contrast-enhancing unilateral supratentorial cerebral tumor suggestive of high-grade glioma\n* Surgical treatment within 4 weeks of the baseline MRI is indicated\n* Karnofsky Performance Score of 60 or higher\n* Patients must have a pathological diagnosis of high-grade (IV) malignant glioma\n* Patients must be willing to use a barrier method of contraception if fertile or if of childbearing potential for up to 2 years after wafer implantation and be counseled regarding the unknown, and potentially harmful, risks to the embryo or fetus while treated on this study\n\nExclusion Criteria:\n\n* Patients who have had prior cytoreductive surgery for high-grade glioma (patients who have had a diagnostic stereotactic biopsy are eligible)\n* Patients with more than one focus of tumor or tumor crossing the midline as assessed by coronal cranial MRI scan\n* Concomitant significant life-threatening disease from which the patient could reasonably be expected to die within the first 12 months of the study\n* Known hypersensitivity reactions to temozolomide, nitrosoureas or any components of the Gliadel wafer\n* Prior CNS radiotherapy\n* Patients who have received any prior chemotherapy for malignant glioma prior to the baseline evaluation or patients who are currently being treated with chemotherapeutic agents\n* Patients with fewer than 100,000 platelets per mm3 or fewer than 3,500 leukocytes per mm3\n* Liver function tests greater than or equal to 2.5 times the upper limit of normal (transaminases (SGOT, SGPT), total bilirubin, alkaline phosphatase)\n* Serum creatinine equal to or greater than 1.5 times the upper limit of normal, blood urea nitrogen (BUN) equal to or greater than 2.5 times the upper limit of normal\n* Pregnancy, or lactating females or females of childbearing potential not employing adequate contraception\n* Participation in any other investigational protocol in the prior twelve months for any type of malignancy\n* Psychological, familial, sociological or geographical conditions which do not permit adequate medical follow-up and compliance with the study protocol",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "72 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Allen K Sills, MD",
              "affiliation": "Methodist University Hospital",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Methodist University Hospital",
              "city": "Memphis",
              "state": "Tennessee",
              "zip": "38104",
              "country": "United States",
              "geoPoint": {
                "lat": 35.14953,
                "lon": -90.04898
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000005909",
              "term": "Glioblastoma"
            },
            {
              "id": "D000005910",
              "term": "Glioma"
            }
          ],
          "ancestors": [
            {
              "id": "D000001254",
              "term": "Astrocytoma"
            },
            {
              "id": "D000018302",
              "term": "Neoplasms, Neuroepithelial"
            },
            {
              "id": "D000017599",
              "term": "Neuroectodermal Tumors"
            },
            {
              "id": "D000009373",
              "term": "Neoplasms, Germ Cell and Embryonal"
            },
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000009375",
              "term": "Neoplasms, Glandular and Epithelial"
            },
            {
              "id": "D000009380",
              "term": "Neoplasms, Nerve Tissue"
            }
          ],
          "browseLeaves": [
            {
              "id": "M4899",
              "name": "Brain Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M8710",
              "name": "Glioma",
              "asFound": "Glioma",
              "relevance": "HIGH"
            },
            {
              "id": "M8709",
              "name": "Glioblastoma",
              "asFound": "Glioblastoma Multiforme",
              "relevance": "HIGH"
            },
            {
              "id": "M4251",
              "name": "Astrocytoma",
              "relevance": "LOW"
            },
            {
              "id": "M20136",
              "name": "Neoplasms, Neuroepithelial",
              "relevance": "LOW"
            },
            {
              "id": "M19535",
              "name": "Neuroectodermal Tumors",
              "relevance": "LOW"
            },
            {
              "id": "M20078",
              "name": "Neuroectodermal Tumors, Primitive",
              "relevance": "LOW"
            },
            {
              "id": "M12008",
              "name": "Neoplasms, Germ Cell and Embryonal",
              "relevance": "LOW"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M12010",
              "name": "Neoplasms, Glandular and Epithelial",
              "relevance": "LOW"
            },
            {
              "id": "M12015",
              "name": "Neoplasms, Nerve Tissue",
              "relevance": "LOW"
            },
            {
              "id": "T2519",
              "name": "Glioma",
              "asFound": "Glioma",
              "relevance": "HIGH"
            },
            {
              "id": "T2518",
              "name": "Glioblastoma",
              "asFound": "Glioblastoma",
              "relevance": "HIGH"
            },
            {
              "id": "T4092",
              "name": "Neuroepithelioma",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC10",
              "name": "Nervous System Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000077204",
              "term": "Temozolomide"
            },
            {
              "id": "D000002330",
              "term": "Carmustine"
            }
          ],
          "ancestors": [
            {
              "id": "D000018906",
              "term": "Antineoplastic Agents, Alkylating"
            },
            {
              "id": "D000000477",
              "term": "Alkylating Agents"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            },
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            }
          ],
          "browseLeaves": [
            {
              "id": "M1692",
              "name": "Temozolomide",
              "asFound": "T cells",
              "relevance": "HIGH"
            },
            {
              "id": "M5275",
              "name": "Carmustine",
              "asFound": "International normalized ratio (INR)",
              "relevance": "HIGH"
            },
            {
              "id": "M20632",
              "name": "Antineoplastic Agents, Alkylating",
              "relevance": "LOW"
            },
            {
              "id": "M3510",
              "name": "Alkylating Agents",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT05150938",
          "orgStudyIdInfo": {
            "id": "21616"
          },
          "organization": {
            "fullName": "Bayer",
            "class": "INDUSTRY"
          },
          "briefTitle": "A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)",
          "officialTitle": "Observational Studies in Cancer Associated Thrombosis for Rivaroxaban in SwEden (OSCAR-SE)"
        },
        "statusModule": {
          "statusVerifiedDate": "2023-12",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2022-03-18",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-02-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02-28",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2021-11-18",
          "studyFirstSubmitQcDate": "2021-12-07",
          "studyFirstPostDateStruct": {
            "date": "2021-12-09",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2023-12-12",
          "lastUpdatePostDateStruct": {
            "date": "2023-12-18",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "Bayer",
            "class": "INDUSTRY"
          },
          "collaborators": [
            {
              "name": "Janssen Research & Development, LLC",
              "class": "INDUSTRY"
            }
          ]
        },
        "oversightModule": {
          "oversightHasDmc": false,
          "isFdaRegulatedDrug": false,
          "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
          "briefSummary": "This is an observational study in which patient data from the past on venous thromboembolism (VTE) in patients with cancer is studied.\n\nVTE is a condition in which a patient has problems due to the formation of blood clots in the veins. Blood clots can reduce the flow of blood to vital organs such as the heart and lungs, which can lead to them becoming damaged. VTE can also be \"recurrent\". This means that the blood clots have returned after treatment. People who have cancer have an increased risk of developing VTE.\n\nThree main types of anticoagulation treatments (\"blood thinners\") have been available for patients with cancer who also have VTE\n\n* Low molecular weight heparins (LMWHs)\n* Vitamin K antagonists (VKAs)\n* Non-vitamin K antagonist oral anticoagulants (NOACs) The treatment rivaroxaban belongs to the NOACs.\n\nCompared to other treatments available to patients who have cancer and VTE, NOACs may cause fewer medical problems and can be easier for patients to take correctly.\n\nIn this study, the researchers will collect data about:\n\n* the type of VTE treatments given and for how long the treatments are taken\n* the risk of blood clots returning in the veins after treatment, any events of major bleeding, and the number of deaths in patients with cancer who do not have a high risk of bleeding\n\nThe researchers will compare this information in the patients\n\n* who received rivaroxaban to the patients who received LMWHs\n* who received NOACs to the patients who received LMWHs.\n\nThere will be no required visits with a study doctor or required tests in this study. The researchers will look at the health information from adult patients in Sweden who were diagnosed with cancer between 2013 and 2019 and also have VTE. The researchers will collect this information from Swedish health registers including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry."
        },
        "conditionsModule": {
          "conditions": [
            "Treatment of Venous Thromboembolism in Cancer Patients"
          ]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "patientRegistry": false,
          "designInfo": {
            "observationalModel": "COHORT",
            "timePerspective": "RETROSPECTIVE"
          },
          "enrollmentInfo": {
            "count": 5737,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Cancer patients with VTE",
              "description": "Cancer patients who received anticoagulation treatment.",
              "interventionNames": [
                "Drug: Rivaroxaban (Xarelto, BAY59-7939)",
                "Drug: Low molecular weight heparin (LMWH)",
                "Drug: vitamin K antagonist (VKA)",
                "Drug: other NOACs"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "Rivaroxaban (Xarelto, BAY59-7939)",
              "description": "Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.",
              "armGroupLabels": [
                "Cancer patients with VTE"
              ]
            },
            {
              "type": "DRUG",
              "name": "Low molecular weight heparin (LMWH)",
              "description": "Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.",
              "armGroupLabels": [
                "Cancer patients with VTE"
              ]
            },
            {
              "type": "DRUG",
              "name": "vitamin K antagonist (VKA)",
              "description": "Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.",
              "armGroupLabels": [
                "Cancer patients with VTE"
              ]
            },
            {
              "type": "DRUG",
              "name": "other NOACs",
              "description": "Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.",
              "armGroupLabels": [
                "Cancer patients with VTE"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Recurrence of VTE",
              "timeFrame": "Retrospective data analysis from 2013 to 2020"
            },
            {
              "measure": "Major bleedings",
              "timeFrame": "Retrospective data analysis from 2013 to 2020"
            },
            {
              "measure": "All-cause death",
              "timeFrame": "Retrospective data analysis from 2013 to 2020"
            },
            {
              "measure": "Choice of anticoagulation treatments for VTE",
              "timeFrame": "Retrospective data analysis from 2013 to 2020"
            },
            {
              "measure": "Duration of anticoagulation treatments for VTE",
              "timeFrame": "Retrospective data analysis from 2013 to 2020"
            },
            {
              "measure": "Recurrence of VTE with different treatment types of LMWH, VKA and NOAC",
              "timeFrame": "Retrospective data analysis from 2013 to 2020"
            },
            {
              "measure": "Major bleedings with different treatment types of LMWH, VKA and NOAC",
              "timeFrame": "Retrospective data analysis from 2013 to 2020"
            },
            {
              "measure": "All-cause death with different treatment types of LMWH, VKA and NOAC",
              "timeFrame": "Retrospective data analysis from 2013 to 2020"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* A resident in Sweden of 18+ years of age\n* A Swedish Person Identification Number\n* A diagnosis of cancer ((ICD10 = C00-C97) in the Swedish Cancer registry during 2013-2019 and a diagnosis of VTE subsequent to the cancer diagnosis.\n\nExclusion Criteria:\n\n* A diagnosis of atrial fibrillation, total hip or knee replacement or acute coronary syndrome (for evaluation of treatment patterns) before the date of VTE diagnosis\n* A dispensed prescription for any oral anticoagulant (OAC) before the date of VTE diagnosis\n* A cancer diagnosis associated with high bleeding risk, including upper gastrointestinal cancer, malignant immunoproliferative diseases and leukemia",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ],
          "studyPopulation": "All patients diagnosed with cancer in Sweden from year 2013 to 2019.",
          "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
          "locations": [
            {
              "facility": "Swedish registries",
              "city": "Multiple Locations",
              "state": "Many Locations",
              "country": "Sweden"
            }
          ]
        },
        "referencesModule": {
          "seeAlsoLinks": [
            {
              "label": "Click here for access to information about Bayer's transparency standards and Bayer studies.",
              "url": "https://clinicaltrials.bayer.com/"
            }
          ]
        },
        "ipdSharingStatementModule": {
          "ipdSharing": "NO",
          "description": "Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA \"Principles for responsible clinical trial data sharing\". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.\n\nInterested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal."
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000013927",
              "term": "Thrombosis"
            },
            {
              "id": "D000013923",
              "term": "Thromboembolism"
            },
            {
              "id": "D000054556",
              "term": "Venous Thromboembolism"
            }
          ],
          "ancestors": [
            {
              "id": "D000016769",
              "term": "Embolism and Thrombosis"
            },
            {
              "id": "D000014652",
              "term": "Vascular Diseases"
            },
            {
              "id": "D000002318",
              "term": "Cardiovascular Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M16376",
              "name": "Thrombosis",
              "asFound": "Thrombosis",
              "relevance": "HIGH"
            },
            {
              "id": "M16372",
              "name": "Thromboembolism",
              "asFound": "Thromboembolism",
              "relevance": "HIGH"
            },
            {
              "id": "M27470",
              "name": "Venous Thromboembolism",
              "asFound": "Venous Thromboembolism",
              "relevance": "HIGH"
            },
            {
              "id": "M7474",
              "name": "Embolism",
              "relevance": "LOW"
            },
            {
              "id": "M18818",
              "name": "Embolism and Thrombosis",
              "relevance": "LOW"
            },
            {
              "id": "M17090",
              "name": "Vascular Diseases",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC14",
              "name": "Heart and Blood Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000014812",
              "term": "Vitamin K"
            },
            {
              "id": "D000006493",
              "term": "Heparin"
            },
            {
              "id": "D000006495",
              "term": "Heparin, Low-Molecular-Weight"
            },
            {
              "id": "D000078222",
              "term": "Tinzaparin"
            },
            {
              "id": "D000017985",
              "term": "Dalteparin"
            },
            {
              "id": "D000069552",
              "term": "Rivaroxaban"
            }
          ],
          "ancestors": [
            {
              "id": "D000014815",
              "term": "Vitamins"
            },
            {
              "id": "D000018977",
              "term": "Micronutrients"
            },
            {
              "id": "D000045505",
              "term": "Physiological Effects of Drugs"
            },
            {
              "id": "D000000925",
              "term": "Anticoagulants"
            },
            {
              "id": "D000005343",
              "term": "Fibrinolytic Agents"
            },
            {
              "id": "D000050299",
              "term": "Fibrin Modulating Agents"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            },
            {
              "id": "D000065427",
              "term": "Factor Xa Inhibitors"
            },
            {
              "id": "D000000991",
              "term": "Antithrombins"
            },
            {
              "id": "D000015842",
              "term": "Serine Proteinase Inhibitors"
            },
            {
              "id": "D000011480",
              "term": "Protease Inhibitors"
            },
            {
              "id": "D000004791",
              "term": "Enzyme Inhibitors"
            },
            {
              "id": "D000000933",
              "term": "Antifibrinolytic Agents"
            },
            {
              "id": "D000006490",
              "term": "Hemostatics"
            },
            {
              "id": "D000003029",
              "term": "Coagulants"
            }
          ],
          "browseLeaves": [
            {
              "id": "M17248",
              "name": "Vitamins",
              "relevance": "LOW"
            },
            {
              "id": "M463",
              "name": "Rivaroxaban",
              "asFound": "Mutation",
              "relevance": "HIGH"
            },
            {
              "id": "M9269",
              "name": "Heparin",
              "asFound": "High Risk",
              "relevance": "HIGH"
            },
            {
              "id": "M9271",
              "name": "Heparin, Low-Molecular-Weight",
              "asFound": "Bile duct",
              "relevance": "HIGH"
            },
            {
              "id": "M19843",
              "name": "Dalteparin",
              "asFound": "Bile duct",
              "relevance": "HIGH"
            },
            {
              "id": "M45780",
              "name": "Calcium heparin",
              "relevance": "LOW"
            },
            {
              "id": "M1943",
              "name": "Tinzaparin",
              "asFound": "Bile duct",
              "relevance": "HIGH"
            },
            {
              "id": "M17245",
              "name": "Vitamin K",
              "asFound": "Fear",
              "relevance": "HIGH"
            },
            {
              "id": "M20699",
              "name": "Micronutrients",
              "relevance": "LOW"
            },
            {
              "id": "M16575",
              "name": "Trace Elements",
              "relevance": "LOW"
            },
            {
              "id": "M3934",
              "name": "Anticoagulants",
              "relevance": "LOW"
            },
            {
              "id": "M8163",
              "name": "Fibrinolytic Agents",
              "relevance": "LOW"
            },
            {
              "id": "M30203",
              "name": "Factor Xa Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M3997",
              "name": "Antithrombins",
              "relevance": "LOW"
            },
            {
              "id": "M3996",
              "name": "Antithrombin III",
              "relevance": "LOW"
            },
            {
              "id": "M14033",
              "name": "Protease Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M18081",
              "name": "Serine Proteinase Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M19299",
              "name": "HIV Protease Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M7641",
              "name": "Enzyme Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M3942",
              "name": "Antifibrinolytic Agents",
              "relevance": "LOW"
            },
            {
              "id": "M9266",
              "name": "Hemostatics",
              "relevance": "LOW"
            },
            {
              "id": "M5949",
              "name": "Coagulants",
              "relevance": "LOW"
            },
            {
              "id": "T481",
              "name": "Vitamin K",
              "asFound": "Fear",
              "relevance": "HIGH"
            },
            {
              "id": "T450",
              "name": "Menaquinone",
              "relevance": "LOW"
            },
            {
              "id": "T449",
              "name": "Menadione",
              "relevance": "LOW"
            },
            {
              "id": "T452",
              "name": "Naphthoquinone",
              "relevance": "LOW"
            },
            {
              "id": "T458",
              "name": "Phylloquinone",
              "relevance": "LOW"
            },
            {
              "id": "T18",
              "name": "Serine",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "Micro",
              "name": "Micronutrients"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            },
            {
              "abbrev": "AnCoag",
              "name": "Anticoagulants"
            },
            {
              "abbrev": "FiAg",
              "name": "Fibrinolytic Agents"
            },
            {
              "abbrev": "Coag",
              "name": "Coagulants"
            },
            {
              "abbrev": "Infe",
              "name": "Anti-Infective Agents"
            },
            {
              "abbrev": "Vi",
              "name": "Vitamins"
            },
            {
              "abbrev": "AA",
              "name": "Amino Acids"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00984438",
          "orgStudyIdInfo": {
            "id": "08081101"
          },
          "organization": {
            "fullName": "University of Cincinnati",
            "class": "OTHER"
          },
          "briefTitle": "Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme",
          "officialTitle": "Phase I/II Trial for Patients With Recurrent Resectable Glioblastoma Multiforme Using Surgery With Implantable BCNU Polymer Followed by Post-operative Irinotecan and Bevacizumab"
        },
        "statusModule": {
          "statusVerifiedDate": "2013-06",
          "overallStatus": "WITHDRAWN",
          "whyStopped": "No accrual",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2009-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2010-06",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2009-09-24",
          "studyFirstSubmitQcDate": "2009-09-24",
          "studyFirstPostDateStruct": {
            "date": "2009-09-25",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2019-11-21",
          "lastUpdatePostDateStruct": {
            "date": "2019-11-25",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "University of Cincinnati",
            "class": "OTHER"
          },
          "collaborators": [
            {
              "name": "Eisai Inc.",
              "class": "INDUSTRY"
            }
          ]
        },
        "oversightModule": {
          "oversightHasDmc": false
        },
        "descriptionModule": {
          "briefSummary": "The purpose of this research study is to try and identify a more effective treatment plan to improve survival rates for patients with a recurrent Glioblastoma Multiforme (GBM) brain tumor that can be removed by brain surgery.\n\nThe study will record what effects (good and bad) the combination of surgery with chemotherapy wafers inserted in the spot where the patient's tumor was during your surgery and post-operative chemotherapy has on the patient and their survival rate over the next 12 months."
        },
        "conditionsModule": {
          "conditions": [
            "Glioblastoma Multiforme"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "BCNU wafter followed by chemotherapy",
              "type": "EXPERIMENTAL",
              "description": "Surgical Implantable BCNU wafer followed by Chemotherapy with Irinotecan and Bevacizumab for up to one year",
              "interventionNames": [
                "Drug: BCNU Wafer",
                "Drug: Irinotecan",
                "Drug: Bevacizumab"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "BCNU Wafer",
              "description": "Implantable during surgical resection into the tumor bed",
              "armGroupLabels": [
                "BCNU wafter followed by chemotherapy"
              ],
              "otherNames": [
                "Gliadel Wafer"
              ]
            },
            {
              "type": "DRUG",
              "name": "Irinotecan",
              "description": "IV every 2 weeks for up to one year",
              "armGroupLabels": [
                "BCNU wafter followed by chemotherapy"
              ],
              "otherNames": [
                "CPT-11"
              ]
            },
            {
              "type": "DRUG",
              "name": "Bevacizumab",
              "description": "IV every 2 weeks for up to one year",
              "armGroupLabels": [
                "BCNU wafter followed by chemotherapy"
              ],
              "otherNames": [
                "Avastin"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "To assess disease free survival",
              "timeFrame": "6 and 12 months"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Histopathologically proven diagnosis of GBM in the past with MRI findings compatible with disease recurrence. Multifocal disease is permitted.\n* Must have had prior treatment with standard doses of Temodar\n* KPS \\>50; ECOG \\<3\n* Predicted life expectancy of \\> 3 months\n* Study entry must be within 5 weeks of surgical resection\n\nExclusion Criteria:\n\n* Prior exposure to VEGF inhibitors or Irinotecan\n* Intracranial bleed as defined by CT or MRI less than 6 months prior to entry\n* GI bleed less than 6 months prior to entry\n* Uncontrolled concurrent illness that would limit compliance with study requirements",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Margie Gerena-Lewis, MD",
              "affiliation": "University of Cincinnati",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "University of Cincinnati",
              "city": "Cincinnati",
              "state": "Ohio",
              "zip": "45219",
              "country": "United States",
              "geoPoint": {
                "lat": 39.12713,
                "lon": -84.51435
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000005909",
              "term": "Glioblastoma"
            }
          ],
          "ancestors": [
            {
              "id": "D000001254",
              "term": "Astrocytoma"
            },
            {
              "id": "D000005910",
              "term": "Glioma"
            },
            {
              "id": "D000018302",
              "term": "Neoplasms, Neuroepithelial"
            },
            {
              "id": "D000017599",
              "term": "Neuroectodermal Tumors"
            },
            {
              "id": "D000009373",
              "term": "Neoplasms, Germ Cell and Embryonal"
            },
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000009375",
              "term": "Neoplasms, Glandular and Epithelial"
            },
            {
              "id": "D000009380",
              "term": "Neoplasms, Nerve Tissue"
            }
          ],
          "browseLeaves": [
            {
              "id": "M14540",
              "name": "Recurrence",
              "relevance": "LOW"
            },
            {
              "id": "M8709",
              "name": "Glioblastoma",
              "asFound": "Glioblastoma Multiforme",
              "relevance": "HIGH"
            },
            {
              "id": "M4251",
              "name": "Astrocytoma",
              "relevance": "LOW"
            },
            {
              "id": "M8710",
              "name": "Glioma",
              "relevance": "LOW"
            },
            {
              "id": "M20136",
              "name": "Neoplasms, Neuroepithelial",
              "relevance": "LOW"
            },
            {
              "id": "M19535",
              "name": "Neuroectodermal Tumors",
              "relevance": "LOW"
            },
            {
              "id": "M20078",
              "name": "Neuroectodermal Tumors, Primitive",
              "relevance": "LOW"
            },
            {
              "id": "M12008",
              "name": "Neoplasms, Germ Cell and Embryonal",
              "relevance": "LOW"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M12010",
              "name": "Neoplasms, Glandular and Epithelial",
              "relevance": "LOW"
            },
            {
              "id": "M12015",
              "name": "Neoplasms, Nerve Tissue",
              "relevance": "LOW"
            },
            {
              "id": "T2518",
              "name": "Glioblastoma",
              "asFound": "Glioblastoma",
              "relevance": "HIGH"
            },
            {
              "id": "T2519",
              "name": "Glioma",
              "relevance": "LOW"
            },
            {
              "id": "T4092",
              "name": "Neuroepithelioma",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC23",
              "name": "Symptoms and General Pathology"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000068258",
              "term": "Bevacizumab"
            },
            {
              "id": "D000077146",
              "term": "Irinotecan"
            }
          ],
          "ancestors": [
            {
              "id": "D000074322",
              "term": "Antineoplastic Agents, Immunological"
            },
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000020533",
              "term": "Angiogenesis Inhibitors"
            },
            {
              "id": "D000043924",
              "term": "Angiogenesis Modulating Agents"
            },
            {
              "id": "D000006133",
              "term": "Growth Substances"
            },
            {
              "id": "D000045505",
              "term": "Physiological Effects of Drugs"
            },
            {
              "id": "D000006131",
              "term": "Growth Inhibitors"
            },
            {
              "id": "D000059004",
              "term": "Topoisomerase I Inhibitors"
            },
            {
              "id": "D000059003",
              "term": "Topoisomerase Inhibitors"
            },
            {
              "id": "D000004791",
              "term": "Enzyme Inhibitors"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            }
          ],
          "browseLeaves": [
            {
              "id": "M1671",
              "name": "Irinotecan",
              "asFound": "Pilot",
              "relevance": "HIGH"
            },
            {
              "id": "M246",
              "name": "Bevacizumab",
              "asFound": "Was",
              "relevance": "HIGH"
            },
            {
              "id": "M5275",
              "name": "Carmustine",
              "relevance": "LOW"
            },
            {
              "id": "M1346",
              "name": "Antineoplastic Agents, Immunological",
              "relevance": "LOW"
            },
            {
              "id": "M22008",
              "name": "Angiogenesis Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M8921",
              "name": "Growth Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M29039",
              "name": "Topoisomerase I Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M7641",
              "name": "Enzyme Inhibitors",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00066638",
          "orgStudyIdInfo": {
            "id": "NCI-2012-03005"
          },
          "secondaryIdInfos": [
            {
              "id": "NCI-2012-03005",
              "type": "REGISTRY",
              "domain": "CTRP (Clinical Trial Reporting Program)"
            },
            {
              "id": "NCI-5996"
            },
            {
              "id": "0403-765",
              "type": "OTHER",
              "domain": "Montefiore Medical Center - Moses Campus"
            },
            {
              "id": "5996",
              "type": "OTHER",
              "domain": "CTEP"
            },
            {
              "id": "N01CM62204",
              "type": "NIH",
              "link": "https://reporter.nih.gov/quickSearch/N01CM62204"
            },
            {
              "id": "P30CA013330",
              "type": "NIH",
              "link": "https://reporter.nih.gov/quickSearch/P30CA013330"
            }
          ],
          "organization": {
            "fullName": "National Cancer Institute (NCI)",
            "class": "NIH"
          },
          "briefTitle": "FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma",
          "officialTitle": "A Phase 2 Study of Depsipeptide in Relapsed/Refractory Multiple Myeloma"
        },
        "statusModule": {
          "statusVerifiedDate": "2012-12",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2003-06"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-03",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2003-08-06",
          "studyFirstSubmitQcDate": "2003-08-06",
          "studyFirstPostDateStruct": {
            "date": "2003-08-07",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2015-03-16",
          "lastUpdatePostDateStruct": {
            "date": "2015-03-17",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)",
            "class": "NIH"
          }
        },
        "descriptionModule": {
          "briefSummary": "Drugs used in chemotherapy such as FR901228 use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of FR901228 in treating patients who have relapsed or refractory multiple myeloma",
          "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. To evaluate the safety and efficacy of depsipeptide in patients with refractory or relapsed multiple myeloma (MM).\n\nOUTLINE: This is a multicenter study.\n\nPatients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a stable plateau (stable paraprotein levels or urine protein excretion over 3 consecutive determinations at least 4 weeks apart) may receive maintenance therapy comprising FR901228 IV on days 1 and 15, with courses repeating every 28 days.\n\nPROJECTED ACCRUAL: A total of 21-50 patients will be accrued for this study within 5-12.5 months."
        },
        "conditionsModule": {
          "conditions": [
            "DS Stage II Plasma Cell Myeloma",
            "DS Stage III Plasma Cell Myeloma",
            "Refractory Plasma Cell Myeloma"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Treatment (romidepsin)",
              "type": "EXPERIMENTAL",
              "description": "Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a stable plateau (stable paraprotein levels or urine protein excretion over 3 consecutive determinations at least 4 weeks apart) may receive maintenance therapy comprising FR901228 IV on days 1 and 15, with courses repeating every 28 days.",
              "interventionNames": [
                "Drug: Romidepsin",
                "Other: Laboratory Biomarker Analysis"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "Romidepsin",
              "description": "Given IV",
              "armGroupLabels": [
                "Treatment (romidepsin)"
              ]
            },
            {
              "type": "OTHER",
              "name": "Laboratory Biomarker Analysis",
              "description": "Correlative studies",
              "armGroupLabels": [
                "Treatment (romidepsin)"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Response rate (complete response [CR] or partial response [PR])",
              "timeFrame": "Up to 8 years"
            },
            {
              "measure": "Event free survival",
              "timeFrame": "Up to 8 years"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Gene array parameters",
              "description": "This analysis will be descriptive and will compare patterns of gene and phenotype expression pre and post therapy.",
              "timeFrame": "Up to 8 years"
            },
            {
              "measure": "Immunochemistry parameters",
              "description": "This analysis will be descriptive and will compare patterns of gene and phenotype expression pre and post therapy.",
              "timeFrame": "Up to 8 years"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed stage IIa or IIIa multiple myeloma\n* Patient has progressive disease and has had 1, 2, 3, or 4 prior lines of therapy\n* Bilirubin \\< 2.0 mg/dL\n* SGOT/SGPT =\\< 2.5 X institutional upper limit of normal\n* Serum creatinine =\\< 1.5 mg/dl OR creatinine clearance \\>= 60 mL/min/1.73 m\\^2 for patients with creatinine levels above institutional normal\n* Karnofsky Performance Status equal or greater than 70%; KPS 60% will be allowed if reduced KPS is due to advanced skeletal disease\n* Measurable disease as defined by serum M protein \\>= 1.0 gm/dl measured by serum protein electrophoresis or free light chain measurement, or quantitative immunoglobulins and/or urinary M protein excretion \\>= 200 mg/24 hrs\n* Ejection fraction \\>= 50% and normal baseline EKG tracing\n* No known central nervous system abnormality including neoplastic, vascular, inflammatory, degenerative or epilepsy\n* Life expectancy of greater than 12 weeks\n* Leukocytes \\>= 3,000/uL\n* Absolute neutrophil count \\>= 1,500/uL\n* Platelets \\>= 100,000/uL\n* Patients in whom cytopenias are considered to be due to myeloma marrow infiltration will be allowed as long as they meet the following criteria:\n\n  * Bone marrow biopsy displaying \\>= normal cellularity for age and \\>= 50% involvement by myeloma\n  * ANC \\> 1,000 and platelets \\> 50,000\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n* Ability to understand and the willingness to sign written informed consent\n\nExclusion Criteria:\n\n* Administration of chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to enrollment or unresolved adverse events due to agents administered more than 4 weeks earlier\n* Prior treatment with a histone deacetylase inhibitor\n* Patients may not be receiving any other investigational agent\n* History of second cancer (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free \\>= 5 years)\n* Non secretory disease or plasma cell leukemia (\\> 2000 circulating plasma cells/uL)\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to depsipeptide\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Patients with left ventricular hypertrophy or history of arrhythmias including atrial fibrillation, myocardial infarction or congestive heart failure; patients may not be taking hydrochlorothiazides\n* Patients that are pregnant or lactating will be excluded from this trial\n* Known HIV positivity; patients infected with the HIV virus will be excluded from this trial",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Ruben Niesvizky-Iszaevich",
              "affiliation": "Montefiore Medical Center - Moses Campus",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Montefiore Medical Center - Moses Campus",
              "city": "Bronx",
              "state": "New York",
              "zip": "10467-2490",
              "country": "United States",
              "geoPoint": {
                "lat": 40.84985,
                "lon": -73.86641
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000009101",
              "term": "Multiple Myeloma"
            },
            {
              "id": "D000054219",
              "term": "Neoplasms, Plasma Cell"
            }
          ],
          "ancestors": [
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000020141",
              "term": "Hemostatic Disorders"
            },
            {
              "id": "D000014652",
              "term": "Vascular Diseases"
            },
            {
              "id": "D000002318",
              "term": "Cardiovascular Diseases"
            },
            {
              "id": "D000010265",
              "term": "Paraproteinemias"
            },
            {
              "id": "D000001796",
              "term": "Blood Protein Disorders"
            },
            {
              "id": "D000006402",
              "term": "Hematologic Diseases"
            },
            {
              "id": "D000006474",
              "term": "Hemorrhagic Disorders"
            },
            {
              "id": "D000008232",
              "term": "Lymphoproliferative Disorders"
            },
            {
              "id": "D000007160",
              "term": "Immunoproliferative Disorders"
            },
            {
              "id": "D000007154",
              "term": "Immune System Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M11748",
              "name": "Multiple Myeloma",
              "asFound": "Plasma Cell Myeloma",
              "relevance": "HIGH"
            },
            {
              "id": "M27278",
              "name": "Neoplasms, Plasma Cell",
              "asFound": "Plasma Cell Myeloma",
              "relevance": "HIGH"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M21667",
              "name": "Hemostatic Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M4749",
              "name": "Blood Coagulation Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M17090",
              "name": "Vascular Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M12868",
              "name": "Paraproteinemias",
              "relevance": "LOW"
            },
            {
              "id": "M4767",
              "name": "Blood Protein Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M9180",
              "name": "Hematologic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M9250",
              "name": "Hemorrhagic Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M10915",
              "name": "Lymphoproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M9896",
              "name": "Immunoproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M9890",
              "name": "Immune System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "T3947",
              "name": "Multiple Myeloma",
              "asFound": "Plasma Cell Myeloma",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC14",
              "name": "Heart and Blood Diseases"
            },
            {
              "abbrev": "BC15",
              "name": "Blood and Lymph Conditions"
            },
            {
              "abbrev": "BC20",
              "name": "Immune System Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "C000087123",
              "term": "Romidepsin"
            }
          ],
          "ancestors": [
            {
              "id": "D000000903",
              "term": "Antibiotics, Antineoplastic"
            },
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000056572",
              "term": "Histone Deacetylase Inhibitors"
            },
            {
              "id": "D000004791",
              "term": "Enzyme Inhibitors"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            }
          ],
          "browseLeaves": [
            {
              "id": "M11837",
              "name": "Myeloma Proteins",
              "relevance": "LOW"
            },
            {
              "id": "M12869",
              "name": "Paraproteins",
              "relevance": "LOW"
            },
            {
              "id": "M109424",
              "name": "Romidepsin",
              "asFound": "Parenteral nutrition",
              "relevance": "HIGH"
            },
            {
              "id": "M3912",
              "name": "Anti-Bacterial Agents",
              "relevance": "LOW"
            },
            {
              "id": "M3914",
              "name": "Antibiotics, Antitubercular",
              "relevance": "LOW"
            },
            {
              "id": "M28201",
              "name": "Histone Deacetylase Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M7641",
              "name": "Enzyme Inhibitors",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            },
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "Infe",
              "name": "Anti-Infective Agents"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06197438",
          "orgStudyIdInfo": {
            "id": "SYLT-025"
          },
          "organization": {
            "fullName": "Fujian Cancer Hospital",
            "class": "OTHER_GOV"
          },
          "briefTitle": "Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer",
          "officialTitle": "PD-1 Antibody(Tislelizumab) Plus Irinotecan Combined With POF in Treatment Naive Advanced Gastric Cancer: A Phase II Study."
        },
        "statusModule": {
          "statusVerifiedDate": "2024-01",
          "overallStatus": "NOT_YET_RECRUITING",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2024-01-01",
            "type": "ESTIMATED"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-04-11",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-04-01",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2023-03-23",
          "studyFirstSubmitQcDate": "2024-01-08",
          "studyFirstPostDateStruct": {
            "date": "2024-01-09",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2024-01-08",
          "lastUpdatePostDateStruct": {
            "date": "2024-01-09",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "Fujian Cancer Hospital",
            "class": "OTHER_GOV"
          }
        },
        "oversightModule": {
          "oversightHasDmc": false,
          "isFdaRegulatedDrug": false,
          "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
          "briefSummary": "This study is a single center, phase II study, to evaluate the effectiveness and safety of PD-1 Antibody(Tislelizumab) Plus Irinotecan Combined With POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the first-line treatment for patients with advanced/metastatic gastric cancer.",
          "detailedDescription": "This is a exploratory, single-arm, open-label trial. The investigator's primary purpose is to compare that ORR of patients with Tislelizumab plus Irinotecan and POF for advanced/metastatic gastric cancer.\n\nIn treatment period, patients will be administrated Tislelizumab plus Irinotecan and POF, every 21 days for 1 cycle, until disease progression, toxicity intolerance, withdrawal of informed consent, patients judged must be terminated study termination.\n\nThe imaging evaluation was performed according to the RECIST 1.1 criteria every 6 weeks."
        },
        "conditionsModule": {
          "conditions": [
            "Gastric Cancer"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "POFI and Tislelizumab",
              "type": "EXPERIMENTAL",
              "interventionNames": [
                "Drug: Tislelizumab",
                "Drug: Oxaliplatin",
                "Drug: Levo-Leucovorin",
                "Drug: 5-fluorouracil",
                "Drug: Irinotecan Hydrochloride",
                "Drug: Paclitaxel"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "Tislelizumab",
              "description": "Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.",
              "armGroupLabels": [
                "POFI and Tislelizumab"
              ]
            },
            {
              "type": "DRUG",
              "name": "Oxaliplatin",
              "description": "Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.",
              "armGroupLabels": [
                "POFI and Tislelizumab"
              ]
            },
            {
              "type": "DRUG",
              "name": "Levo-Leucovorin",
              "description": "Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.",
              "armGroupLabels": [
                "POFI and Tislelizumab"
              ]
            },
            {
              "type": "DRUG",
              "name": "5-fluorouracil",
              "description": "5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.",
              "armGroupLabels": [
                "POFI and Tislelizumab"
              ]
            },
            {
              "type": "DRUG",
              "name": "Irinotecan Hydrochloride",
              "description": "Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 once every 14 days.",
              "armGroupLabels": [
                "POFI and Tislelizumab"
              ]
            },
            {
              "type": "DRUG",
              "name": "Paclitaxel",
              "description": "Paclitaxel will be administered on day 1 of each cycle at 90 mg/m2 once every 14 days.",
              "armGroupLabels": [
                "POFI and Tislelizumab"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Objective response rate(ORR)",
              "description": "ORR was defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR. ORR was assessed by the investigator according to RECIST version 1.1 and is based on BOR, which is defined as best response recorded from start of study treatment until disease progression/recurrence or death. Participants needed to have two consecutive assessments of PR or CR to be a responder. Only participants with measurable disease at baseline were included in the analysis of BOR and who did not have any evaluable post-baseline assessments were classified as not evaluable.The ORR will be reported by percentage with each arms and appropriate confidence intervals.",
              "timeFrame": "From enrollment to 12 month"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "1.Progression-Free Survival(PFS)",
              "description": "PFS was defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) or death from any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.The PFS will be will be estimated using Kaplan-Meier method. A Kaplan-Meier curve, median PFS, hazard ratio with appropriate confidence intervals will be reported.The PFS will be will be estimated using Kaplan-Meier method. A Kaplan-Meier curve, median PFS, hazard ratio with appropriate confidence intervals will be reported.",
              "timeFrame": "From enrollment to 12 month"
            },
            {
              "measure": "Overall Survival (OS)",
              "description": "Overall Survival (OS), defined as the time from the date of randomization to the date of death, regardless of the cause of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication and participants with no post-baseline information were censored at the date of randomization.The OS will be will be estimated using Kaplan-Meier method. A Kaplan-Meier curve, median OS, hazard ratio with appropriate confidence intervals will be reported.",
              "timeFrame": "From enrollment to 12 month"
            },
            {
              "measure": "Disease control rate(DCR)",
              "description": "DCR was defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR or SD. ORR was assessed by the investigator according to RECIST version 1.1 and is based on BOR, which is defined as best response recorded from start of study treatment until disease progression/recurrence or death. Participants needed to have two consecutive assessments of PR or CR or SD to be a responder. Only participants with measurable disease at baseline were included in the analysis of BOR and who did not have any evaluable post-baseline assessments were classified as not evaluable.The ORR will be reported by percentage with each arms and appropriate confidence intervals.",
              "timeFrame": "From enrollment to 12 month"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with advanced unresectable, histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction.\n2. With or without measurable lesions.\n3. Patients must have a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale.\n4. Without serious system dysfunction and could tolerate chemotherapy. With normal marrow, liver and renal function: a hemoglobin (HGB) of ≥100g/L (without blood transfusion during 14 days); a leucopenia count of ≥4.0×109/L; a platelet count of ≥100×109/L; a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL); a creatinine (Cr) of ≤ 1.5 UNL; a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault); a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis.\n5. Life expectancy ≥3 months.\n6. With normal electrocardiogram results and no history of congestive heart failure.\n7. With normal coagulation function: activated partial thromboplastin time (APTT), prothrombin time (PT) and INR, each ≤ 1.5 x ULN.\n8. Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of Tislelizumab until 8 weeks after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 8 weeks after last dose of study drug\n9. With written informed consent signed voluntarily by patients themselves or their supervisors witted by doctors.\n10. With good compliance and agree to accept follow-up of disease progression and adverse events.\n\nExclusion Criteria:\n\n1. Patients with a history of another neoplastic disease within the past three years, excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or nonmetastatic prostate cancer.\n2. Patients with brain or central nervous system metastases, including leptomeningeal disease.\n3. Pregnant (positive pregnancy test) or breast feeding.\n4. Serious, non-healing wound, ulcer, or bone fracture.\n5. Significant cardiac disease as defined as: unstable angina, New York Heart 6.Association (NYHA) grade II or greater, congestive heart failure, history of myocardial infarction within 6 months Evidence of bleeding diathesis or coagulopathy.\n\n7.History of a stroke or CVA within 6 months. 8.Clinically significant peripheral vascular disease. 9.Inability to comply with study and/or follow-up procedures. Patients with any other medical condition or reason, in that investigator's opinion, makes the patient unstable to participate in a clinical trial.",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "centralContacts": [
            {
              "name": "Rongbo Lin",
              "role": "CONTACT",
              "phone": "13705919382",
              "email": "rongbo_lin@163.com"
            }
          ]
        },
        "ipdSharingStatementModule": {
          "ipdSharing": "NO"
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000013274",
              "term": "Stomach Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000005770",
              "term": "Gastrointestinal Neoplasms"
            },
            {
              "id": "D000004067",
              "term": "Digestive System Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000004066",
              "term": "Digestive System Diseases"
            },
            {
              "id": "D000005767",
              "term": "Gastrointestinal Diseases"
            },
            {
              "id": "D000013272",
              "term": "Stomach Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M15754",
              "name": "Stomach Neoplasms",
              "asFound": "Gastric Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M8576",
              "name": "Gastrointestinal Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M6946",
              "name": "Digestive System Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M8573",
              "name": "Gastrointestinal Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M6945",
              "name": "Digestive System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M15752",
              "name": "Stomach Diseases",
              "relevance": "LOW"
            },
            {
              "id": "T5486",
              "name": "Stomach Cancer",
              "asFound": "Gastric Cancer",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC06",
              "name": "Digestive System Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000002955",
              "term": "Leucovorin"
            },
            {
              "id": "D000017239",
              "term": "Paclitaxel"
            },
            {
              "id": "D000005472",
              "term": "Fluorouracil"
            },
            {
              "id": "D000077150",
              "term": "Oxaliplatin"
            },
            {
              "id": "D000077146",
              "term": "Irinotecan"
            },
            {
              "id": "C000707970",
              "term": "Tislelizumab"
            },
            {
              "id": "D000058766",
              "term": "Levoleucovorin"
            }
          ],
          "ancestors": [
            {
              "id": "D000000972",
              "term": "Antineoplastic Agents, Phytogenic"
            },
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000050257",
              "term": "Tubulin Modulators"
            },
            {
              "id": "D000050256",
              "term": "Antimitotic Agents"
            },
            {
              "id": "D000050258",
              "term": "Mitosis Modulators"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            },
            {
              "id": "D000000963",
              "term": "Antimetabolites"
            },
            {
              "id": "D000000964",
              "term": "Antimetabolites, Antineoplastic"
            },
            {
              "id": "D000007166",
              "term": "Immunosuppressive Agents"
            },
            {
              "id": "D000007155",
              "term": "Immunologic Factors"
            },
            {
              "id": "D000045505",
              "term": "Physiological Effects of Drugs"
            },
            {
              "id": "D000059004",
              "term": "Topoisomerase I Inhibitors"
            },
            {
              "id": "D000059003",
              "term": "Topoisomerase Inhibitors"
            },
            {
              "id": "D000004791",
              "term": "Enzyme Inhibitors"
            },
            {
              "id": "D000000931",
              "term": "Antidotes"
            },
            {
              "id": "D000020011",
              "term": "Protective Agents"
            },
            {
              "id": "D000014803",
              "term": "Vitamin B Complex"
            },
            {
              "id": "D000014815",
              "term": "Vitamins"
            },
            {
              "id": "D000018977",
              "term": "Micronutrients"
            },
            {
              "id": "D000074322",
              "term": "Antineoplastic Agents, Immunological"
            }
          ],
          "browseLeaves": [
            {
              "id": "M137784",
              "name": "Tislelizumab",
              "asFound": "Discretion",
              "relevance": "HIGH"
            },
            {
              "id": "M1671",
              "name": "Irinotecan",
              "asFound": "Advanced Solid Tumors",
              "relevance": "HIGH"
            },
            {
              "id": "M5881",
              "name": "Leucovorin",
              "asFound": "Containing",
              "relevance": "HIGH"
            },
            {
              "id": "M8290",
              "name": "Fluorouracil",
              "asFound": "Function",
              "relevance": "HIGH"
            },
            {
              "id": "M1674",
              "name": "Oxaliplatin",
              "asFound": "Into",
              "relevance": "HIGH"
            },
            {
              "id": "M3915",
              "name": "Antibodies",
              "relevance": "LOW"
            },
            {
              "id": "M9874",
              "name": "Immunoglobulins",
              "relevance": "LOW"
            },
            {
              "id": "M19227",
              "name": "Paclitaxel",
              "asFound": "In Patients",
              "relevance": "HIGH"
            },
            {
              "id": "M231",
              "name": "Albumin-Bound Paclitaxel",
              "relevance": "LOW"
            },
            {
              "id": "M28923",
              "name": "Levoleucovorin",
              "asFound": "Bio-Gide",
              "relevance": "HIGH"
            },
            {
              "id": "M25887",
              "name": "Tubulin Modulators",
              "relevance": "LOW"
            },
            {
              "id": "M25886",
              "name": "Antimitotic Agents",
              "relevance": "LOW"
            },
            {
              "id": "M3971",
              "name": "Antimetabolites",
              "relevance": "LOW"
            },
            {
              "id": "M9902",
              "name": "Immunosuppressive Agents",
              "relevance": "LOW"
            },
            {
              "id": "M9891",
              "name": "Immunologic Factors",
              "relevance": "LOW"
            },
            {
              "id": "M29039",
              "name": "Topoisomerase I Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M7641",
              "name": "Enzyme Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M3940",
              "name": "Antidotes",
              "relevance": "LOW"
            },
            {
              "id": "M21559",
              "name": "Protective Agents",
              "relevance": "LOW"
            },
            {
              "id": "M17248",
              "name": "Vitamins",
              "relevance": "LOW"
            },
            {
              "id": "M8308",
              "name": "Folic Acid",
              "relevance": "LOW"
            },
            {
              "id": "M17236",
              "name": "Vitamin B Complex",
              "relevance": "LOW"
            },
            {
              "id": "M20699",
              "name": "Micronutrients",
              "relevance": "LOW"
            },
            {
              "id": "M16575",
              "name": "Trace Elements",
              "relevance": "LOW"
            },
            {
              "id": "M1346",
              "name": "Antineoplastic Agents, Immunological",
              "relevance": "LOW"
            },
            {
              "id": "T447",
              "name": "Folinic Acid",
              "asFound": "Bio-Gide",
              "relevance": "HIGH"
            },
            {
              "id": "T446",
              "name": "Folic Acid",
              "relevance": "LOW"
            },
            {
              "id": "T448",
              "name": "Folate",
              "relevance": "LOW"
            },
            {
              "id": "T475",
              "name": "Vitamin B9",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            },
            {
              "abbrev": "Micro",
              "name": "Micronutrients"
            },
            {
              "abbrev": "Hemat",
              "name": "Hematinics"
            },
            {
              "abbrev": "Vi",
              "name": "Vitamins"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01874938",
          "orgStudyIdInfo": {
            "id": "15007"
          },
          "secondaryIdInfos": [
            {
              "id": "I4C-JE-JTBE",
              "type": "OTHER",
              "domain": "Eli Lilly and Company"
            }
          ],
          "organization": {
            "fullName": "Eli Lilly and Company",
            "class": "INDUSTRY"
          },
          "briefTitle": "A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer",
          "officialTitle": "A Non-Randomized, Open-Label, Single-Arm, Phase 2 Study of LY2875358 in Patients With MET Diagnostic Positive, Advanced Gastric Cancer"
        },
        "statusModule": {
          "statusVerifiedDate": "2015-01",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2013-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2014-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2014-12",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2013-05-22",
          "studyFirstSubmitQcDate": "2013-06-07",
          "studyFirstPostDateStruct": {
            "date": "2013-06-11",
            "type": "ESTIMATED"
          },
          "dispFirstSubmitDate": "2014-09-29",
          "dispFirstSubmitQcDate": "2014-11-03",
          "dispFirstPostDateStruct": {
            "date": "2014-11-07",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2015-01-07",
          "lastUpdatePostDateStruct": {
            "date": "2015-01-16",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "Eli Lilly and Company",
            "class": "INDUSTRY"
          }
        },
        "oversightModule": {
          "oversightHasDmc": false
        },
        "descriptionModule": {
          "briefSummary": "The main purpose of this study is to evaluate the effectiveness of LY2875358 in participants with MET diagnostic positive (+), advanced gastric or gastroesophageal junction (GEJ) cancer."
        },
        "conditionsModule": {
          "conditions": [
            "Gastric Cancer"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "LY2875358",
              "type": "EXPERIMENTAL",
              "description": "LY2875358 will be administered intravenously (IV) at 2000 milligram (mg) bi-weekly in 28 day Cycle.",
              "interventionNames": [
                "Biological: LY2875358"
              ]
            }
          ],
          "interventions": [
            {
              "type": "BIOLOGICAL",
              "name": "LY2875358",
              "description": "Administered IV",
              "armGroupLabels": [
                "LY2875358"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Progression Free Survival (PFS) Rate",
              "timeFrame": "8 Weeks"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Proportion of Participants who Exhibit Confirmed Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])",
              "timeFrame": "Baseline to Confirmed CR or PR (Estimated up to 4 Months)"
            },
            {
              "measure": "Proportion of Participants who Exhibit Stable Disease (SD) or Confirmed CR or PR (Disease Control Rate [DCR])",
              "timeFrame": "Baseline to Measured Progressive Disease or Death from Any Cause (Estimated up to 4 Months)"
            },
            {
              "measure": "Duration of Response",
              "timeFrame": "Date of CR or PR to Date of Measured Recurrent or Progressive Disease or Death from Any Cause (Estimated up to 4 Months)"
            },
            {
              "measure": "Overall Survival (OS)",
              "timeFrame": "Baseline to Death from Any Cause (Estimated up to 6 Months)"
            },
            {
              "measure": "Pharmacokinetics (PK): Systemic Clearance (CL) of LY287358",
              "timeFrame": "Baseline to Study Completion (Estimated up to 4 Months)"
            },
            {
              "measure": "Pharmacokinetics (PK): Volume of distribution (V) of LY287358",
              "timeFrame": "Baseline to Study Completion (Estimated up to 4 Months)"
            },
            {
              "measure": "PFS",
              "timeFrame": "Baseline to Measured Progressive Disease or Death from Any Cause (Estimated up to 6 Months)"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Have a diagnosis of a histopathologically or cytologically confirmed local and/or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma which is unresectable\n* Have received 2 regimens of prior chemotherapies for gastric or GEJ adenocarcinoma\n* Have the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)\n* Have consent to provide a tissue sample for pre-screening\n* Determined to be MET diagnostic positive based upon testing of a tumor sample obtained at any time before enrollment\n* Have discontinued all previous treatments for cancer, including chemotherapy and radiotherapy, for at least 3 weeks before enrollment and have recovered from the acute effects of therapy\n* Have adequate organ function\n* Male participants: must agree to use a reliable method of birth control and to not donate sperm during the study and for at least 4 months following last dose of study drug or country requirements, whichever is longer\n* Female participants: are women of child-bearing potential who test negative for pregnancy ≤14 days before enrollment based on a serum pregnancy test and agree to use a reliable method of birth control during the study and for 4 months following the last dose of the study drug and must also not be breastfeeding\n* Have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale\n* Have an estimated life expectancy, in the judgment of the investigator, of at least 12 weeks\n\nExclusion Criteria:\n\n* Are currently enrolled in, or discontinued within the last 21 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study\n* Have previously completed or withdrawn from this study or any other study investigating LY2875358\n* Have an active fungal, bacterial, and/or known viral infection\n* Have a history of New York Heart Association class ≥3, unstable angina, myocardial infarction (MI) in 6 months prior to study drug administration\n* Have symptomatic central nervous system (CNS) malignancy or metastasis\n* Have previous or concurrent malignancies\n* Have received a liver transplant, or have liver cirrhosis with a Child-Pugh Stage of B or C\n* Have corrected QT interval (QTc) of \\>470 millisecond (msec) on screening electrocardiogram (ECG)\n* Have received previous treatment with any hepatocyte growth factor (HGF)/MET targeting therapeutics\n* Have a history of radiation therapy involving more than 25% of the bone marrow. Previous radiation therapy is allowed but should have been limited and must not have included whole pelvis radiation",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST)",
              "affiliation": "Eli Lilly and Company",
              "role": "STUDY_DIRECTOR"
            }
          ],
          "locations": [
            {
              "facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
              "city": "Aichi",
              "zip": "464-8681",
              "country": "Japan",
              "geoPoint": {
                "lat": 32.51879,
                "lon": 130.62158
              }
            },
            {
              "facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
              "city": "Osaka",
              "zip": "565-0871",
              "country": "Japan",
              "geoPoint": {
                "lat": 34.69374,
                "lon": 135.50218
              }
            },
            {
              "facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.",
              "city": "Seoul",
              "zip": "135 720",
              "country": "Korea, Republic of",
              "geoPoint": {
                "lat": 37.566,
                "lon": 126.9784
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000013274",
              "term": "Stomach Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000005770",
              "term": "Gastrointestinal Neoplasms"
            },
            {
              "id": "D000004067",
              "term": "Digestive System Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000004066",
              "term": "Digestive System Diseases"
            },
            {
              "id": "D000005767",
              "term": "Gastrointestinal Diseases"
            },
            {
              "id": "D000013272",
              "term": "Stomach Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M15754",
              "name": "Stomach Neoplasms",
              "asFound": "Gastric Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M8576",
              "name": "Gastrointestinal Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M6946",
              "name": "Digestive System Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M8573",
              "name": "Gastrointestinal Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M6945",
              "name": "Digestive System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M15752",
              "name": "Stomach Diseases",
              "relevance": "LOW"
            },
            {
              "id": "T5486",
              "name": "Stomach Cancer",
              "asFound": "Gastric Cancer",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC06",
              "name": "Digestive System Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00866138",
          "orgStudyIdInfo": {
            "id": "AB04019"
          },
          "organization": {
            "fullName": "AB Science",
            "class": "INDUSTRY"
          },
          "briefTitle": "Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3",
          "officialTitle": "Phase II Study of AB1010 in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not Expressing FGFR3"
        },
        "statusModule": {
          "statusVerifiedDate": "2019-12",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2005-02",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2011-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-01",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2009-03-19",
          "studyFirstSubmitQcDate": "2009-03-19",
          "studyFirstPostDateStruct": {
            "date": "2009-03-20",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2019-12-02",
          "lastUpdatePostDateStruct": {
            "date": "2019-12-03",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "AB Science",
            "class": "INDUSTRY"
          }
        },
        "oversightModule": {
          "oversightHasDmc": false
        },
        "descriptionModule": {
          "briefSummary": "This phase 2 study was designed to assess the safety and efficacy of masitinib (AB1010) in patients with relapsing/refractory t(4;14) Multiple Myeloma. Response and progression were assessed according to the Bladé revised IMWG criteria1 from lowest point."
        },
        "conditionsModule": {
          "conditions": [
            "Multiple Myeloma"
          ],
          "keywords": [
            "multiple myeloma",
            "t(4/14)",
            "relapsing",
            "refractory"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "1",
              "type": "EXPERIMENTAL",
              "description": "masitinib (AB1010)",
              "interventionNames": [
                "Drug: masitinib (AB1010)"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "masitinib (AB1010)",
              "description": "masitinib 9 mg/kg/day per os",
              "armGroupLabels": [
                "1"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Tumor Response Rate, based on the criteria published by Blade and on the criteria SWOG",
              "timeFrame": "16 weeks"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Tumor response rate with AB1010 plus dexamethasone",
              "timeFrame": "16 weeks"
            },
            {
              "measure": "Time to tumor progression and duration of response in responder patients",
              "timeFrame": "16 weeks"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed multiple myeloma with a t (4; 14) translocation by FISH and PCR, expressing or not expressing FGFR3 identified by FACS\n* Patients with Multiple Myeloma progressing or relapsing after at least two prior therapies (including conventional chemotherapy and/or high dose therapy) or who get a reduction of M-protein less than 75% within 3 months after a high dose treatment (Melphalan 200mg/m2) or after the plateau obtained for 3 months duration following to a conventional chemotherapy\n* Patient with rapidly progressive disease with cytopenia and / or renal failure have to be stabilized with chemotherapy (if possible 3 cycles of VTD ( Bortezomib/Thalidomide/dexamethasone) or high dose Melphalan regimen followed by a 4 weeks washout period before the inclusion in the study.\n* Patients must have a clearly detectable and quantifiable monoclonal M- component value (\\>5 g/l) in the serum and / or urine light chain excretion (\\>0,5 g/d)\n\nExclusion Criteria:\n\n* Prior corticosteroids within two weeks before enrolment\n* Prior local irradiation within two weeks before enrolment\n* Prior experimental or standard treatment (other than steroids and local irradiation) within 30 days before enrolment",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "locations": [
            {
              "facility": "Hopital Saint Louis",
              "city": "Paris",
              "country": "France",
              "geoPoint": {
                "lat": 48.85341,
                "lon": 2.3488
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000009101",
              "term": "Multiple Myeloma"
            },
            {
              "id": "D000054219",
              "term": "Neoplasms, Plasma Cell"
            }
          ],
          "ancestors": [
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000020141",
              "term": "Hemostatic Disorders"
            },
            {
              "id": "D000014652",
              "term": "Vascular Diseases"
            },
            {
              "id": "D000002318",
              "term": "Cardiovascular Diseases"
            },
            {
              "id": "D000010265",
              "term": "Paraproteinemias"
            },
            {
              "id": "D000001796",
              "term": "Blood Protein Disorders"
            },
            {
              "id": "D000006402",
              "term": "Hematologic Diseases"
            },
            {
              "id": "D000006474",
              "term": "Hemorrhagic Disorders"
            },
            {
              "id": "D000008232",
              "term": "Lymphoproliferative Disorders"
            },
            {
              "id": "D000007160",
              "term": "Immunoproliferative Disorders"
            },
            {
              "id": "D000007154",
              "term": "Immune System Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M11748",
              "name": "Multiple Myeloma",
              "asFound": "Multiple Myeloma",
              "relevance": "HIGH"
            },
            {
              "id": "M27278",
              "name": "Neoplasms, Plasma Cell",
              "asFound": "Multiple Myeloma",
              "relevance": "HIGH"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M21667",
              "name": "Hemostatic Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M4749",
              "name": "Blood Coagulation Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M17090",
              "name": "Vascular Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M12868",
              "name": "Paraproteinemias",
              "relevance": "LOW"
            },
            {
              "id": "M4767",
              "name": "Blood Protein Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M9180",
              "name": "Hematologic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M9250",
              "name": "Hemorrhagic Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M10915",
              "name": "Lymphoproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M9896",
              "name": "Immunoproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M9890",
              "name": "Immune System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "T3947",
              "name": "Multiple Myeloma",
              "asFound": "Multiple Myeloma",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC14",
              "name": "Heart and Blood Diseases"
            },
            {
              "abbrev": "BC15",
              "name": "Blood and Lymph Conditions"
            },
            {
              "abbrev": "BC20",
              "name": "Immune System Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03713138",
          "orgStudyIdInfo": {
            "id": "6099"
          },
          "organization": {
            "fullName": "Allied Hospital Faisalabad",
            "class": "OTHER"
          },
          "briefTitle": "Therapeutic Role of Flax Seed for Poly Cystic Ovary Syndrome",
          "officialTitle": "Therapeutic Role of Flax Seed for Poly Cystic Ovary Syndrome"
        },
        "statusModule": {
          "statusVerifiedDate": "2018-10",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2017-03-23",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-01-01",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2018-10-13",
          "studyFirstSubmitQcDate": "2018-10-17",
          "studyFirstPostDateStruct": {
            "date": "2018-10-19",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2018-10-19",
          "lastUpdatePostDateStruct": {
            "date": "2018-10-22",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "PRINCIPAL_INVESTIGATOR",
            "investigatorFullName": "Farhat Younas",
            "investigatorTitle": "Clinical Nutritionist",
            "investigatorAffiliation": "Allied Hospital Faisalabad"
          },
          "leadSponsor": {
            "name": "Allied Hospital Faisalabad",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": true,
          "isFdaRegulatedDrug": false,
          "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
          "briefSummary": "The study was conducted to determine the therapeutic role of flax seed for Poly cystic ovary syndrome. A sample of 100 subjects were collected. The subjects were from various age group ranging from 18 to 45 years. Subjects showing the signs, symptoms, biochemical, and clinical parameters of the diseases were included in the study. Three different quantities of flax seed were introduced to the subjects for 90 days.\n\nObjectives:\n\n1. To assess the nutritional status of Poly cystic Ovary Syndrome patients\n2. To determine the therapeutic role of flax seed for PCOS patients\n\nMaterial and method: The level of follicle stimulating hormone, leutinizing hormone, sex hormone binding globulin, serum prolactin, ultrasound were analyzed. To determine the side effects of the flax seed, the liver-enzymatic, lipid profile, and renal tests were conducted.",
          "detailedDescription": "Material and methods\n\nStudy Population:\n\nThe data were collected from the Allied Hospital. All Females of ages 18 to 45 years, having PCOS attending the OPD of Allied Hospital was taken as the study population. Efficacy trials were conducted on the patients of PCOS, including females of age 18-45 years. They were divided into different groups (as per no. of selected treatments along with the control). Ten subjects left the study and were replaced. The project was approved by the ethical review committee.The feeding study was conducted with the cooperation of Allied Hospital. The study protocol was discussed with medical professionals and finalized after through technical suggestions.\n\nSelection of subjects and Study Design\n\nThe patients were assorted randomly into four groups, 25 in each, namely control (T0),\n\nA total 100 female subjects were included in the study as under A) Control: To: 25 B) Experimental groups (PCOS): 75\n\n1. T1: 25\n2. T2: 25\n3. T3: 25\n\nInclusion Criteria:\n\nAll females of age 18 to 45 having PCOS\n\nWomen showing the presence of two out of three features (Oligo- or anovulation, hyper-androgenism, or poly cystic ovaries (Ovarian volume \\>10cc, 12 or more peripherally located follicles 2-9 mm in diameter or hypo-echoic enlarged ovaries with hyper-echoic central stroma in USG). Patients on Metformin (used for insulin resistance)\n\nExclusion Criteria:\n\n* Females under 18 and above 45 years of age\n* Those on any other medical therapy\n* Pregnant and lactating women\n* Those with a history of allergy to flax seed\n* Women on anti-platelet and fibrinolytic drugs\n* Women showing signs of PCOS but showing normal ovaries on ultrasound\n\nStudy Design\n\nIt was literature review based intervention study. The selected population for intervention purposes was studied twice, i.e. before and after the intervention of the selected nutraceutical. The same subjects were studied once again after one month of stopping the intake of selected nutraceutical. The change in results has confirmed the effects of the intervention.\n\nThis has been divided into four phases.\n\n1. Phase-1:Assessment of the nutritional Status in PCOS\n2. Phase -2:Development of nutraceutical (flaxseed sachets)\n3. Phase -3:Intervention to study the effect of selected nutraceutical\n4. Phase-4:Blood Analysis\n\n   The procedure adopted in each of the above phases is explained as follows:\n\n   Phase-1: Assessment of the nutritional status of selected patients\n\n   This was done in Allied Hospital, patients attending OPD of gynecology ward was assessed for nutritional status. Following parameters were studied for this purpose\n   * Family History\n   * Medical history\n   * Physical signs (thyroid gland, height, weight, skin, hair, breasts, belly, and BMI)\n   * Menstrual cycle detail (menarche, frequency, duration, and severity)\n   * History of dysmenorrhea\n   * Ferriman-Gall way scoring for hirsutism\n   * Marital status, parity, and difficulty in conception\n\n   Phase -2: Development of Nutraceutical (flaxseed sachets)\n\n   Procurement of raw materials Preparation of flax seed powder Preparation of flax seed sachets\n\n   Phase-3: Intervention\n\n   An acceptable number of human volunteers were selected keeping in view all ethical considerations. (25 in each group)\n   1. Control group (To)\n   2. Flaxseed (5 g) xTTS = 15 g/day (T1)\n   3. Flaxseed (6.6 g) x TTS = 20 g/day (T2)\n   4. Flaxseed (8.3 g) xTTS = 25 g/day (T3)\n\n   The flaxseed powder from the selected treatments was given daily for a period of 12 weeks. The dietary history of the subjects was monitored with the help of a Food Diary on a weekly basis. Education/counselling were provided to the patients for necessary compliance with the restricted diet for PCOS.\n\n   Phase-4: Blood Analysis and Ultrasound\n\n   After three months of intervention blood tests: follicle stimulating hormone (FSH), Luteinizing hormone (LH) thyroid stimulating hormone (TSH), serum prolactin, and ultrasound will be repeated.\n\n   Biochemical assays\n\n   Follicles stimulating hormone\n\n   The blood sample was taken to determine the quantitative level of serum follicles stimulating hormone (FSH) in patients fed with flaxseed powder by following the Immuno-enzymatic calorimetric method (ELISA).\n\n   Luteinizing hormone\n\n   The blood sample was taken to determine the quantitative level of serum luteinizing hormone (LH) in patients fed with flaxseed powder by following the Immuno-enzymatic calorimetric method.\n\n   Sex hormone binding globulin\n\n   The serum sex hormone binding globulin hormone (SHBG) in patients fed with flaxseed powder was determined by following the Rosner's method.\n\n   Prolactin\n\n   The serum sex prolactin level in patients fed with flaxseed powder was determined by following the radio-immunological method.\n\n   Thyroid stimulating hormone\n\n   The thyroid stimulating hormone (TSH) level in patients fed with flaxseed powder was performed to determine the thyroid gland functioning by following the third-generation non-isotopic method.\n\n   Liver Function Test\n\n   Alkaline Phosphatase (ALP)\n\n   The activity of alanine phosphatase in the plasma was determined by using enzyme-linked immune-sorbent assay kit method.\n\n   Aspartate Aminotransferase (AST)\n\n   The activity alanine transferase in the plasma was determined by using di-nitrophenyl hydrazine (DNPH) method using Sigma kits 59-50 and 58-50 under the conditions.\n\n   Alanine Aminotransferase (ALT)\n\n   The activity alanine aminotransferase in the plasma was determined by using enzyme-linked immune-sorbent assay kit method.\n\n   Lipid Profile\n\n   Low-density lipoprotein (LDL)\n\n   Serum low-density lipoprotein (LDL) was estimated by following the protocol of Vinson.\n\n   High-density lipoprotein (HDL)\n\n   The high-density lipoprotein (HDL) was assessed by HDL-Cholesterol precipitation.\n\n   Triglyceride\n\n   The triglyceride in the collected serum was determined by liquid triglyceride (GPO-PAP) method.\n\n   Renal Function Tests\n\n   Urea\n\n   The flax seed fed patients were diagnosed with urea content by GLDH method with the help of commercial kit.\n\n   Creatinine\n\n   The blood creatinine of the patients fed on flax seed powder was determined by the Jaffe method using creatinine commercial kit.\n\n   Follicles present in ovaries\n\n   Ultrasound of the ovaries was carried out to check the number of follicles present in the ovaries.\n\n   Size of the ovaries\n\n   The size of the ovaries of patients fed with flax seed powder was also checked in ultrasound.\n\n   Fasting blood glucose level\n\n   The blood sample was taken to check the fasting blood glucose level. The sample was taken eight hours after eating. Fasting blood glucose level as determined by glucose dye oxido-reductase mediator reaction which is specific for glucose by glucometer Accuchek active.\n\n   Research instruments\n   1. Questionnaire: For screening/nutritional assessment of PCOS patients\n   2. Hormonal analysis: Follicle stimulating hormone (FSH), luteinizing hormone (LH) thyroid stimulating hormone (TSH), Sex Hormone binding globulin (SHBG), and serum prolactin.\n   3. Biochemical assay: ALP, ALT, AST, urea, Creatinine, Fasting blood glucose level, LDL, HDL, and triglyceride.\n\n   Ethical Considerations:Written ethical approval was taken from the management of the concerned hospital and HOD of Gynecology department of the selected hospital. The consent was taken from the subjects after explaining the purpose of the study and after getting their consent for their menstrual cycle history, blood tests and ultrasound.\n\n   Statistical analysis\n\n   The data were subjected to statistical analysis by using the SPSS statistical package, analysis of variance (ANOVA) and least significant difference (LSD) was used to determine any significant difference among the treatments at p\\<0.05."
        },
        "conditionsModule": {
          "conditions": [
            "Poly Cystic Ovary Syndrome"
          ],
          "keywords": [
            "Follicle stimulating hormone",
            "Leutinizing hormone",
            "Sex hormone binding globulin",
            "Serum Prolactin",
            "Flaxseed sachets",
            "Lipid profile"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "NA"
          ],
          "designInfo": {
            "allocation": "RANDOMIZED",
            "interventionModel": "PARALLEL",
            "interventionModelDescription": "Randomized controlled placebo trial",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "SINGLE",
              "maskingDescription": "Single-blinded trial, Intervention and placebo given",
              "whoMasked": [
                "PARTICIPANT"
              ]
            }
          },
          "enrollmentInfo": {
            "count": 120,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Intervention Flaxseed powder",
              "type": "EXPERIMENTAL",
              "description": "Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.\n\nIntervention/ Dietary Supplement:\n\nFlax seed powder\n\nThree different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.\n\nOther Name: intervention",
              "interventionNames": [
                "Dietary Supplement: flaxseed powder"
              ]
            },
            {
              "label": "Control group; Comparison group",
              "type": "NO_INTERVENTION",
              "description": "The controlled group was given no intervention. No intervention was done to this group.\n\nThree different quantities of white flour were intervened to the subjects. One group was given 15 grams of white flour a day. Second group was given 20 grams and third group was given 25 grams of white flour a day."
            }
          ],
          "interventions": [
            {
              "type": "DIETARY_SUPPLEMENT",
              "name": "flaxseed powder",
              "description": "Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.",
              "armGroupLabels": [
                "Intervention Flaxseed powder"
              ],
              "otherNames": [
                "Intervention"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Follicle stimulating hormone (mIU/MI)",
              "description": "The blood sample was taken to determine the quantitative level of serum follicles stimulating hormone (FSH) in patients fed with flaxseed powder by following the Immuno-enzymatic calorimetric method (ELISA).",
              "timeFrame": "3 months"
            },
            {
              "measure": "Leutinizing Hormone (mIU/MI)",
              "description": "The blood sample was taken to determine the quantitative level of serum luteinizing hormone (LH) in patients fed with flaxseed powder by following the Immuno-enzymatic calorimetric method (ELISA-ALPCO)",
              "timeFrame": "3 months"
            },
            {
              "measure": "Sex hormone binding globulin (mg/dL)",
              "description": "The serum sex hormone binding globulin hormone (SHBG) in patients fed with flaxseed powder was determined by following the Rosner's method.",
              "timeFrame": "3 months"
            },
            {
              "measure": "Serum Prolactin (ng/ml)",
              "description": "The serum sex prolactin level in patients fed with flaxseed powder was determined by following the radio-immunological method.",
              "timeFrame": "3 months"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "blood sugar fasting (mg/dL)",
              "description": "The blood sample was taken to check the fasting blood glucose level. The sample was taken eight hours after eating. Fasting blood glucose level as determined by glucose dye oxido-reductase mediator reaction which is specific for glucose by glucometer Accuchek active",
              "timeFrame": "3 months"
            },
            {
              "measure": "Thyroid stimulating hormone (Ml/L)",
              "description": "The thyroid stimulating hormone (TSH) level in patients fed with flaxseed powder was performed to determine the thyroid gland functioning by following the third-generation non-isotopic method.",
              "timeFrame": "3 months"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* • All females of age 18 to 45 having PCOS\n\n  * Women showing the presence of two out of three features (Oligo- or anovulation, hyper-androgenism, or polycystic ovaries (Ovarian volume \\>10cc, 12 or more peripherally located follicles 2-9 mm in diameter or hypo-echoic enlarged ovaries with hyper-echoic central stroma in USG)\n  * Patients on Metformin (used for insulin resistance)\n\nExclusion Criteria:\n\n* • Females under 18 and above 45 years of age\n\n  * Those on any other medical therapy\n  * Pregnant and lactating women\n  * Those with a history of allergy to flaxseed\n  * Women on antiplatelet and fibrinolytic drugs\n  * Women showing signs of PCOS but showing normal ovaries on ultrasound",
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "45 Years",
          "stdAges": [
            "ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Khalid Mahmood, MPhill",
              "affiliation": "Akuwat",
              "role": "STUDY_DIRECTOR"
            }
          ],
          "locations": [
            {
              "facility": "Allama Iqbal Open University",
              "city": "Islamabad",
              "state": "Punjab",
              "zip": "45710",
              "country": "Pakistan",
              "geoPoint": {
                "lat": 33.72148,
                "lon": 73.04329
              }
            }
          ]
        },
        "ipdSharingStatementModule": {
          "ipdSharing": "NO"
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000010048",
              "term": "Ovarian Cysts"
            },
            {
              "id": "D000013577",
              "term": "Syndrome"
            }
          ],
          "ancestors": [
            {
              "id": "D000004194",
              "term": "Disease"
            },
            {
              "id": "D000010335",
              "term": "Pathologic Processes"
            },
            {
              "id": "D000003560",
              "term": "Cysts"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000010049",
              "term": "Ovarian Diseases"
            },
            {
              "id": "D000000291",
              "term": "Adnexal Diseases"
            },
            {
              "id": "D000005831",
              "term": "Genital Diseases, Female"
            },
            {
              "id": "D000052776",
              "term": "Female Urogenital Diseases"
            },
            {
              "id": "D000005261",
              "term": "Female Urogenital Diseases and Pregnancy Complications"
            },
            {
              "id": "D000091642",
              "term": "Urogenital Diseases"
            },
            {
              "id": "D000091662",
              "term": "Genital Diseases"
            },
            {
              "id": "D000006058",
              "term": "Gonadal Disorders"
            },
            {
              "id": "D000004700",
              "term": "Endocrine System Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M16045",
              "name": "Syndrome",
              "asFound": "Syndrome",
              "relevance": "HIGH"
            },
            {
              "id": "M12661",
              "name": "Ovarian Cysts",
              "asFound": "Cystic Ovary",
              "relevance": "HIGH"
            },
            {
              "id": "M6455",
              "name": "Cysts",
              "relevance": "LOW"
            },
            {
              "id": "M12662",
              "name": "Ovarian Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M3333",
              "name": "Adnexal Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M2877",
              "name": "Genital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M8633",
              "name": "Genital Diseases, Female",
              "relevance": "LOW"
            },
            {
              "id": "M2876",
              "name": "Urogenital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M26783",
              "name": "Female Urogenital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M13817",
              "name": "Pregnancy Complications",
              "relevance": "LOW"
            },
            {
              "id": "M8089",
              "name": "Female Urogenital Diseases and Pregnancy Complications",
              "relevance": "LOW"
            },
            {
              "id": "M8853",
              "name": "Gonadal Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M7552",
              "name": "Endocrine System Diseases",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC23",
              "name": "Symptoms and General Pathology"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BXS",
              "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
            },
            {
              "abbrev": "BC19",
              "name": "Gland and Hormone Related Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "browseLeaves": [
            {
              "id": "M9479",
              "name": "Hormones",
              "relevance": "LOW"
            },
            {
              "id": "M8449",
              "name": "Follicle Stimulating Hormone",
              "relevance": "LOW"
            },
            {
              "id": "T156",
              "name": "Flax",
              "asFound": "Sphincter",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            },
            {
              "abbrev": "HB",
              "name": "Herbal and Botanical"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01105338",
          "orgStudyIdInfo": {
            "id": "C11046/A10052"
          },
          "secondaryIdInfos": [
            {
              "id": "ISRCTN-95931417",
              "type": "REGISTRY",
              "domain": "ISRCTN"
            }
          ],
          "organization": {
            "fullName": "University of Bristol",
            "class": "OTHER"
          },
          "briefTitle": "Lycopene or Green Tea for Men at Risk of Prostate Cancer",
          "officialTitle": "Lycopene or Green Tea a Feasibility Study in Men at Risk of Prostate Cancer",
          "acronym": "ProDiet"
        },
        "statusModule": {
          "statusVerifiedDate": "2018-01",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2009-08"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2010-08",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2010-04-15",
          "studyFirstSubmitQcDate": "2010-04-15",
          "studyFirstPostDateStruct": {
            "date": "2010-04-16",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2018-01-19",
          "lastUpdatePostDateStruct": {
            "date": "2018-01-23",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "PRINCIPAL_INVESTIGATOR",
            "investigatorFullName": "Dr Athene Lane",
            "investigatorTitle": "Study Coordinator and Senior Research Fellow",
            "investigatorAffiliation": "University of Bristol"
          },
          "leadSponsor": {
            "name": "University of Bristol",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": false
        },
        "descriptionModule": {
          "briefSummary": "RATIONALE: Lycopene and green tea may stop or delay the development of recurrent prostate cancer in patients has been treated for prostate cancer. It is not yet known whether lycopene or green tea may be more effective in preventing prostate cancer.\n\nPURPOSE: This randomized phase II trial is studying lycopene to see how well it works compared with green tea in preventing prostate cancer in patients previously enrolled in the ProtecT trial",
          "detailedDescription": "OBJECTIVES:\n\nPrimary\n\n* To assess serum lycopene and epigallocatechin-3-gallate (green tea) levels at 6 months following randomization in patients with prostate cancer previously enrolled on ProtecT\n\nSecondary\n\n* To evaluate trial recruitment and randomization rates of patients treated with this regimen.\n* To evaluate intervention tolerability in patients treated with this regimen.\n* To evaluate compliance of patients treated with this regimen.\n* To evaluate trial retention of patients treated with this regimen.\n* To assess PSA values in patients treated with this regimen.\n* To evaluate dietary compliance with recommendations of patients treated with this regimen.\n* To assess weight and body mass index of patients treated with this regimen.\n* To evaluate attitudes and views of men and their spouses about dietary modification and participation in long-term study.\n\nOUTLINE: Patients are stratified according to PSA test levels obtained from ProtecT study recruitment clinic (\\< 3.0 ng/mL vs 3.0-19.99 ng/mL). Patients are randomized to 1 of 2 treatment arms."
        },
        "conditionsModule": {
          "conditions": [
            "Prostate Cancer"
          ],
          "keywords": [
            "prostate cancer"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2",
            "PHASE3"
          ],
          "designInfo": {
            "allocation": "RANDOMIZED",
            "interventionModel": "FACTORIAL",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "QUADRUPLE",
              "whoMasked": [
                "PARTICIPANT",
                "CARE_PROVIDER",
                "INVESTIGATOR",
                "OUTCOMES_ASSESSOR"
              ]
            }
          },
          "enrollmentInfo": {
            "count": 126,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Green tea drink",
              "type": "ACTIVE_COMPARATOR",
              "description": "Green tea drink",
              "interventionNames": [
                "Behavioral: Green tea drink"
              ]
            },
            {
              "label": "Green tea capsules",
              "type": "ACTIVE_COMPARATOR",
              "description": "Green tea capsules",
              "interventionNames": [
                "Dietary Supplement: green tea capsules"
              ]
            },
            {
              "label": "Green tea placebo capsules",
              "type": "PLACEBO_COMPARATOR",
              "description": "Green tea placebo capsules",
              "interventionNames": [
                "Other: Green tea placebo capsules"
              ]
            },
            {
              "label": "Lycopene capsules",
              "type": "ACTIVE_COMPARATOR",
              "description": "Lycopene capsules",
              "interventionNames": [
                "Dietary Supplement: Lycopene capsules"
              ]
            },
            {
              "label": "Lycopene placebo capsules",
              "type": "PLACEBO_COMPARATOR",
              "description": "Lycopene placebo capsules",
              "interventionNames": [
                "Other: Lycopene placebo capsules"
              ]
            },
            {
              "label": "Tomato rich diet",
              "type": "ACTIVE_COMPARATOR",
              "description": "Tomato rich diet",
              "interventionNames": [
                "Other: Tomato rich diet"
              ]
            }
          ],
          "interventions": [
            {
              "type": "BEHAVIORAL",
              "name": "Green tea drink",
              "description": "Green tea drink",
              "armGroupLabels": [
                "Green tea drink"
              ]
            },
            {
              "type": "DIETARY_SUPPLEMENT",
              "name": "green tea capsules",
              "description": "green tea capsules",
              "armGroupLabels": [
                "Green tea capsules"
              ]
            },
            {
              "type": "OTHER",
              "name": "Green tea placebo capsules",
              "description": "Green tea placebo capsules",
              "armGroupLabels": [
                "Green tea placebo capsules"
              ]
            },
            {
              "type": "DIETARY_SUPPLEMENT",
              "name": "Lycopene capsules",
              "description": "Lycopene capsules",
              "armGroupLabels": [
                "Lycopene capsules"
              ]
            },
            {
              "type": "OTHER",
              "name": "Lycopene placebo capsules",
              "description": "Lycopene placebo capsules",
              "armGroupLabels": [
                "Lycopene placebo capsules"
              ]
            },
            {
              "type": "OTHER",
              "name": "Tomato rich diet",
              "description": "Tomato rich diet",
              "armGroupLabels": [
                "Tomato rich diet"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Serum lycopene and epigallocatechin-3-gallate (green tea) levels at 6 months following randomization",
              "timeFrame": "6 months"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Trial recruitment and randomization rates at each stage of the study",
              "timeFrame": "6 months"
            },
            {
              "measure": "Intervention tolerability (adverse event reporting during the six months of follow-up)",
              "timeFrame": "6 months"
            },
            {
              "measure": "Compliance (returned tablet counts and self-reported counts at 6 months)",
              "timeFrame": "6 months"
            },
            {
              "measure": "Trial retention (participants completing 6-month follow-up and questionnaires)",
              "timeFrame": "6 months"
            },
            {
              "measure": "PSA values at baseline and at 6 months",
              "timeFrame": "6 months"
            },
            {
              "measure": "Dietary compliance with recommendations (dietary questionnaire completed at 6 months and participant data reporting dietary change)",
              "timeFrame": "6 months"
            },
            {
              "measure": "Weight and body mass index at 1 and 6 months",
              "timeFrame": "6 months"
            },
            {
              "measure": "Blood pressure at 1 and 6 months",
              "timeFrame": "6 months"
            },
            {
              "measure": "Attitudes and views of men and their spouses about dietary modification and participation in long-term study (qualitative interviews conducted throughout the study)",
              "timeFrame": "6 months"
            },
            {
              "measure": "Anxiety, depression, and psychological state as measured by the Hospital Anxiety and Depression Scale and the Profile of Moods States",
              "timeFrame": "6 months"
            },
            {
              "measure": "Urinary symptoms as measured by the ICSmaleSF questionnaire (including voiding and incontinence scores, nocturia, frequency, and urinary-specific quality-of-life care data sources)",
              "timeFrame": "6 months"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion criteria: PSA level 2.0-2.95 ng/mL OR PSA level ≥ 3.0 ng/mL with a negative biopsy No major comorbidities No other cancers or prior prostate malignancy No history of allergic reactions to green tea or lycopene-containing products, including guava or watermelon Exclusion criteria: No concurrent finasteride or dutasteride",
          "healthyVolunteers": true,
          "sex": "MALE",
          "minimumAge": "50 Years",
          "maximumAge": "69 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Athene Lane, PhD",
              "affiliation": "University of Bristol",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Southmead Hospital",
              "city": "Bristol",
              "state": "England",
              "country": "United Kingdom",
              "geoPoint": {
                "lat": 51.45523,
                "lon": -2.59665
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000011471",
              "term": "Prostatic Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000005834",
              "term": "Genital Neoplasms, Male"
            },
            {
              "id": "D000014565",
              "term": "Urogenital Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000005832",
              "term": "Genital Diseases, Male"
            },
            {
              "id": "D000091662",
              "term": "Genital Diseases"
            },
            {
              "id": "D000091642",
              "term": "Urogenital Diseases"
            },
            {
              "id": "D000011469",
              "term": "Prostatic Diseases"
            },
            {
              "id": "D000052801",
              "term": "Male Urogenital Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M14025",
              "name": "Prostatic Neoplasms",
              "asFound": "Prostate Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M8636",
              "name": "Genital Neoplasms, Male",
              "relevance": "LOW"
            },
            {
              "id": "M17005",
              "name": "Urogenital Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M2877",
              "name": "Genital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M8634",
              "name": "Genital Diseases, Male",
              "relevance": "LOW"
            },
            {
              "id": "M2876",
              "name": "Urogenital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M14023",
              "name": "Prostatic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M26785",
              "name": "Male Urogenital Diseases",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BXS",
              "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000077276",
              "term": "Lycopene"
            }
          ],
          "ancestors": [
            {
              "id": "D000000893",
              "term": "Anti-Inflammatory Agents"
            },
            {
              "id": "D000000975",
              "term": "Antioxidants"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            },
            {
              "id": "D000020011",
              "term": "Protective Agents"
            },
            {
              "id": "D000045505",
              "term": "Physiological Effects of Drugs"
            },
            {
              "id": "D000011837",
              "term": "Radiation-Protective Agents"
            },
            {
              "id": "D000016588",
              "term": "Anticarcinogenic Agents"
            },
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            }
          ],
          "browseLeaves": [
            {
              "id": "M1732",
              "name": "Lycopene",
              "asFound": "Vinblastine",
              "relevance": "HIGH"
            },
            {
              "id": "M3907",
              "name": "Anti-Inflammatory Agents",
              "relevance": "LOW"
            },
            {
              "id": "M3982",
              "name": "Antioxidants",
              "relevance": "LOW"
            },
            {
              "id": "M21559",
              "name": "Protective Agents",
              "relevance": "LOW"
            },
            {
              "id": "M14374",
              "name": "Radiation-Protective Agents",
              "relevance": "LOW"
            },
            {
              "id": "T316",
              "name": "Tomato",
              "asFound": "Mm2",
              "relevance": "HIGH"
            },
            {
              "id": "T312",
              "name": "Tea",
              "asFound": "Lung Disease",
              "relevance": "HIGH"
            },
            {
              "id": "T408",
              "name": "Lycopene",
              "asFound": "Vinblastine",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "Infl",
              "name": "Anti-Inflammatory Agents"
            },
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            },
            {
              "abbrev": "HB",
              "name": "Herbal and Botanical"
            },
            {
              "abbrev": "Ot",
              "name": "Other Dietary Supplements"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04497038",
          "orgStudyIdInfo": {
            "id": "UMCC 2020.007"
          },
          "secondaryIdInfos": [
            {
              "id": "HUM00176488",
              "type": "OTHER",
              "domain": "University of Michigan"
            }
          ],
          "organization": {
            "fullName": "University of Michigan Rogel Cancer Center",
            "class": "OTHER"
          },
          "briefTitle": "Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy",
          "officialTitle": "Phase 1/2 Trial to Evaluate Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy"
        },
        "statusModule": {
          "statusVerifiedDate": "2023-11",
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2021-08-06",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2020-06-29",
          "studyFirstSubmitQcDate": "2020-07-31",
          "studyFirstPostDateStruct": {
            "date": "2020-08-04",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2023-11-02",
          "lastUpdatePostDateStruct": {
            "date": "2023-11-07",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "University of Michigan Rogel Cancer Center",
            "class": "OTHER"
          },
          "collaborators": [
            {
              "name": "Exelixis",
              "class": "INDUSTRY"
            }
          ]
        },
        "oversightModule": {
          "isFdaRegulatedDrug": true,
          "isFdaRegulatedDevice": false,
          "isUsExport": true
        },
        "descriptionModule": {
          "briefSummary": "The aim of this study is to determine the safety and efficacy of cabozantinib in the management of unresectable or metastatic hepatocellular carcinoma (HCC) with underlying Child-Pugh class B cirrhosis."
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Adult Hepatocellular Carcinoma"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE1",
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Cabozantinib",
              "type": "EXPERIMENTAL",
              "description": "Cabozantinib 20-60 mg by mouth once daily.",
              "interventionNames": [
                "Drug: Cabozantinib"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "Cabozantinib",
              "description": "Patients will receive therapy with cabozantinib. Dosage in the trial will start at 40 mg PO daily. Each patient will be assessed for the development of toxicity according to the NCI Common Terminology Criteria for Adverse Events, version 5.0. Dose adjustments may be made per the Time-To-Event modification of the Continual Reassessment Method (TITE-CRM). The maximum dosage will be 60 mg PO daily and the minimum will be 20 mg PO daily.",
              "armGroupLabels": [
                "Cabozantinib"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D)",
              "description": "MTD/RP2D determined by dose limiting toxicities (DLT) during the first 29 days of therapy. DLTs are outlined in the protocol and assessed per the NCI CTCAE v5.0. The MTD/RP2D will be determined as the dose level with the highest probability of DLT not exceeding 35%.",
              "timeFrame": "Up to 29 days after initiating treatment"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Progression-free survival (PFS)",
              "description": "PFS defined as time from date of treatment to date of radiological or clinical progressing (leading to withdrawal from the study), or death from any cause, whichever comes first. PFS will be estimated using the product-limit method of Kaplan and Meier.",
              "timeFrame": "Up to 3 years"
            },
            {
              "measure": "Median time to progression (TTP)",
              "description": "TTP defined as time from date of treatment to date of radiological or clinical progression (leading to withdrawal from the study).",
              "timeFrame": "Until date of last disease evaluation (up to 2 years)"
            },
            {
              "measure": "Overall survival (OS)",
              "description": "Patients will be followed for up to 2 years from treatment discontinuation or until death, whichever comes first, or 3 years after first date of treatment initiation for those that remain on treatment. OS will be estimated using the product-limit method of Kaplan and Meier.",
              "timeFrame": "Up to 3 years"
            },
            {
              "measure": "Overall response rate (ORR) (partial response + complete response)",
              "description": "ORR (PR + CR) per RECIST v1.1 criteria during active study treatment.",
              "timeFrame": "Up to 2 years"
            },
            {
              "measure": "Pharmacokinetic (PK) profile: Elimination clearance (L/hr)",
              "description": "Blood draws pre-dose, every 2 weeks until the start of cycle 3",
              "timeFrame": "Up to 2 months"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have a radiologically consistent (early enhancement and delayed enhancement washout) or pathologically confirmed diagnosis of hepatocellular carcinoma that is not eligible for curative resection, transplantation, or ablative therapies.\n* Prior radiation, liver directed therapy (including bland, chemo- or radioembolization, or ablation), or hepatic resection are permitted if ≥4 weeks from start of therapy. Extra-hepatic palliative radiation is permitted if completed ≥2 weeks prior to first dose of study therapy and the patient has recovered to ≤ grade 1 toxicity.\n* Patients must have radiographically measurable disease (RECIST1.1) in at least one site not previously treated or with progression after radiation or liver directed therapy (including bland, chemo- or radio-embolization, or ablation) either within the liver or in a metastatic site.\n* Patients must have either progressed or deemed intolerant of first-line systemic therapy. More than one line of systemic therapy is not permitted. The last dose should be at least 2 weeks from first dose of study therapy. Prior treatment may not contain cabozantinib.\n* Recovery to ≤ grade 1 from toxicities related to any prior treatments, unless the AEs were clinically non-significant and/or stable on supportive therapy\n* Must have a Child-Pugh score of B7 or B8\n* Must have an ECOG performance status of 0-1.\n* Ability to understand and willingness to sign IRB-approved informed consent.\n* Willing to provide archived tissue, if available, from a previous diagnostic biopsy.\n* Must be able to tolerate CT and/or MRI with contrast.\n* Adequate organ function obtained ≤ 2 weeks prior to enrollment.\n\nExclusion Criteria:\n\n* Must not have uncontrolled ascites (requiring paracentesis within 3 months of screening) or hepatic encephalopathy requiring hospitalization (within 6 months of screening)\n* Must not have prior history of organ transplantation.\n* No known brain metastasis unless adequately treated with radiotherapy and/or surgery and stable for at least 4 weeks before registration. Eligible subjects must have been without corticosteroid treatment at the time of registration.\n* Must not have undergone a major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before first dose and from minor surgery (e.g., simple excision, tooth extraction) at least 10 days before first dose. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\n* Must not have an active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ. Patients with history of malignancy are eligible provided primary treatment of that cancer was completed \\> 1 year prior to enrollment and the patient is free of clinical or radiologic evidence of recurrent or progressive malignancy.\n* Must not have uncontrolled, significant intercurrent or recent illness including, but not limited to the following conditions:\n\n  * Cardiovascular disorders (Congestive heart failure or uncontrolled hypertension; or stroke, myocardial infarction, or other ischemic or thromboembolic event within 6 months before first dose)\n  * Gastrointestinal disorders, including those associated with a high risk of perforation or fistula formation\n  * Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon of red blood or other history of significant bleeding within 12 weeks before first dose\n  * Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation\n  * Lesions invading or encasing any major blood vessels except thromboses of portal/hepatic vasculature attributed to underlying liver disease and/or liver tumor\n  * Other clinically significant disorders that would preclude safe study participation (serious non-healing wound/ulcer/bone fracture; uncompensated/symptomatic hypothyroidism; known HIV)\n* Must not have untreated or incompletely treated varices with bleeding or high risk for bleeding. Subjects treated with adequate endoscopic therapy (in accordance with institutional standards) without any episodes of recurrent overt GI bleeding requiring transfusion or hospitalization for at least 6 months prior to study entry are eligible\n* Must not have a psychiatric illness, other significant medical illness, or social situation (such as involuntary incarceration) which, in the investigator's opinion, would limit compliance or ability to comply with study requirements\n* Women must not be pregnant or breastfeeding since cabozantinib may harm the fetus or child.\n* Women of child-bearing potential (not surgically sterilized and between menarche and 1-year post menopause) and men must agree to use 2 methods of adequate contraception (hormonal plus barrier or 2 barrier forms) OR abstinence prior to study entry, for the duration of study participation, and for 4 months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Prisoners or subjects who are involuntarily incarcerated, or compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness would be excluded.\n* Concomitant treatment with strong inducers or inhibitors of CYP3A4 is not allowed. Patients must discontinue the drug(s) at least 14 days prior to first study dose on the study.\n* Concomitant anticoagulation with oral anticoagulants (e.g. warfarin, direct thrombin and factor Xa inhibitors), or platelet inhibitors (e.g. clopidogrel) is not allowed.\n* Must not have corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment.",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Vaibhav Sahai, MBBS, MS",
              "affiliation": "University of Michigan",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Northwestern University",
              "city": "Chicago",
              "state": "Illinois",
              "zip": "60611",
              "country": "United States",
              "geoPoint": {
                "lat": 41.85003,
                "lon": -87.65005
              }
            },
            {
              "facility": "University of Chicago",
              "city": "Chicago",
              "state": "Illinois",
              "zip": "60637",
              "country": "United States",
              "geoPoint": {
                "lat": 41.85003,
                "lon": -87.65005
              }
            },
            {
              "facility": "University of Michigan Rogel Cancer Center",
              "city": "Ann Arbor",
              "state": "Michigan",
              "zip": "48109",
              "country": "United States",
              "geoPoint": {
                "lat": 42.27756,
                "lon": -83.74088
              }
            },
            {
              "facility": "University of Texas Southwestern Medical Center",
              "city": "Dallas",
              "state": "Texas",
              "zip": "75390",
              "country": "United States",
              "geoPoint": {
                "lat": 32.78306,
                "lon": -96.80667
              }
            }
          ]
        },
        "ipdSharingStatementModule": {
          "ipdSharing": "NO"
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000002277",
              "term": "Carcinoma"
            },
            {
              "id": "D000006528",
              "term": "Carcinoma, Hepatocellular"
            }
          ],
          "ancestors": [
            {
              "id": "D000009375",
              "term": "Neoplasms, Glandular and Epithelial"
            },
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000000230",
              "term": "Adenocarcinoma"
            },
            {
              "id": "D000008113",
              "term": "Liver Neoplasms"
            },
            {
              "id": "D000004067",
              "term": "Digestive System Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000004066",
              "term": "Digestive System Diseases"
            },
            {
              "id": "D000008107",
              "term": "Liver Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M5224",
              "name": "Carcinoma",
              "asFound": "Carcinoma",
              "relevance": "HIGH"
            },
            {
              "id": "M9303",
              "name": "Carcinoma, Hepatocellular",
              "asFound": "Hepatocellular Carcinoma",
              "relevance": "HIGH"
            },
            {
              "id": "M10793",
              "name": "Liver Cirrhosis",
              "relevance": "LOW"
            },
            {
              "id": "M12010",
              "name": "Neoplasms, Glandular and Epithelial",
              "relevance": "LOW"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M3275",
              "name": "Adenocarcinoma",
              "relevance": "LOW"
            },
            {
              "id": "M10803",
              "name": "Liver Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M8576",
              "name": "Gastrointestinal Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M6946",
              "name": "Digestive System Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M8573",
              "name": "Gastrointestinal Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M6945",
              "name": "Digestive System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M10797",
              "name": "Liver Diseases",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC06",
              "name": "Digestive System Diseases"
            },
            {
              "abbrev": "BC23",
              "name": "Symptoms and General Pathology"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00448838",
          "orgStudyIdInfo": {
            "id": "20057548"
          },
          "secondaryIdInfos": [
            {
              "id": "SCCC-2005141",
              "type": "OTHER",
              "domain": "University of Miami Sylvester Comprehensive Cancer Center"
            },
            {
              "id": "WIRB-20052717",
              "type": "OTHER",
              "domain": "Western Insitutional Review Board"
            }
          ],
          "organization": {
            "fullName": "University of Miami",
            "class": "OTHER"
          },
          "briefTitle": "Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",
          "officialTitle": "Pilot Study of Gemcitabine, Oxaliplatin, and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "statusVerifiedDate": "2016-12",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2006-05"
          },
          "primaryCompletionDateStruct": {
            "date": "2007-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-03",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2007-03-15",
          "studyFirstSubmitQcDate": "2007-03-15",
          "studyFirstPostDateStruct": {
            "date": "2007-03-19",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2016-12-14",
          "lastUpdatePostDateStruct": {
            "date": "2016-12-15",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "University of Miami",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": true
        },
        "descriptionModule": {
          "briefSummary": "RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with combination chemotherapy may kill more tumor cells.\n\nPURPOSE: This clinical trial is studying how well giving cetuximab together with gemcitabine and oxaliplatin works in treating patients with locally advanced or metastatic pancreatic cancer.",
          "detailedDescription": "OBJECTIVES:\n\nPrimary\n\n* Determine the progression-free survival of patients with locally advanced or metastatic pancreatic cancer treated with cetuximab, gemcitabine hydrochloride, and oxaliplatin.\n\nSecondary\n\n* Determine the complete response and partial response in patients treated with this regimen.\n* Determine the time to progression in patients treated with this regimen.\n* Determine the duration of response in patients treated with this regimen.\n* Determine the survival of patients treated with this regimen.\n* Determine the toxicity of this regimen in these patients.\n\nOUTLINE: This is a nonrandomized, open-label, pilot study.\n\nPatients receive cetuximab IV over 1-2 hours on days 1 and 8, gemcitabine hydrochloride IV over 100 minutes on day 1, and oxaliplatin IV over 2-4 hours on day 2. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study treatment, patients are followed every 3 months.\n\nPROJECTED ACCRUAL: A total of 40 patients will be accrued for this study."
        },
        "conditionsModule": {
          "conditions": [
            "Pancreatic Cancer"
          ],
          "keywords": [
            "recurrent pancreatic cancer",
            "stage III pancreatic cancer",
            "stage IV pancreatic cancer",
            "stage II pancreatic cancer"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "NA"
          ],
          "designInfo": {
            "allocation": "NON_RANDOMIZED",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 42,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "interventions": [
            {
              "type": "BIOLOGICAL",
              "name": "Cetuximab",
              "description": "Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.",
              "otherNames": [
                "C-225"
              ]
            },
            {
              "type": "DRUG",
              "name": "Gemcitabine Hydrochloride",
              "description": "Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.",
              "otherNames": [
                "Gemcitabine HCl"
              ]
            },
            {
              "type": "DRUG",
              "name": "Oxaliplatin",
              "description": "Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles."
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Progression-free survival",
              "description": "The corresponding progression-free survival curve and cumulative risk of progression as a function of time post treatment initiation will be estimated using the Kaplan-Meier method",
              "timeFrame": "The cumulative percentage of intent to treat patients who experience disease progression at 1, 2, 3, 4, 5, and 6 months will be characterized with corresponding 95% confidence intervals"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Toxicity",
              "timeFrame": "Frequency and severity of adverse events according to the NCI CTCAE V 3.0 body system and severity criteria will be described."
            },
            {
              "measure": "Response rate (complete response and partial response)",
              "description": "The response rate will be determined by the RECIST criteria. After every 4th cycle; End of Treatment and Follow-up",
              "timeFrame": "After every 4th cycle; End of Treatment and Follow-up"
            },
            {
              "measure": "Duration of response",
              "description": "the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started",
              "timeFrame": "The time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented"
            },
            {
              "measure": "Overall survival",
              "description": "Overall survival will also be estimated using the product-limit method of Kaplan-Meier.",
              "timeFrame": "Overall survival will also be estimated using the product-limit method of Kaplan-Meier."
            },
            {
              "measure": "Time to progression",
              "description": "The time from the start of the treatment until the criteria for disease progression are met, taking as reference the smallest measurements recorded since the treatment started (also referred to in the RECIST criteria as duration of stable disease).",
              "timeFrame": "The time from the start of the treatment until the criteria for disease progression are met"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed pancreatic cancer\n* Locally advanced or metastatic disease\n* No active CNS metastases\n\n  * Patients with stable CNS disease, who have undergone radiotherapy within the past 4 weeks and who have been on a stable dose of corticosteroids for \\> 3 weeks, are eligible\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-1\n* Absolute neutrophil count ≥ 1,500/mm³\n* Platelet count ≥ 100,000/mm³\n* Bilirubin ≤ 1.5 mg/dL\n* Alkaline phosphatase ≤ 3 times upper limit of normal (ULN) (5 times ULN if known hepatic metastases)\n* AST and ALT ≤ 3 times ULN (5 times ULN if known hepatic metastases)\n* Creatinine ≤ 1.5 mg/dL\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 90 days after completion of study treatment\n* No significant history of uncontrolled cardiac disease, including any of the following:\n\n  * Uncontrolled hypertension\n  * Unstable angina\n  * Myocardial infarction within the past 6 months\n  * Uncontrolled congestive heart failure\n  * Cardiomyopathy with decreased ejection fraction\n* No prior severe infusion reaction to a monoclonal antibody\n* No active infection or fever ≥ 38.5°C within the past 3 days\n* No known hypersensitivity to any components of gemcitabine hydrochloride, oxaliplatin, or to a monoclonal antibody\n* No peripheral neuropathy ≥ grade 2\n* No known HIV positivity\n* No hepatitis B or C infection (active, previously treated, or both)\n* No other medical condition, including mental illness or substance abuse, that would preclude study compliance\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Recovered from all prior therapy, including surgery\n* More than 30 days since prior investigational therapy\n* More than 4 weeks since prior radiotherapy\n* No prior radiotherapy to more than 25% of bone marrow\n* More than 30 days since prior chemotherapy\n* No prior chemotherapy for metastatic pancreatic cancer\n* Prior fluoropyrimidine as a radiosensitizer allowed\n* Prior gemcitabine hydrochloride in the adjuvant setting allowed\n* No prior therapy that specifically and directly targets the epidermal growth factor receptor (EGFR) pathway\n* No prior allogeneic transplantation\n* No other concurrent investigational therapy, chemotherapy, or systemic antineoplastic therapy\n* No other concurrent treatment that targets the EGFR\n* No other concurrent monoclonal antibody therapy\n* No concurrent radiotherapy except for local control of bone pain",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Caio Max S. Rocha Lima, MD",
              "affiliation": "University of Miami Sylvester Comprehensive Cancer Center",
              "role": "STUDY_CHAIR"
            }
          ],
          "locations": [
            {
              "facility": "University of Miami Sylvester Comprehensive Cancer Center - Miami",
              "city": "Miami",
              "state": "Florida",
              "zip": "33136",
              "country": "United States",
              "geoPoint": {
                "lat": 25.77427,
                "lon": -80.19366
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000010190",
              "term": "Pancreatic Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000004067",
              "term": "Digestive System Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000004701",
              "term": "Endocrine Gland Neoplasms"
            },
            {
              "id": "D000004066",
              "term": "Digestive System Diseases"
            },
            {
              "id": "D000010182",
              "term": "Pancreatic Diseases"
            },
            {
              "id": "D000004700",
              "term": "Endocrine System Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M12800",
              "name": "Pancreatic Neoplasms",
              "asFound": "Pancreatic Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M14540",
              "name": "Recurrence",
              "relevance": "LOW"
            },
            {
              "id": "M8576",
              "name": "Gastrointestinal Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M6946",
              "name": "Digestive System Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M7553",
              "name": "Endocrine Gland Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M8573",
              "name": "Gastrointestinal Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M6945",
              "name": "Digestive System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M12792",
              "name": "Pancreatic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M7552",
              "name": "Endocrine System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "T4387",
              "name": "Pancreatic Cancer",
              "asFound": "Pancreatic Cancer",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC06",
              "name": "Digestive System Diseases"
            },
            {
              "abbrev": "BC19",
              "name": "Gland and Hormone Related Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC23",
              "name": "Symptoms and General Pathology"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000093542",
              "term": "Gemcitabine"
            },
            {
              "id": "D000077150",
              "term": "Oxaliplatin"
            },
            {
              "id": "D000068818",
              "term": "Cetuximab"
            }
          ],
          "ancestors": [
            {
              "id": "D000000964",
              "term": "Antimetabolites, Antineoplastic"
            },
            {
              "id": "D000000963",
              "term": "Antimetabolites"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            },
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000074322",
              "term": "Antineoplastic Agents, Immunological"
            }
          ],
          "browseLeaves": [
            {
              "id": "M2986",
              "name": "Gemcitabine",
              "asFound": "Evaluation",
              "relevance": "HIGH"
            },
            {
              "id": "M1674",
              "name": "Oxaliplatin",
              "asFound": "Into",
              "relevance": "HIGH"
            },
            {
              "id": "M315",
              "name": "Cetuximab",
              "asFound": "Per week",
              "relevance": "HIGH"
            },
            {
              "id": "M3971",
              "name": "Antimetabolites",
              "relevance": "LOW"
            },
            {
              "id": "M1346",
              "name": "Antineoplastic Agents, Immunological",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT03242538",
          "orgStudyIdInfo": {
            "id": "H00013328"
          },
          "organization": {
            "fullName": "University of Massachusetts, Worcester",
            "class": "OTHER"
          },
          "briefTitle": "Prehabilitation for Pelvic Cancer: Changes in Setup Variability",
          "officialTitle": "Prehabilitation for Port Films: Phase 1. Evaluating Orthopedic Measurements of Pelvic Tilt During Radiation Treatments for Pelvic Cancer"
        },
        "statusModule": {
          "statusVerifiedDate": "2019-09",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2017-06-23",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2018-07-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-01-17",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2017-07-31",
          "studyFirstSubmitQcDate": "2017-08-03",
          "studyFirstPostDateStruct": {
            "date": "2017-08-08",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2019-09-10",
          "lastUpdatePostDateStruct": {
            "date": "2019-09-11",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "PRINCIPAL_INVESTIGATOR",
            "investigatorFullName": "Janaki Moni",
            "investigatorTitle": "Associate Professor, Department of Radiation Oncology",
            "investigatorAffiliation": "University of Massachusetts, Worcester"
          },
          "leadSponsor": {
            "name": "University of Massachusetts, Worcester",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": false,
          "isFdaRegulatedDrug": false,
          "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
          "briefSummary": "The investigators hypothesize that two pelvic relaxation exercises will be feasible and safe to perform by subjects daily before radiation during the participant's treatment and will decrease variability of sacral slope measurements on daily port films. The investigators will observe trends in the daily variability and change in the sacral slope in each participant to determine if this could decrease variability. The investigators will compare these measurements to a retrospective cohort that did not have the exercises, but did demonstrate variability. Reducing set-up variability (which inadvertently occurs during radiation) is important to improve radiation targets and diminish potential adverse effects. The investigators will query participants for objective and subjective feedback on the exercises and record frequency and duration of the two exercises."
        },
        "conditionsModule": {
          "conditions": [
            "Pelvic Cancer"
          ],
          "keywords": [
            "Exercise"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "NA"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "PREVENTION",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Pelvic Exercise Intervention",
              "type": "EXPERIMENTAL",
              "description": "Patients will perform two pelvic exercises prior to each external beam radiation treatment.",
              "interventionNames": [
                "Behavioral: Pelvic Exercise"
              ]
            }
          ],
          "interventions": [
            {
              "type": "BEHAVIORAL",
              "name": "Pelvic Exercise",
              "description": "Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.",
              "armGroupLabels": [
                "Pelvic Exercise Intervention"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Sacral Slope Variation",
              "description": "Reduced variation in sacral slope angle measured on daily port films.",
              "timeFrame": "Daily, through duration of radiation treatment, averaging 6-10 weeks"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients will be \\>21 yrs of age and will have an oncologic diagnosis that requires a course of pelvic radiation therapy for a minimum of 5 weeks.\n* They will have an ECOG Performance Status (This scale, developed by the Eastern Cooperative Oncology Group (ECOG), now part of the ECOG-ACRIN (American College of Radiology Imaging Network) Cancer Research Group, describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.)) of 1 or better as determined by patient history.\n* They will be ambulatory without needing any ambulatory aids such as a cane or walker.\n* Both men and women will be eligible as there is no significant anatomical difference in sacral slope measurement. Joint replacement patients will not be excluded.\n\nExclusion Criteria:\n\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Pregnant women\n* Prisoners\n* Non-English speaking subjects",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "21 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Jennifer Baima, MD",
              "affiliation": "UMass Medical - Department of Orthopedics",
              "role": "PRINCIPAL_INVESTIGATOR"
            },
            {
              "name": "Janaki Moni, MD",
              "affiliation": "UMass Medical - Department of Radiation Oncology",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "University of Massachusetts Medical School",
              "city": "Worcester",
              "state": "Massachusetts",
              "zip": "01655",
              "country": "United States",
              "geoPoint": {
                "lat": 42.26259,
                "lon": -71.80229
              }
            }
          ]
        },
        "referencesModule": {
          "references": [
            {
              "pmid": "31713056",
              "type": "DERIVED",
              "citation": "O'Loughlin L, Lukez A, Ma Y, Baima J, Moni J. Prehabilitation for patient positioning: pelvic exercises assist in minimizing inter-fraction sacral slope variability during radiation therapy. Med Oncol. 2019 Nov 12;37(1):3. doi: 10.1007/s12032-019-1322-9."
            }
          ]
        },
        "ipdSharingStatementModule": {
          "ipdSharing": "NO"
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000010386",
              "term": "Pelvic Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            }
          ],
          "browseLeaves": [
            {
              "id": "M12987",
              "name": "Pelvic Neoplasms",
              "asFound": "Pelvic Cancer",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT02730338",
          "orgStudyIdInfo": {
            "id": "GAP4"
          },
          "organization": {
            "fullName": "Movember Foundation",
            "class": "OTHER"
          },
          "briefTitle": "INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4)",
          "officialTitle": "INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4): A Multicentre, Randomised, Controlled, Phase III Study",
          "acronym": "INTERVAL"
        },
        "statusModule": {
          "statusVerifiedDate": "2023-03",
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2016-01",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2025-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-10",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2016-03-10",
          "studyFirstSubmitQcDate": "2016-03-31",
          "studyFirstPostDateStruct": {
            "date": "2016-04-06",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2023-03-13",
          "lastUpdatePostDateStruct": {
            "date": "2023-03-15",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "Movember Foundation",
            "class": "OTHER"
          },
          "collaborators": [
            {
              "name": "University of California, San Francisco",
              "class": "OTHER"
            },
            {
              "name": "Edith Cowan University",
              "class": "OTHER"
            },
            {
              "name": "King's College London",
              "class": "OTHER"
            },
            {
              "name": "Centre hospitalier de l'Université de Montréal (CHUM)",
              "class": "OTHER"
            }
          ]
        },
        "oversightModule": {
          "oversightHasDmc": true,
          "isFdaRegulatedDrug": false,
          "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
          "briefSummary": "To determine if supervised high intensity aerobic and resistance training increases overall survival compared to self-directed exercise in patients with metastatic prostate cancer."
        },
        "conditionsModule": {
          "conditions": [
            "Metastatic Prostate Cancer"
          ],
          "keywords": [
            "Castrate resistant",
            "Exercise",
            "Metastatic",
            "Prostate cancer",
            "Hormone sensitive"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "NA"
          ],
          "designInfo": {
            "allocation": "RANDOMIZED",
            "interventionModel": "PARALLEL",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 866,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Arm A: Supervised exercise group",
              "type": "ACTIVE_COMPARATOR",
              "description": "Supervised high intensity aerobic and resistance exercise tapering to self management with psychosocial support",
              "interventionNames": [
                "Behavioral: High intensity aerobic and resistance training",
                "Behavioral: Psychosocial support"
              ]
            },
            {
              "label": "Arm B: Self directed exercise group",
              "type": "OTHER",
              "description": "Self directed exercise and psychosocial support group",
              "interventionNames": [
                "Behavioral: Psychosocial support"
              ]
            }
          ],
          "interventions": [
            {
              "type": "BEHAVIORAL",
              "name": "High intensity aerobic and resistance training",
              "armGroupLabels": [
                "Arm A: Supervised exercise group"
              ]
            },
            {
              "type": "BEHAVIORAL",
              "name": "Psychosocial support",
              "armGroupLabels": [
                "Arm A: Supervised exercise group",
                "Arm B: Self directed exercise group"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Overall Survival",
              "description": "Overall survival will be measured from the time of randomization until death",
              "timeFrame": "up to 5 years"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Disease Progression",
              "description": "Time to disease progression will be measured from randomization until the first of the following: first CT or bone scan documenting disease progression, initiation of a new therapy for mPC (clinical progression), or first occurrence of a Symptomatic Skeletal Related Event (SSE).",
              "timeFrame": "up to 5 years"
            },
            {
              "measure": "Symptomatic Skeletal Related Events (SSE)",
              "description": "Time to first occurrence of SSE will be defined as the time from randomization to documentation of any of the following (whichever occurs first) + 1 day:\n\n* Use of external beam radiation therapy to relieve bone pain\n* Occurrence of new symptomatic pathological bone fractures that may be vertebral or non-vertebral. Asymptomatic compression fractures detected by radiology review only will not be considered a SSE.\n* Spinal cord compression\n* Change in antineoplastic therapy to treat bone pain\n* Surgical intervention to treat bone pain",
              "timeFrame": "up to 5 years"
            },
            {
              "measure": "Opiate Use",
              "description": "Opiate use will be assessed via BPI-SF, the medical record review at entry with a lead-in period (\\<28 days). The questionnaires will be administered every three cycles until month 24, and in month 36.",
              "timeFrame": "up to 5 years"
            },
            {
              "measure": "Analgesic Use",
              "description": "Analgesic use will be assessed via BPI-SF, the World Health Organisation (WHO) analgesic scale, and medical record review at entry with a lead-in period (\\<28 days). The WHO analgesic scale will be completed every three cycles (based on medical review) and questionnaires will be administered every three cycles until month 24, and in month 36.",
              "timeFrame": "up to 5 years"
            },
            {
              "measure": "Biomarker analysis",
              "description": "Inflammatory and cytokine systemic milieu",
              "timeFrame": "up to 5 years"
            },
            {
              "measure": "Biomarker analysis",
              "description": "Insulin/Glucose Metabolism",
              "timeFrame": "up to 5 years"
            },
            {
              "measure": "Biomarker analysis",
              "description": "Androgen biosynthesis",
              "timeFrame": "up to 5 years"
            },
            {
              "measure": "Quality of Life",
              "description": "Physical and emotional quality of life measured by the questionnaires- Functional Assessment of Cancer Therapy- Prostate (FACT-P), Functional assessment of Chronic Illness Therapy (FACIT-Fatigue), and EuroQOL Five Dimension Questionnaire (EQ5D) will be assessed every 3 cycles.",
              "timeFrame": "up to 5 years"
            },
            {
              "measure": "Physical Function",
              "description": "Physical function will be assessed using strength assessments (1RM), a cardiopulmonary exercise test (CPET) and a functional performance test (400m walk)",
              "timeFrame": "up to 5 years"
            },
            {
              "measure": "Pain",
              "description": "Pain will be assessed via questionnaire Brief Pain Inventory- short form (BPI-SF) and medical record review at entry with a lead-in period (\\<28 days) and repeated measures will occur every three cycles",
              "timeFrame": "up to 5 years"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\nmCRPC status:\n\n* mCRPC patients defined as; adenocarcinoma of the prostate with systemic metastatic disease despite castrate levels of testosterone (\\<50 ng/dL) due to orchiectomy or LHRH agonist.\n\n  o Patients must have one or more of the following to be considered mCRPC\n* Metastatic Disease Progression: \\>20% increase in the sum of diameters of measurable lesions from the time of maximal regression or appearance of one or more new lesions.\n* Bone Scan Progression: Appearance of one or more new lesions on bone scan attributable to prostate cancer.\n* PSA Progression: PSA ≥2 ng/ml that has risen serially on at least two occasions, each at least one week apart (PSA1 \\< PSA2 \\< PSA3).\n* PSMA PET/CT scan progression: Appearance of one or more new lesions on PSMA PET/CT scan attributable to prostate cancer.\n* At enrolment, mCRPC patients must fit into one of the following 5 categories:\n\n  1. Treatment naïve for mCRPC (have not yet started approved therapies for CRPC ie: Abiraterone/Enzalutamide/Apalutamide / or Docetaxel, Cabazitaxel or other approved first line chemotherapy; less than 4 weeks on approved therapies is still considered to be treatment naïve) Or\n  2. Receiving Abi/Enza/Apa for mCRPC AND responding or stable (PSA values must be stable or declining after at least 4 weeks since starting Abi/Enza/Apa for mCRPC) Or\n  3. Patients with PSA progression while on Abi/Enza/Apa are eligible as long as they are asymptomatic AND there is no intent on starting chemotherapy within 6 months Or\n  4. Patients treated with Docetaxel, Cabazitaxel or other approved first line chemotherapy as first line for mCRPC who are asymptomatic without ANY evidence of progression Or\n  5. Patients may have progressed following first line Docetaxel, Cabazitaxel or other first line chemotherapy and are now receiving treatment with Abi/Enza/Apa. These patients must absolutely be responding or stable (PSA values must be stable or declining after starting Abi/Enza/Apa treatment) and have an estimated life expectancy of more than 1 year.\n\n     mHSPC Status:\n* mHSPC patients must be classified as either high-risk or high-volume mHSPC. These groups are defined as adenocarcinoma of the prostate with systemic metastatic disease and patients also fit into one of the following 2 categories: 6. High-risk: defined as having at least 2 of three criteria: (i) Gleason score ≥8, (ii) presence of ≥3 lesions on bone scan, or (iii) presence of INTERVAL Protocol Version 5.0, 19 August 2019 4 measurable visceral lesions (PSMA PET imaging should not be used in the definition of high-risk disease) Or 7. High-volume: defined as having the presence of visceral metastases and/or ≥ four bone metastases with at least one outside of the vertebral column and pelvis (PSMA PET imaging should not be used in the definition of high-volume disease)\n\nAdditional criteria for all groups:\n\n* All patients will be required to be on ADT during the study period or have had a prior bilateral orchiectomy.\n* Men with small cell neuroendocrine tumours or features of small cell disease are not eligible.\n* ≥4 weeks since last major surgery and fully recovered.\n* No known contraindications to high intensity exercise, including, but not limited to: brain metastases; current congestive heart failure (New York Heart Association Class II, III or IV); serious or non-healing wound, ulcer, or bone fracture; spinal cord compromise or instrumentation due to metastatic disease; peripheral neuropathy ≥grade 3. No serious cardiovascular events within 12 months including, but not limited to, transient ischemic attack (TIA), cerebrovascular accident (CVA), or myocardial infarction (MI). Patients with a history of hypertension must be well-controlled (\\< 160/90) on anti-hypertensive therapy.\n* Halabi Nomogram score \\<1951 (Risk Category rated as low or intermediate risk)\n* Age ≥18 years\n* Required Baseline Laboratory Values: ANC ≥ 1500/uL; Platelet count ≥ 100,000/uL; Creatinine ≤ 1.5 x upper limits of normal; Bilirubin ≤ 1.5 x upper limits of normal; AST ≤ 1.5 x upper limits of normal; Serum testosterone ≤ 50 ng/dL\n* ECOG performance status 0-1\n* Medical clearance by treating physician to undergo a symptom-limited cardiopulmonary exercise test and vigorous aerobic and resistance exercise training, and able to complete an acceptable cardiopulmonary exercise test.\n* Exercise Coordination Centre (ECC) review and approval of subject's screening bone scan / areas with bone metastases.\n* Men participating in vigorous aerobic exercise for \\>60 min/week or structured resistance exercise ≥2 days/week, are not eligible.\n* Subject is willing and able to use technological aspects of the trial.\n* The subject is fluent in the language as designated by the institution at which he would be enrolled.",
          "healthyVolunteers": false,
          "sex": "MALE",
          "genderBased": true,
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Robert Newton",
              "affiliation": "Edith Cowan University",
              "role": "STUDY_CHAIR"
            },
            {
              "name": "Fred Saad",
              "affiliation": "Centre hospitalier de l'Université de Montréal (CHUM)",
              "role": "STUDY_CHAIR"
            }
          ],
          "locations": [
            {
              "facility": "Cedars Sinai Medical Centre",
              "city": "Los Angeles",
              "state": "California",
              "country": "United States",
              "geoPoint": {
                "lat": 34.05223,
                "lon": -118.24368
              }
            },
            {
              "facility": "UCSF",
              "city": "San Francisco",
              "state": "California",
              "country": "United States",
              "geoPoint": {
                "lat": 37.77493,
                "lon": -122.41942
              }
            },
            {
              "facility": "UC Denver",
              "city": "Denver",
              "state": "Colorado",
              "country": "United States",
              "geoPoint": {
                "lat": 39.73915,
                "lon": -104.9847
              }
            },
            {
              "facility": "University of Minnesota",
              "city": "Minneapolis",
              "state": "Minnesota",
              "country": "United States",
              "geoPoint": {
                "lat": 44.97997,
                "lon": -93.26384
              }
            },
            {
              "facility": "Oregon Health & Science University",
              "city": "Portland",
              "state": "Oregon",
              "country": "United States",
              "geoPoint": {
                "lat": 45.52345,
                "lon": -122.67621
              }
            },
            {
              "facility": "Fred Hutchinson Cancer Centre",
              "city": "Seattle",
              "state": "Washington",
              "country": "United States",
              "geoPoint": {
                "lat": 47.60621,
                "lon": -122.33207
              }
            },
            {
              "facility": "University of Canberra",
              "city": "Canberra",
              "state": "Australian Capital Territory",
              "country": "Australia",
              "geoPoint": {
                "lat": -35.28346,
                "lon": 149.12807
              }
            },
            {
              "facility": "Chris O'Brien Lifehouse",
              "city": "Sydney",
              "state": "New South Wales",
              "country": "Australia",
              "geoPoint": {
                "lat": -33.86785,
                "lon": 151.20732
              }
            },
            {
              "facility": "Australian Prostate Cncr Research Centre",
              "city": "Brisbane",
              "state": "Queensland",
              "country": "Australia",
              "geoPoint": {
                "lat": -27.46794,
                "lon": 153.02809
              }
            },
            {
              "facility": "University of Queensland",
              "city": "Brisbane",
              "state": "Queensland",
              "country": "Australia",
              "geoPoint": {
                "lat": -27.46794,
                "lon": 153.02809
              }
            },
            {
              "facility": "Victoria University / Sunshine Hospital",
              "city": "Melbourne",
              "state": "Victoria",
              "country": "Australia",
              "geoPoint": {
                "lat": -37.814,
                "lon": 144.96332
              }
            },
            {
              "facility": "Edith Cowan University",
              "city": "Perth",
              "state": "Western Australia",
              "country": "Australia",
              "geoPoint": {
                "lat": -31.95224,
                "lon": 115.8614
              }
            },
            {
              "facility": "University of Alberta",
              "city": "Edmonton",
              "state": "Alberta",
              "country": "Canada",
              "geoPoint": {
                "lat": 53.55014,
                "lon": -113.46871
              }
            },
            {
              "facility": "QEII Cancer Centre / Dalhousie University",
              "city": "Halifax",
              "state": "Nova Scotia",
              "country": "Canada",
              "geoPoint": {
                "lat": 44.64533,
                "lon": -63.57239
              }
            },
            {
              "facility": "Centre Hospitalier de l'Université de Montréal (CRCHUM)",
              "city": "Montreal",
              "country": "Canada",
              "geoPoint": {
                "lat": 45.50884,
                "lon": -73.58781
              }
            },
            {
              "facility": "German Sport University Cologne",
              "city": "Cologne",
              "country": "Germany",
              "geoPoint": {
                "lat": 50.93333,
                "lon": 6.95
              }
            },
            {
              "facility": "Trinity University",
              "city": "Dublin",
              "country": "Ireland",
              "geoPoint": {
                "lat": 53.33306,
                "lon": -6.24889
              }
            },
            {
              "facility": "Erasmus MC",
              "city": "Rotterdam",
              "country": "Netherlands",
              "geoPoint": {
                "lat": 51.9225,
                "lon": 4.47917
              }
            },
            {
              "facility": "University of Surrey",
              "city": "Guildford",
              "state": "Surrey",
              "country": "United Kingdom",
              "geoPoint": {
                "lat": 51.23536,
                "lon": -0.57427
              }
            },
            {
              "facility": "Queen's University Belfast",
              "city": "Belfast",
              "country": "United Kingdom",
              "geoPoint": {
                "lat": 54.59682,
                "lon": -5.92541
              }
            },
            {
              "facility": "University of Glasgow",
              "city": "Glasgow",
              "country": "United Kingdom",
              "geoPoint": {
                "lat": 55.86515,
                "lon": -4.25763
              }
            },
            {
              "facility": "Kings College London",
              "city": "London",
              "country": "United Kingdom",
              "geoPoint": {
                "lat": 51.50853,
                "lon": -0.12574
              }
            }
          ]
        },
        "referencesModule": {
          "references": [
            {
              "pmid": "29764892",
              "type": "DERIVED",
              "citation": "Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, Buzza M, Gledhill S, Zhang L, Galvao DA, Ryan CJ, Saad F. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open. 2018 May 14;8(5):e022899. doi: 10.1136/bmjopen-2018-022899."
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "removedCountries": [
            "China"
          ],
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000011471",
              "term": "Prostatic Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000005834",
              "term": "Genital Neoplasms, Male"
            },
            {
              "id": "D000014565",
              "term": "Urogenital Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000005832",
              "term": "Genital Diseases, Male"
            },
            {
              "id": "D000091662",
              "term": "Genital Diseases"
            },
            {
              "id": "D000091642",
              "term": "Urogenital Diseases"
            },
            {
              "id": "D000011469",
              "term": "Prostatic Diseases"
            },
            {
              "id": "D000052801",
              "term": "Male Urogenital Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M14025",
              "name": "Prostatic Neoplasms",
              "asFound": "Prostate Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M9708",
              "name": "Hypersensitivity",
              "relevance": "LOW"
            },
            {
              "id": "M8636",
              "name": "Genital Neoplasms, Male",
              "relevance": "LOW"
            },
            {
              "id": "M17005",
              "name": "Urogenital Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M2877",
              "name": "Genital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M8634",
              "name": "Genital Diseases, Male",
              "relevance": "LOW"
            },
            {
              "id": "M2876",
              "name": "Urogenital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M14023",
              "name": "Prostatic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M26785",
              "name": "Male Urogenital Diseases",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BXS",
              "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC20",
              "name": "Immune System Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "browseLeaves": [
            {
              "id": "M9479",
              "name": "Hormones",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00595972",
          "orgStudyIdInfo": {
            "id": "ECF/endo-MGC"
          },
          "organization": {
            "fullName": "Fudan University",
            "class": "OTHER"
          },
          "briefTitle": "Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer",
          "officialTitle": "Phase II Trial of Epirubicin Cisplatin and FU Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer"
        },
        "statusModule": {
          "statusVerifiedDate": "2010-09",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2007-11"
          },
          "primaryCompletionDateStruct": {
            "date": "2010-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2010-12",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2008-01-04",
          "studyFirstSubmitQcDate": "2008-01-15",
          "studyFirstPostDateStruct": {
            "date": "2008-01-16",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2011-06-27",
          "lastUpdatePostDateStruct": {
            "date": "2011-06-28",
            "type": "ESTIMATED"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "oldNameTitle": "Base for drug clinical trials, Fudan University cancer hospital",
            "oldOrganization": "Department of medical oncology, Cancer Hospital, Fuandan University"
          },
          "leadSponsor": {
            "name": "Fudan University",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": false
        },
        "descriptionModule": {
          "briefSummary": "The purpose of this study is to evaluate the efficacy and tolerability of the ECF regimen (epirubicin, cisplatin and FU) combined with endostar-- a inhibitor of angiogenesis, in patients with advanced or metastatic gastric cancer (A/MGC).",
          "detailedDescription": "Although there is no standard regimen in the treatment of metastatic gastric cancer, ECF regimen (epirubicin, cisplatin and FU) is often considered as a reference regimen. And ECF regimen has been suggested as the first line therapy for A/MGC by FDA. According to the result of a Chinese phase III clinical trial in metastatic lung cancer, endostar-- a new angiogenesis inhibitor prolonged the overall survival, time to progression and improved response rate. So we designed this clinical trial to evaluate whether endostar can bring survival benefits to patients with advanced and metastatic gastric cancer patients."
        },
        "conditionsModule": {
          "conditions": [
            "Gastric Cancer"
          ],
          "keywords": [
            "Time to Progression",
            "Overall survival",
            "Response rate",
            "Quality of Live",
            "Toxicities"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE2"
          ],
          "designInfo": {
            "allocation": "NON_RANDOMIZED",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "A",
              "type": "EXPERIMENTAL",
              "description": "patients will be treated by ECF regimen (epirubicin, cisplatin plus 5-FU) combined with endostar",
              "interventionNames": [
                "Drug: ECF-endostar"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "ECF-endostar",
              "description": "Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent",
              "armGroupLabels": [
                "A"
              ],
              "otherNames": [
                "treatment group"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "time to progression",
              "timeFrame": "every two cycles"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "toxicity",
              "timeFrame": "3 weeks"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed advanced or metastatic adenocarcinoma of the stomach\n* ECOG performance scale ≤ 2\n* At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)\n* Adequate hepatic, renal, heart, and hematologic functions (platelets\\>80×109/L, neutrophil\\> 2.0 × 109/L, serum creatinine ≤ 1.5mg/dl, total bilirubin within upper limit of normal(ULN), and serum transaminase ≤ 2.5×the ULN)\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Concurrent cancer\n* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix\n* Neuropathy, brain, or leptomeningeal involvement\n* Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months or high risk/uncontrolled arrhythmia\n* Uncontrolled significant comorbid conditions and previous radiotherapy",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Jin Li, PhD, M.D",
              "affiliation": "Fudan University",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Fudan University Cancer Hospital",
              "city": "ShangHai",
              "state": "Shanghai",
              "zip": "200032",
              "country": "China",
              "geoPoint": {
                "lat": 31.22222,
                "lon": 121.45806
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000013274",
              "term": "Stomach Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000005770",
              "term": "Gastrointestinal Neoplasms"
            },
            {
              "id": "D000004067",
              "term": "Digestive System Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000004066",
              "term": "Digestive System Diseases"
            },
            {
              "id": "D000005767",
              "term": "Gastrointestinal Diseases"
            },
            {
              "id": "D000013272",
              "term": "Stomach Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M15754",
              "name": "Stomach Neoplasms",
              "asFound": "Gastric Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M20249",
              "name": "Disease Progression",
              "relevance": "LOW"
            },
            {
              "id": "M8576",
              "name": "Gastrointestinal Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M6946",
              "name": "Digestive System Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M8573",
              "name": "Gastrointestinal Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M6945",
              "name": "Digestive System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M15752",
              "name": "Stomach Diseases",
              "relevance": "LOW"
            },
            {
              "id": "T5486",
              "name": "Stomach Cancer",
              "asFound": "Gastric Cancer",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC06",
              "name": "Digestive System Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC23",
              "name": "Symptoms and General Pathology"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "C000522911",
              "term": "Endostar protein"
            }
          ],
          "ancestors": [
            {
              "id": "D000020533",
              "term": "Angiogenesis Inhibitors"
            },
            {
              "id": "D000043924",
              "term": "Angiogenesis Modulating Agents"
            },
            {
              "id": "D000006133",
              "term": "Growth Substances"
            },
            {
              "id": "D000045505",
              "term": "Physiological Effects of Drugs"
            },
            {
              "id": "D000006131",
              "term": "Growth Inhibitors"
            },
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            }
          ],
          "browseLeaves": [
            {
              "id": "M8290",
              "name": "Fluorouracil",
              "relevance": "LOW"
            },
            {
              "id": "M5872",
              "name": "Cisplatin",
              "relevance": "LOW"
            },
            {
              "id": "M17644",
              "name": "Epirubicin",
              "relevance": "LOW"
            },
            {
              "id": "M255231",
              "name": "Endostar protein",
              "asFound": "Curative",
              "relevance": "HIGH"
            },
            {
              "id": "M22008",
              "name": "Angiogenesis Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M8921",
              "name": "Growth Inhibitors",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT06126172",
          "orgStudyIdInfo": {
            "id": "202002364B0"
          },
          "organization": {
            "fullName": "Chang Gung Memorial Hospital",
            "class": "OTHER"
          },
          "briefTitle": "Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions",
          "officialTitle": "Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions"
        },
        "statusModule": {
          "statusVerifiedDate": "2023-11",
          "overallStatus": "ACTIVE_NOT_RECRUITING",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2022-02-15",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2024-02-27",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2024-02-27",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2023-11-06",
          "studyFirstSubmitQcDate": "2023-11-09",
          "studyFirstPostDateStruct": {
            "date": "2023-11-13",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2023-11-09",
          "lastUpdatePostDateStruct": {
            "date": "2023-11-13",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "PRINCIPAL_INVESTIGATOR",
            "investigatorFullName": "Li-Jen Wang",
            "investigatorTitle": "Medical Imaging Department Director",
            "investigatorAffiliation": "Chang Gung Memorial Hospital"
          },
          "leadSponsor": {
            "name": "Chang Gung Memorial Hospital",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "oversightHasDmc": false,
          "isFdaRegulatedDrug": false,
          "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
          "briefSummary": "Prostate cancers (PCA) are a heterogeneous group which include indolent tumors that has no clinical significance to very aggressive cancer that could result in morbidities and mortality. Thus, an accurate risk stratification at the time of PCA diagnosis is crucial. The histological examination of PCA biopsy specimens could not accurately predict the final tumor aggressiveness shown on radical prostatectomy specimens because of heterogeneous distributions of the most malignant tumor cells. Prostate multiparametric magnetic resonance imaging (mpMRI) has been generally accepted to be the best imaging modality for detecting and localizing prostate cancers themselves. Furthermore, the rapid development of radiomics provide comprehensive quantitative information of all tumor data which could be used for risk stratification and prognosis prediction. Thus, this study plans to enroll 200 eligible patients who undergo prostate mpMRI first, followed by radical prostatectomy for prostate cancers. We use radiomics extracted from prostate mpMRI for risk stratification patients of histological aggressiveness as well as to predict very early recurrence of PCA patients within 6 months after radical prostatectomy.",
          "detailedDescription": "Prostate cancer is the 2nd most common malignancy in the world as well as the leading cancer in male population in Taiwan. The treatment selections of prostate cancer are limited by the uncertainty of its aggressiveness (i.e.: histological graded) and staging before treatment. Although prostate mpMRI has much better ability for detection and localization of prostate cancers than other imaging modalities and diagnostic tests, there is still gap for risk stratifications and treatment selection based on prostate mpMRI findings. Thus, a robust radiomics prediction models based on imaging biomarkers on prostate mpMRI with high prediction accuracy could fill the gap of misclassification of risk stratifications of prostate cancers, guides treatment selections and providing monitoring schedules for treated patients as well as early timely additional treatments (i.e.: target therapy or immunotherapy) for patients with high risk of early recurrence. Furthermore, radiomics could provide consistent information which help in decreasing interobserver and intra-observer variability of interpretating prostate cancer even in the use of PIRADS. In this way, this would save the fee of inappropriate or ineffective treatment and avoid unnecessary time and cost of monitoring low risk patients as well as improve patients' survivals and possibly life-quality as well."
        },
        "conditionsModule": {
          "conditions": [
            "Prostate Cancer"
          ],
          "keywords": [
            "Prostate cancer",
            "Multiparametric MRI",
            "Radiomics",
            "Risk stratification",
            "Recurrence",
            "Prediction"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "NA"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "OTHER",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 125,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Multiparametric magnetic resonance imaging",
              "type": "EXPERIMENTAL",
              "description": "Detecting and localizing prostate cancers. The radiomics provide comprehensive quantitative information of all tumor data which could be used for risk stratification and prognosis prediction.",
              "interventionNames": [
                "Diagnostic Test: Multiparametric magnetic resonance imaging (mpMRI)"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DIAGNOSTIC_TEST",
              "name": "Multiparametric magnetic resonance imaging (mpMRI)",
              "description": "Detecting and localizing prostate cancers and using radiomics extracted from prostate mpMRI for risk stratification patients of histological aggressiveness as well as to predict very early recurrence of PCA patients within 6 months after radical prostatectomy.",
              "armGroupLabels": [
                "Multiparametric magnetic resonance imaging"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "MR characteristics assessment-T2WI",
              "description": "T2-weighted images (T2WI)",
              "timeFrame": "1.5 year"
            },
            {
              "measure": "MR characteristics assessment- DWI",
              "description": "Axial diffusion weighted images (DWI)",
              "timeFrame": "1.5 year"
            },
            {
              "measure": "MR characteristics assessment- ADC",
              "description": "Apparent diffusion coefficient maps (ADC)",
              "timeFrame": "1.5 year"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n1. Aged over 20 years old.\n2. Suspected or confirmed prostate cancer.\n3. Undergoing prostate mpMRI before clinical treatment.\n4. Normal renal function(i.e.: estimated GFR ≧60).\n5. No allergy history to gadolinium based contrast agent.\n6. Agree to participate this study and sign informed consent.\n\nExclusion Criteria:\n\n1. mpMRI photography not completed.\n2. mpMRI images are damaged or poor in quality and cannot be interpreted.\n3. Without pathological examination confirmed prostate cancer.\n4. Patient withdraw informed consent.",
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "20 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Li-Jen Wang, M.D., M.P.H.",
              "affiliation": "Chang Gung Memorial Hospital",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Li-Jen Wang",
              "city": "Taoyuan",
              "zip": "333",
              "country": "Taiwan",
              "geoPoint": {
                "lat": 24.95233,
                "lon": 121.20193
              }
            }
          ]
        },
        "ipdSharingStatementModule": {
          "ipdSharing": "NO",
          "description": "Plan to make individual participant data."
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000011471",
              "term": "Prostatic Neoplasms"
            }
          ],
          "ancestors": [
            {
              "id": "D000005834",
              "term": "Genital Neoplasms, Male"
            },
            {
              "id": "D000014565",
              "term": "Urogenital Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000005832",
              "term": "Genital Diseases, Male"
            },
            {
              "id": "D000091662",
              "term": "Genital Diseases"
            },
            {
              "id": "D000091642",
              "term": "Urogenital Diseases"
            },
            {
              "id": "D000011469",
              "term": "Prostatic Diseases"
            },
            {
              "id": "D000052801",
              "term": "Male Urogenital Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M14540",
              "name": "Recurrence",
              "relevance": "LOW"
            },
            {
              "id": "M14025",
              "name": "Prostatic Neoplasms",
              "asFound": "Prostate Cancer",
              "relevance": "HIGH"
            },
            {
              "id": "M8636",
              "name": "Genital Neoplasms, Male",
              "relevance": "LOW"
            },
            {
              "id": "M17005",
              "name": "Urogenital Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M2877",
              "name": "Genital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M8634",
              "name": "Genital Diseases, Male",
              "relevance": "LOW"
            },
            {
              "id": "M2876",
              "name": "Urogenital Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M14023",
              "name": "Prostatic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M26785",
              "name": "Male Urogenital Diseases",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC23",
              "name": "Symptoms and General Pathology"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BXS",
              "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04560972",
          "orgStudyIdInfo": {
            "id": "20068"
          },
          "secondaryIdInfos": [
            {
              "id": "NCI-2020-04297",
              "type": "REGISTRY",
              "domain": "CTRP (Clinical Trial Reporting Program)"
            },
            {
              "id": "20068",
              "type": "OTHER",
              "domain": "City of Hope Comprehensive Cancer Center"
            },
            {
              "id": "P30CA033572",
              "type": "NIH",
              "link": "https://reporter.nih.gov/quickSearch/P30CA033572"
            }
          ],
          "organization": {
            "fullName": "City of Hope Medical Center",
            "class": "OTHER"
          },
          "briefTitle": "LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer",
          "officialTitle": "A Phase Ib Open-Label Study of LB-100 in Combination With Carboplatin/Etoposide/Atezolizumab in Untreated Extensive-Stage Small Cell Lung Carcinoma"
        },
        "statusModule": {
          "statusVerifiedDate": "2023-03",
          "overallStatus": "RECRUITING",
          "startDateStruct": {
            "date": "2021-05-28",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2026-03-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-03-09",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2020-06-22",
          "studyFirstSubmitQcDate": "2020-09-17",
          "studyFirstPostDateStruct": {
            "date": "2020-09-23",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2023-03-10",
          "lastUpdatePostDateStruct": {
            "date": "2023-03-13",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "City of Hope Medical Center",
            "class": "OTHER"
          },
          "collaborators": [
            {
              "name": "National Cancer Institute (NCI)",
              "class": "NIH"
            }
          ]
        },
        "oversightModule": {
          "oversightHasDmc": true,
          "isFdaRegulatedDrug": true,
          "isFdaRegulatedDevice": false,
          "isUsExport": false
        },
        "descriptionModule": {
          "briefSummary": "This phase Ib trial studies the side effects and best dose of LB-100 when given together with carboplatin, etoposide, and atezolizumab for the treatment of untreated extensive-stage small cell lung cancer. Drugs such as carboplatin and etoposide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. LB-100 has been shown to make anticancer drugs (chemotherapy) work better at killing cancer. LB-100 blocks a protein on the surface of cells called PP2A. Blocking this protein makes the tumor cells that express PP2A divide. This allows standard chemotherapy drugs such as carboplatin, etoposide, and atezolizumab work better at killing the tumor cells since these drugs work best at destroying cells that are dividing. Giving LB-100 in combination with standard chemotherapy drugs may work better to treat extensive-stage small cell lung cancer compared to standard chemotherapy drugs alone.",
          "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To determine the recommended phase II dose (RP2D) of protein phosphatase 2A inhibitor LB-100 (LB-100) when given in combination with standard carboplatin/etoposide/atezolizumab in treatment naive patients with extensive-stage small cell lung cancer (ED-SCLC).\n\nSECONDARY OBJECTIVES:\n\nI. To assess objective response rate (ORR). II. To assess progression-free survival (PFS). III. To assess overall survival (OS). IV. To assess duration of overall response (DOR). V. To assess safety and adverse events (AEs).\n\nEXPLORATORY OBJECTIVES:\n\nI. The pharmacokinetics (PK) of LB-100 and etoposide. II. The biomarkers relevant to LB-100 and the disease state as well as their correlation to clinical outcomes.\n\nOUTLINE: This is a dose-escalation study of LB-100.\n\nINDUCTION: Patients receive LB-100 intravenously (IV) over 15 minutes on days 1 and 3, atezolizumab IV over 30-60 minutes on day 1, carboplatin IV over 30-60 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE: After completion of induction therapy, patients receive LB-100 IV over 15 minutes on days 1 and 3 and atezolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study treatment, patients are followed for up to 30 days, and patients who discontinue study treatment without disease progression are followed every 6-8 weeks thereafter."
        },
        "conditionsModule": {
          "conditions": [
            "Extensive Stage Lung Small Cell Carcinoma"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE1"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 21,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Treatment (LB-100, carboplatin, etoposide, atezolizumab)",
              "type": "EXPERIMENTAL",
              "description": "INDUCTION: Patients receive LB-100 IV over 15 minutes on days 1 and 3, atezolizumab IV over 30-60 minutes on day 1, carboplatin IV over 30-60 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE: After completion of induction therapy, patients receive LB-100 IV over 15 minutes on days 1 and 3 and atezolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.",
              "interventionNames": [
                "Drug: Atezolizumab",
                "Drug: Carboplatin",
                "Drug: Etoposide",
                "Drug: Protein Phosphatase 2A Inhibitor LB-100"
              ]
            }
          ],
          "interventions": [
            {
              "type": "DRUG",
              "name": "Atezolizumab",
              "description": "Given IV",
              "armGroupLabels": [
                "Treatment (LB-100, carboplatin, etoposide, atezolizumab)"
              ],
              "otherNames": [
                "MPDL 3280A",
                "MPDL 328OA",
                "MPDL-3280A",
                "MPDL3280A",
                "MPDL328OA",
                "RG7446",
                "RO5541267",
                "Tecentriq"
              ]
            },
            {
              "type": "DRUG",
              "name": "Carboplatin",
              "description": "Given IV",
              "armGroupLabels": [
                "Treatment (LB-100, carboplatin, etoposide, atezolizumab)"
              ],
              "otherNames": [
                "Blastocarb",
                "Carboplat",
                "Carboplatin Hexal",
                "Carboplatino",
                "Carboplatinum",
                "Carbosin",
                "Carbosol",
                "Carbotec",
                "CBDCA",
                "Displata",
                "Ercar",
                "JM-8",
                "Nealorin",
                "Novoplatinum",
                "Paraplatin",
                "Paraplatin AQ",
                "Paraplatine",
                "Platinwas",
                "Ribocarbo"
              ]
            },
            {
              "type": "DRUG",
              "name": "Etoposide",
              "description": "Given IV",
              "armGroupLabels": [
                "Treatment (LB-100, carboplatin, etoposide, atezolizumab)"
              ],
              "otherNames": [
                "Demethyl Epipodophyllotoxin Ethylidine Glucoside",
                "EPEG",
                "Lastet",
                "Toposar",
                "Vepesid",
                "VP 16",
                "VP 16-213",
                "VP-16",
                "VP-16-213",
                "VP16"
              ]
            },
            {
              "type": "DRUG",
              "name": "Protein Phosphatase 2A Inhibitor LB-100",
              "description": "Given IV",
              "armGroupLabels": [
                "Treatment (LB-100, carboplatin, etoposide, atezolizumab)"
              ],
              "otherNames": [
                "LB-100",
                "PP2A Inhibitor LB-100"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Recommended phase II dose (RP2D)",
              "description": "Measured using dose-limiting toxicity (DLT) during the first cycle as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.",
              "timeFrame": "End of first cycle (21 days)"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Objective response rate (ORR)",
              "description": "Measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Patients who respond to treatment and die without progressive disease (PD) (including death from study disease), duration of response will be censored at the date of the last objective progression-free disease assessment. For responding patients not known to have died as of the data cut-off date and who do not have PD, duration of response will be censored at the last progression-free assessment date. For responding patients who receive subsequent anticancer therapy (after discontinuation from all study treatment excluding PCI) prior to disease progression, duration of response will be censored at the date of last progression-free assessment prior to the initiation of post discontinuation anticancer therapy.",
              "timeFrame": "Up to 2 years"
            },
            {
              "measure": "Duration of overall response",
              "description": "Measured by RECIST v1.1.",
              "timeFrame": "Up to 2 years"
            },
            {
              "measure": "Incidence of safety and adverse events",
              "description": "Assessed by CTCAE version 5.0.",
              "timeFrame": "Up to 2 years"
            },
            {
              "measure": "Progression-free survival (PFS)",
              "description": "As defined by RECIST v1.1.",
              "timeFrame": "Up to 2 years"
            },
            {
              "measure": "Overall survival (OS)",
              "description": "OS which is defined as the time from the date of study enrollment to the date of death from any cause. For patients who are still alive as of the data cutoff date, OS time will be censored on the date of the patient's last contact (last contact for patients in post discontinuation is last known alive date in mortality status).",
              "timeFrame": "Time from the date of study enrollment to the date of death from any cause, assessed up to 2 years"
            }
          ],
          "otherOutcomes": [
            {
              "measure": "Cmax of LB-100",
              "description": "Plasma sampling for pharmacokinetic (PK) measurements of LB-100 will be performed . Blood samples will be collected to determine the Cmax of LB-100.",
              "timeFrame": "Cycle 1 day 1: Pre-dose, immediately post LB-100 infusion, at 15 & 30 minutes, at 1, 2, 4, and 8 hours post LB-100 infusion (Each cycle is 21 days); Cycle 1, days 2-3: Pre-dose and 24 hours post LB-100 infusion (Each cycle is 21 days)]"
            },
            {
              "measure": "Cmax of endothall",
              "description": "Plasma sampling for pharmacokinetic (PK) measurements of endothall, the metabolite of LB-100, will be performed .\n\nBlood samples will be collected to determine the Cmax of endothall.",
              "timeFrame": "Cycle 1 day 1: Pre-dose, immediately post LB-100 infusion, at 15 & 30 minutes, at 1, 2, 4, and 8 hours post LB-100 infusion (Each cycle is 21 days); Cycle 1, days 2-3: Pre-dose and 24 hours post LB-100 infusion (Each cycle is 21 days)]"
            },
            {
              "measure": "Tmax of LB-100",
              "description": "Plasma sampling for pharmacokinetic (PK) measurements of LB-100 will be performed . Blood samples will be collected to determine the Tmax of LB-100.",
              "timeFrame": "Cycle 1 day 1: Pre-dose, immediately post LB-100 infusion, at 15 & 30 minutes, at 1, 2, 4, and 8 hours post LB-100 infusion (Each cycle is 21 days); Cycle 1, days 2-3: Pre-dose and 24 hours post LB-100 infusion (Each cycle is 21 days)]"
            },
            {
              "measure": "Tmax of endothall",
              "description": "Plasma sampling for pharmacokinetic (PK) measurements of endothall, the metabolite of LB-100, will be performed .\n\nBlood samples will be collected to determine the Tmax of endothall.",
              "timeFrame": "Cycle 1 day 1: Pre-dose, immediately post LB-100 infusion, at 15 & 30 minutes, at 1, 2, 4, and 8 hours post LB-100 infusion (Each cycle is 21 days); Cycle 1, days 2-3: Pre-dose and 24 hours post LB-100 infusion (Each cycle is 21 days)]"
            },
            {
              "measure": "t1/2 of LB-100",
              "description": "Plasma sampling for pharmacokinetic (PK) measurements of LB-100 will be performed . Blood samples will be collected to determine the t1/2 of LB-100.",
              "timeFrame": "Cycle 1 day 1: Pre-dose, immediately post LB-100 infusion, at 15 & 30 minutes, at 1, 2, 4, and 8 hours post LB-100 infusion (Each cycle is 21 days); Cycle 1, days 2-3: Pre-dose and 24 hours post LB-100 infusion (Each cycle is 21 days)]"
            },
            {
              "measure": "t1/2 of endothall",
              "description": "Plasma sampling for pharmacokinetic (PK) measurements of endothall, the metabolite of LB-100, will be performed .\n\nBlood samples will be collected to determine the t1/2 of endothall.",
              "timeFrame": "[Time Frame: Cycle 1 day 1: Pre-dose, immediately post LB-100 infusion, at 15 & 30 minutes, at 1, 2, 4, and 8 hours post LB-100 infusion (Each cycle is 21 days); Cycle 1, days 2-3: Pre-dose and 24 hours post LB-100 infusion (Each cycle is 21 days)]"
            },
            {
              "measure": "AUC0-t of LB-100",
              "description": "Plasma sampling for pharmacokinetic (PK) measurements of LB-100 will be performed . Blood samples will be collected to determine the AUC0-t of LB-100.",
              "timeFrame": "Cycle 1 day 1: Pre-dose, immediately post LB-100 infusion, at 15 & 30 minutes, at 1, 2, 4, and 8 hours post LB-100 infusion (Each cycle is 21 days); Cycle 1, days 2-3: Pre-dose and 24 hours post LB-100 infusion (Each cycle is 21 days)]"
            },
            {
              "measure": "AUC0-t of endothall",
              "description": "Plasma sampling for pharmacokinetic (PK) measurements of endothall, the metabolite of LB-100, will be performed .\n\nBlood samples will be collected to determine the AUC0-t of endothall.",
              "timeFrame": "Cycle 1 day 1: Pre-dose, immediately post LB-100 infusion, at 15 & 30 minutes, at 1, 2, 4, and 8 hours post LB-100 infusion (Each cycle is 21 days); Cycle 1, days 2-3: Pre-dose and 24 hours post LB-100 infusion (Each cycle is 21 days)]"
            },
            {
              "measure": "CL of LB-100",
              "description": "Plasma sampling for pharmacokinetic (PK) measurements of LB-100 will be performed . Blood samples will be collected to determine the CL of LB-100.",
              "timeFrame": "Cycle 1 day 1: Pre-dose, immediately post LB-100 infusion, at 15 & 30 minutes, at 1, 2, 4, and 8 hours post LB-100 infusion (Each cycle is 21 days); Cycle 1, days 2-3: Pre-dose and 24 hours post LB-100 infusion (Each cycle is 21 days)]"
            },
            {
              "measure": "CL of endothall",
              "description": "Plasma sampling for pharmacokinetic (PK) measurements of endothall, the metabolite of LB-100, will be performed .\n\nBlood samples will be collected to determine the CL of endothall.",
              "timeFrame": "Cycle 1 day 1: Pre-dose, immediately post LB-100 infusion, at 15 & 30 minutes, at 1, 2, 4, and 8 hours post LB-100 infusion (Each cycle is 21 days); Cycle 1, days 2-3: Pre-dose and 24 hours post LB-100 infusion (Each cycle is 21 days)]"
            },
            {
              "measure": "Relative abundance of immune cell populations",
              "description": "The signaling states that evolve in immune cells during treatment and that differentiate responders from nonresponders.\n\nNumber of effector memory T cells Number of classical monocytes",
              "timeFrame": "Up to 2 years]"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed extensive-stage disease small cell lung carcinoma per the Veterans Administration Lung Study Group (VALG) staging system\n* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST): Revised RECIST guideline (version 1.1)\n* Estimated life expectancy of at least 12 weeks\n* For women: Must be surgically sterile (surgical procedure: bilateral tubal ligation), post-menopausal (at least 12 consecutive months of amenorrhea) or have a negative pregnancy test. Women of childbearing potential must be compliant with a medically approved contraceptive regimen (intrauterine device \\[IUD\\], birth control pills, or barrier device) during and for 3 months after the treatment period; must have a negative serum or urine pregnancy test within 14 days before study drug treatment and must not be breastfeeding\n* For men: agreement to remain abstinent or use medically approved contraceptive measures, as defined below:\n\n  * With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during study therapy and for at least 6 months after the last dose of study therapy to avoid exposing the embryo\n* A performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale\n* Absolute neutrophil (segmented and bands) count (ANC) \\>= 1.5 x 10/L\n* Platelets \\>= 100 x 10/L\n* Hemoglobin \\>= 9 g/dL\n* Bilirubin =\\< 1.5 times upper limits of normal (ULN) may be enrolled\n* Alkaline phosphatase (AP), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\< 3.0 times ULN (AP, AST, and ALT =\\< 5 times ULN are acceptable if the liver has tumor involvement)\n* Calculated creatinine clearance (CrCl) \\>= 60 mL/min based on the Cockcroft and Gault formula\n* All subjects must have the ability to understand and the willingness to sign a written informed consent\n* No prior systemic chemotherapy, immunotherapy, biological, hormonal, or investigational therapy for SCLC\n\nExclusion Criteria:\n\n* Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study\n* Diagnosis of non-small cell lung cancer (NSCLC) or mixed NSCLC and small cell lung cancer (SCLC)\n* No prior malignancy other than SCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated 5 or more years prior to study entry with no subsequent evidence of recurrence. Patients with a history of low grade (Gleason score =\\< 6 = Gleason group 1) localized prostate cancer will be eligible even if diagnosed less than 5 years prior to study entry\n* Serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol\n* Active or ongoing infection during screening requiring the use of systemic antibiotics\n* Serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease as defined by the New York Heart Association class III or IV\n* Clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroid medication for 1 week prior to the first dose of study drug and have completed radiation 2 weeks prior to the first dose of study drug\n* Known or suspected allergy to any agent given in association with this trial\n* Pregnant or lactating women\n* History of autoimmune disease, including minor/mild autoimmune disease not requiring immunosuppressants (such as eczema on less than 10% of the body surface area and long term diabetes mellitus type 1 on stable insulin)\n* Known hepatitis B or hepatitis C\n* Known human immunodeficiency virus (HIV) positive\n* Treatment with systemic corticosteroid or other immunosuppressive medication. The use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed\n* Administration of a live, attenuated vaccine within 28 days prior to study\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed\n* Uncontrolled or symptomatic hypercalcemia (\\> 1.5 mmol/L ionized calcium or calcium \\> 12 mg/dL or corrected serum calcium \\> ULN). Patients who are receiving denosumab prior to study entry must be willing and eligible to discontinue its use and replace it with a bisphosphonate while in the study\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted\n* Prior allogeneic bone marrow transplantation or solid organ transplant\n* QTcF (Fridericia Correction Formula) \\> 470 on 2 out of 3 electrocardiograms (EKG's)\n* Diagnosis of congenital long QT syndrome\n* Treatment, within 7 days prior to first dose of study drug, with medications that are known to prolong the QT interval and/or are associated with a risk of torsades de pointes\n* Treatment with CYP450 substrates within 7 days prior to first dose of study drug\n* Treatment with nephrotoxic compounds within 7 days prior to first dose of study drug\n* Treatment with warfarin within 7 days prior to first dose of study drug\n* Treatment with antiepileptic medications that may increase etoposide clearance (including but not limited to phenytoin, phenobarbital, carbamazepine, and valproic acid) within 7 days prior to first dose of study drug\n* Treatment with strong P-glycoprotein inhibitors within 7 days prior to first dose of study drug\n* Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Ravi Salgia",
              "affiliation": "City of Hope Medical Center",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "City of Hope Medical Center",
              "status": "RECRUITING",
              "city": "Duarte",
              "state": "California",
              "zip": "91010",
              "country": "United States",
              "contacts": [
                {
                  "name": "Ravi Salgia",
                  "role": "CONTACT",
                  "phone": "626-218-3712",
                  "email": "rsalgia@coh.org"
                },
                {
                  "name": "Ravi Salgia",
                  "role": "PRINCIPAL_INVESTIGATOR"
                }
              ],
              "geoPoint": {
                "lat": 34.13945,
                "lon": -117.97729
              }
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000002277",
              "term": "Carcinoma"
            },
            {
              "id": "D000018288",
              "term": "Carcinoma, Small Cell"
            },
            {
              "id": "D000055752",
              "term": "Small Cell Lung Carcinoma"
            }
          ],
          "ancestors": [
            {
              "id": "D000009375",
              "term": "Neoplasms, Glandular and Epithelial"
            },
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000002283",
              "term": "Carcinoma, Bronchogenic"
            },
            {
              "id": "D000001984",
              "term": "Bronchial Neoplasms"
            },
            {
              "id": "D000008175",
              "term": "Lung Neoplasms"
            },
            {
              "id": "D000012142",
              "term": "Respiratory Tract Neoplasms"
            },
            {
              "id": "D000013899",
              "term": "Thoracic Neoplasms"
            },
            {
              "id": "D000009371",
              "term": "Neoplasms by Site"
            },
            {
              "id": "D000008171",
              "term": "Lung Diseases"
            },
            {
              "id": "D000012140",
              "term": "Respiratory Tract Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M5224",
              "name": "Carcinoma",
              "asFound": "Carcinoma",
              "relevance": "HIGH"
            },
            {
              "id": "M10862",
              "name": "Lung Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M28013",
              "name": "Small Cell Lung Carcinoma",
              "asFound": "Lung Small Cell Carcinoma",
              "relevance": "HIGH"
            },
            {
              "id": "M20123",
              "name": "Carcinoma, Small Cell",
              "asFound": "Small Cell Carcinoma",
              "relevance": "HIGH"
            },
            {
              "id": "M12010",
              "name": "Neoplasms, Glandular and Epithelial",
              "relevance": "LOW"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M5230",
              "name": "Carcinoma, Bronchogenic",
              "relevance": "LOW"
            },
            {
              "id": "M4950",
              "name": "Bronchial Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M14669",
              "name": "Respiratory Tract Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M16348",
              "name": "Thoracic Neoplasms",
              "relevance": "LOW"
            },
            {
              "id": "M10858",
              "name": "Lung Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M14667",
              "name": "Respiratory Tract Diseases",
              "relevance": "LOW"
            },
            {
              "id": "T5271",
              "name": "Small Cell Lung Cancer",
              "asFound": "Lung Small Cell Carcinoma",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC08",
              "name": "Respiratory Tract (Lung and Bronchial) Diseases"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000016190",
              "term": "Carboplatin"
            },
            {
              "id": "D000005047",
              "term": "Etoposide"
            },
            {
              "id": "C000061400",
              "term": "Etoposide phosphate"
            },
            {
              "id": "C000594389",
              "term": "Atezolizumab"
            },
            {
              "id": "D000011034",
              "term": "Podophyllotoxin"
            },
            {
              "id": "C000708580",
              "term": "LB100"
            },
            {
              "id": "D000000911",
              "term": "Antibodies, Monoclonal"
            }
          ],
          "ancestors": [
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000000972",
              "term": "Antineoplastic Agents, Phytogenic"
            },
            {
              "id": "D000059005",
              "term": "Topoisomerase II Inhibitors"
            },
            {
              "id": "D000059003",
              "term": "Topoisomerase Inhibitors"
            },
            {
              "id": "D000004791",
              "term": "Enzyme Inhibitors"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            },
            {
              "id": "D000082082",
              "term": "Immune Checkpoint Inhibitors"
            },
            {
              "id": "D000074322",
              "term": "Antineoplastic Agents, Immunological"
            },
            {
              "id": "D000007155",
              "term": "Immunologic Factors"
            },
            {
              "id": "D000045505",
              "term": "Physiological Effects of Drugs"
            },
            {
              "id": "D000007641",
              "term": "Keratolytic Agents"
            },
            {
              "id": "D000003879",
              "term": "Dermatologic Agents"
            },
            {
              "id": "D000050257",
              "term": "Tubulin Modulators"
            },
            {
              "id": "D000050256",
              "term": "Antimitotic Agents"
            },
            {
              "id": "D000050258",
              "term": "Mitosis Modulators"
            }
          ],
          "browseLeaves": [
            {
              "id": "M18340",
              "name": "Carboplatin",
              "asFound": "1000",
              "relevance": "HIGH"
            },
            {
              "id": "M349350",
              "name": "Atezolizumab",
              "asFound": "Every 28 days",
              "relevance": "HIGH"
            },
            {
              "id": "M7881",
              "name": "Etoposide",
              "asFound": "Toxin",
              "relevance": "HIGH"
            },
            {
              "id": "M341584",
              "name": "Etoposide phosphate",
              "asFound": "Toxin",
              "relevance": "HIGH"
            },
            {
              "id": "M13614",
              "name": "Podophyllotoxin",
              "asFound": "Navigator",
              "relevance": "HIGH"
            },
            {
              "id": "M347822",
              "name": "LB100",
              "asFound": "Asthma action plan",
              "relevance": "HIGH"
            },
            {
              "id": "M3915",
              "name": "Antibodies",
              "relevance": "LOW"
            },
            {
              "id": "M9874",
              "name": "Immunoglobulins",
              "relevance": "LOW"
            },
            {
              "id": "M3920",
              "name": "Antibodies, Monoclonal",
              "asFound": "Every 28 days",
              "relevance": "HIGH"
            },
            {
              "id": "M7641",
              "name": "Enzyme Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M2343",
              "name": "Immune Checkpoint Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M1346",
              "name": "Antineoplastic Agents, Immunological",
              "relevance": "LOW"
            },
            {
              "id": "M9891",
              "name": "Immunologic Factors",
              "relevance": "LOW"
            },
            {
              "id": "M10357",
              "name": "Keratolytic Agents",
              "relevance": "LOW"
            },
            {
              "id": "M6764",
              "name": "Dermatologic Agents",
              "relevance": "LOW"
            },
            {
              "id": "M25887",
              "name": "Tubulin Modulators",
              "relevance": "LOW"
            },
            {
              "id": "M25886",
              "name": "Antimitotic Agents",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            },
            {
              "abbrev": "Derm",
              "name": "Dermatologic Agents"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT00244972",
          "orgStudyIdInfo": {
            "id": "NCI-2009-00132"
          },
          "secondaryIdInfos": [
            {
              "id": "NCI-2009-00132",
              "type": "REGISTRY",
              "domain": "CTRP (Clinical Trial Reporting Program)"
            },
            {
              "id": "2005-0363"
            },
            {
              "id": "CDR0000446569"
            },
            {
              "id": "2005-0363",
              "type": "OTHER",
              "domain": "M D Anderson Cancer Center"
            },
            {
              "id": "7156",
              "type": "OTHER",
              "domain": "CTEP"
            },
            {
              "id": "P30CA016672",
              "type": "NIH",
              "link": "https://reporter.nih.gov/quickSearch/P30CA016672"
            },
            {
              "id": "U01CA062461",
              "type": "NIH",
              "link": "https://reporter.nih.gov/quickSearch/U01CA062461"
            }
          ],
          "organization": {
            "fullName": "National Cancer Institute (NCI)",
            "class": "NIH"
          },
          "briefTitle": "Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer",
          "officialTitle": "Phase I Study of Tipifarnib (R115777) and Sorafenib (BAY 43-9006) in Patients With Biopsiable Advanced Cancers"
        },
        "statusModule": {
          "statusVerifiedDate": "2017-04",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2005-10"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-03",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2005-10-25",
          "studyFirstSubmitQcDate": "2005-10-25",
          "studyFirstPostDateStruct": {
            "date": "2005-10-27",
            "type": "ESTIMATED"
          },
          "lastUpdateSubmitDate": "2017-04-26",
          "lastUpdatePostDateStruct": {
            "date": "2017-04-27",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR"
          },
          "leadSponsor": {
            "name": "National Cancer Institute (NCI)",
            "class": "NIH"
          }
        },
        "descriptionModule": {
          "briefSummary": "This phase I trial studies the side effects and best dose of tipifarnib when given together with sorafenib tosylate in treating patients with biopsiable cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Tipifarnib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.",
          "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. To evaluate the safety and toxicity and to determine maximum tolerated dose (MTD) of tipifarnib in combination with sorafenib (sorafenib tosylate).\n\nSECONDARY OBJECTIVES:\n\nI. Preliminary assessment of tipifarnib and sorafenib efficacy (objective response).\n\nII. To determine signaling pathway profiles of patients treated with tipifarnib and sorafenib who are amenable to biopsy by reverse phase protein microarray (RPPA) analysis.\n\nOUTLINE: This is a dose-escalation study of tipifarnib.\n\nPatients receive sorafenib tosylate orally (PO) once daily (QD) or twice daily (BID) on days 1-28 and tipifarnib PO QD or BID on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients may be allowed to continue the treatment after the 12 courses if there is continued clinical response or disease stabilization, and patients do not have significant toxicities.\n\nAfter completion of study treatment, patients are followed up for 4 weeks."
        },
        "conditionsModule": {
          "conditions": [
            "Advanced Malignant Neoplasm"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE1"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 74,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Treatment (sorafenib tosylate, tipifarnib)",
              "type": "EXPERIMENTAL",
              "description": "Patients receive sorafenib tosylate PO QD or BID on days 1-28 and tipifarnib PO QD or BID on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients may be allowed to continue the treatment after the 12 courses if there is continued clinical response or disease stabilization, and patients do not have significant toxicities.",
              "interventionNames": [
                "Other: Laboratory Biomarker Analysis",
                "Drug: Sorafenib Tosylate",
                "Drug: Tipifarnib"
              ]
            }
          ],
          "interventions": [
            {
              "type": "OTHER",
              "name": "Laboratory Biomarker Analysis",
              "description": "Correlative studies",
              "armGroupLabels": [
                "Treatment (sorafenib tosylate, tipifarnib)"
              ]
            },
            {
              "type": "DRUG",
              "name": "Sorafenib Tosylate",
              "description": "Given PO",
              "armGroupLabels": [
                "Treatment (sorafenib tosylate, tipifarnib)"
              ],
              "otherNames": [
                "BAY 43-9006 Tosylate",
                "BAY 54-9085",
                "Nexavar",
                "sorafenib"
              ]
            },
            {
              "type": "DRUG",
              "name": "Tipifarnib",
              "description": "Given PO",
              "armGroupLabels": [
                "Treatment (sorafenib tosylate, tipifarnib)"
              ],
              "otherNames": [
                "R115777",
                "Zarnestra"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "MTD defined as the highest dose level in which fewer than 2 patients experience a dose limiting toxicity as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",
              "description": "Descriptive statistics and graphical analysis will be used to summarize the data. Categorical variables will be summarized in frequency tables.",
              "timeFrame": "28 days"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Clinical response evaluated using Response Evaluation Criteria In Solid Tumors criteria",
              "description": "Descriptive statistics and graphical analysis will be used to summarize the data. For continuous variables, mean (standard deviation) or median (range) will be used to summarize outcomes.",
              "timeFrame": "Up to 4 weeks"
            },
            {
              "measure": "Signaling pathway inhibition in tumor tissue by RPPA",
              "description": "The analysis of the activated signaling pathways using Pathway Analysis (Ingenuity) will determine whether particular molecular profiles are likely to respond to tipifarnib and sorafenib.",
              "timeFrame": "Up to 4 weeks"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have had =\\< 4 prior chemotherapy regimens; patients must have advanced cancer that is refractory to standard therapy or for whom there is no standard therapy that increases survival by three months\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\< 2 (Karnofsky \\>= 60%)\n* Life expectancy of greater than 12 weeks\n* Leukocytes \\>= 3,000/mcL\n* Absolute neutrophil count \\>= 1,500/mcL\n* Platelets \\>= 100,000/mcL\n* Total bilirubin =\\< 1.5\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\< 2.5 x institutional upper limit of normal\n* Creatinine within normal institutional limits OR creatinine clearance \\>= 60 mL/min/1.73 m\\^2 for patients with creatinine levels above institutional normal (a calculated creatinine clearance \\[CrCL\\] is acceptable)\n* International normalized ratio (INR)/prothrombin time (PT) =\\< within institutional guidelines for biopsy procedures (=\\< 16 seconds)\n* Eligibility of patients receiving any other medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of BAY 43-9006 (sorafenib tosylate) or R115777 (tipifarnib) will be determined following review of their case by the Principal Investigator\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n* Tumor accessible for repeat biopsies\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\n* Patients may not be receiving any investigational agents other than BAY 43-9006 and R115777\n* Patients with known brain metastases are excluded except for patients who have had treated brain metastases and are currently not taking anti-seizure medications or steroids\n* Patients may not have allergies to imidazoles (e.g., clotrimazole, ketoconazole, miconazole, econazole) or a history of allergic reactions attributed to any other compound of similar chemical or biologic composition to either BAY 43-9006 or R115777\n* Uncontrolled hypertension with systolic blood pressure of \\> 140 mmHg or diastolic pressure \\> 90 mmHg; however, patients with well-controlled hypertension are eligible\n* Patients must not have any evidence of current history of bleeding diathesis\n* Patients cannot be on therapeutic anticoagulation; prophylactic anticoagulation therapy (e.g., low-dose warfarin) of venous or arterial access devices is allowed provided that the requirements for prothrombin time (INR; international normalized ratio of prothrombin time) and partial thromboplastin time (PTT) are maintained; patients will be monitored on a weekly basis for the first (1st) cycle of treatment until the INR/PT has stabilized for 2 weeks consecutively; if patients discontinue the R115777 patients will be monitored weekly until INR/PT is stabilized for 2 weeks consecutively\n* Patients may not have grade 2 or greater peripheral neuropathy\n* Patients with any condition that impairs their ability to swallow pills are excluded\n* Patients cannot be receiving enzyme-inducing antiepileptic drugs (EIAEDs) (e.g., phenytoin, carbamazepine, phenobarbital) nor any other cytochrome P450 family 3, subfamily A, polypeptide (CYP3A4) inducer such as rifampin or St. John's wort\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Patients with a New York Heart Association (NYHA) classification \\> 2\n* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either of these agents\n* Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "David Hong",
              "affiliation": "M.D. Anderson Cancer Center",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "M D Anderson Cancer Center",
              "city": "Houston",
              "state": "Texas",
              "zip": "77030",
              "country": "United States",
              "geoPoint": {
                "lat": 29.76328,
                "lon": -95.36327
              }
            }
          ]
        },
        "referencesModule": {
          "references": [
            {
              "pmid": "23676418",
              "type": "DERIVED",
              "citation": "Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep;24(9):2256-61. doi: 10.1093/annonc/mdt177. Epub 2013 May 14."
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000009369",
              "term": "Neoplasms"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000077157",
              "term": "Sorafenib"
            },
            {
              "id": "C000402769",
              "term": "Tipifarnib"
            }
          ],
          "ancestors": [
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000047428",
              "term": "Protein Kinase Inhibitors"
            },
            {
              "id": "D000004791",
              "term": "Enzyme Inhibitors"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            }
          ],
          "browseLeaves": [
            {
              "id": "M1680",
              "name": "Sorafenib",
              "asFound": "Carboplatin",
              "relevance": "HIGH"
            },
            {
              "id": "M249895",
              "name": "Tipifarnib",
              "asFound": "EPI",
              "relevance": "HIGH"
            },
            {
              "id": "M25510",
              "name": "Protein Kinase Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M7641",
              "name": "Enzyme Inhibitors",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            }
          ]
        }
      },
      "hasResults": false
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT01300572",
          "orgStudyIdInfo": {
            "id": "2468.00"
          },
          "secondaryIdInfos": [
            {
              "id": "NCI-2011-00150",
              "type": "REGISTRY",
              "domain": "CTRP (Clinical Trial Reporting Program)"
            },
            {
              "id": "2468.00A"
            },
            {
              "id": "2468"
            },
            {
              "id": "2468.00",
              "type": "OTHER",
              "domain": "Fred Hutch/University of Washington Cancer Consortium"
            },
            {
              "id": "P01CA044991",
              "type": "NIH",
              "link": "https://reporter.nih.gov/quickSearch/P01CA044991"
            },
            {
              "id": "P30CA015704",
              "type": "NIH",
              "link": "https://reporter.nih.gov/quickSearch/P30CA015704"
            }
          ],
          "organization": {
            "fullName": "Fred Hutchinson Cancer Center",
            "class": "OTHER"
          },
          "briefTitle": "Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS",
          "officialTitle": "A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (Anti-CD45) Antibody Followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)"
        },
        "statusModule": {
          "statusVerifiedDate": "2019-12",
          "overallStatus": "COMPLETED",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2012-01",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2017-10-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-11-22",
            "type": "ACTUAL"
          },
          "studyFirstSubmitDate": "2011-02-15",
          "studyFirstSubmitQcDate": "2011-02-18",
          "studyFirstPostDateStruct": {
            "date": "2011-02-21",
            "type": "ESTIMATED"
          },
          "resultsFirstSubmitDate": "2018-10-18",
          "resultsFirstSubmitQcDate": "2019-01-22",
          "resultsFirstPostDateStruct": {
            "date": "2019-01-25",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2019-12-02",
          "lastUpdatePostDateStruct": {
            "date": "2019-12-10",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "PRINCIPAL_INVESTIGATOR",
            "investigatorFullName": "Brenda Sandmaier",
            "investigatorTitle": "Principal Investigator",
            "investigatorAffiliation": "Fred Hutchinson Cancer Center"
          },
          "leadSponsor": {
            "name": "Fred Hutchinson Cancer Center",
            "class": "OTHER"
          },
          "collaborators": [
            {
              "name": "National Cancer Institute (NCI)",
              "class": "NIH"
            }
          ]
        },
        "oversightModule": {
          "oversightHasDmc": true
        },
        "descriptionModule": {
          "briefSummary": "This phase I trial studies the side effects and maximum tolerated dose of yttrium Y 90 anti-cluster of differentiation 45 (CD45) monoclonal antibody BC8 (90Y-BC8) followed by donor stem cell transplant in treating patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS) that is likely to come back or spread. Giving chemotherapy drugs, such as fludarabine phosphate (FLU), and total-body irradiation (TBI) before a donor peripheral blood stem cell (PBSC) or bone marrow transplant helps stop the growth of cancer or abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. Radiolabeled monoclonal antibodies, such as 90Y-BC8, can find cancer cells and carry cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving FLU, 90Y-BC8, and TBI before the transplant together with cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.",
          "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. To estimate the maximum tolerated dose (MTD) of radiation delivered via 90Y-DOTA-BC8 (90Y-BC8) when combined with FLU and 2 Gy TBI as a preparative regimen for patients aged \\>= 18 with advanced AML, ALL, and high-risk MDS.\n\nSECONDARY OBJECTIVES:\n\nI. To determine disease response and duration of remission.\n\nII. To determine the rates of engraftment and donor chimerism resulting from this combined preparative regimen, and to correlate level of donor chimerism with estimated radiation doses delivered to hematopoietic tissues via antibody.\n\nOUTLINE:\n\nPREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12 and FLU intravenously (IV) over 30 minutes on days -4 to -2.\n\nTRANSPLANTATION: Patients undergo TBI followed by allogeneic PBSC or bone marrow transplant on day 0.\n\nGRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive mycophenolate mofetil orally (PO) or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAfter completion of study treatment, patients are followed up at 6, 9, 12, 18, and 24 months, and then annually thereafter."
        },
        "conditionsModule": {
          "conditions": [
            "Chronic Myelomonocytic Leukemia",
            "Previously Treated Myelodysplastic Syndrome",
            "Recurrent Adult Acute Lymphoblastic Leukemia",
            "Recurrent Adult Acute Myeloid Leukemia",
            "Refractory Anemia With Excess Blasts",
            "Secondary Acute Myeloid Leukemia"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE1"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Y-90-BC8 & Allogeneic Transplant",
              "type": "EXPERIMENTAL",
              "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.",
              "interventionNames": [
                "Procedure: Allogeneic Bone Marrow Transplantation",
                "Procedure: Allogeneic Hematopoietic Stem Cell Transplantation",
                "Drug: Cyclosporine",
                "Drug: Fludarabine Phosphate",
                "Biological: Indium In 111 Anti-CD45 Monoclonal Antibody BC8",
                "Other: Laboratory Biomarker Analysis",
                "Drug: Mycophenolate Mofetil",
                "Procedure: Peripheral Blood Stem Cell Transplantation",
                "Other: Pharmacological Study",
                "Radiation: Total-Body Irradiation",
                "Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8"
              ]
            }
          ],
          "interventions": [
            {
              "type": "PROCEDURE",
              "name": "Allogeneic Bone Marrow Transplantation",
              "description": "Undergo allogeneic bone marrow transplant",
              "armGroupLabels": [
                "Y-90-BC8 & Allogeneic Transplant"
              ],
              "otherNames": [
                "Allo BMT",
                "Allogeneic BMT"
              ]
            },
            {
              "type": "PROCEDURE",
              "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
              "description": "Undergo allogeneic PBSC or bone marrow transplant",
              "armGroupLabels": [
                "Y-90-BC8 & Allogeneic Transplant"
              ],
              "otherNames": [
                "allogeneic stem cell transplantation",
                "HSC",
                "HSCT"
              ]
            },
            {
              "type": "DRUG",
              "name": "Cyclosporine",
              "description": "Given PO or IV",
              "armGroupLabels": [
                "Y-90-BC8 & Allogeneic Transplant"
              ],
              "otherNames": [
                "27-400",
                "Ciclosporin",
                "CsA",
                "Cyclosporin",
                "Cyclosporin A",
                "Gengraf",
                "Neoral",
                "OL 27-400",
                "Sandimmun",
                "Sandimmune",
                "SangCya"
              ]
            },
            {
              "type": "DRUG",
              "name": "Fludarabine Phosphate",
              "description": "Given IV",
              "armGroupLabels": [
                "Y-90-BC8 & Allogeneic Transplant"
              ],
              "otherNames": [
                "2-F-ara-AMP",
                "9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-",
                "Beneflur",
                "Fludara",
                "SH T 586"
              ]
            },
            {
              "type": "BIOLOGICAL",
              "name": "Indium In 111 Anti-CD45 Monoclonal Antibody BC8",
              "description": "Given IV (dosimetric dose)",
              "armGroupLabels": [
                "Y-90-BC8 & Allogeneic Transplant"
              ],
              "otherNames": [
                "In 111 MOAB BC8",
                "In 111 Monoclonal Antibody BC8",
                "Indium In 111 Monoclonal Antibody BC8",
                "monoclonal antibody BC8, indium In 111"
              ]
            },
            {
              "type": "OTHER",
              "name": "Laboratory Biomarker Analysis",
              "description": "Correlative studies",
              "armGroupLabels": [
                "Y-90-BC8 & Allogeneic Transplant"
              ]
            },
            {
              "type": "DRUG",
              "name": "Mycophenolate Mofetil",
              "description": "Given PO or IV",
              "armGroupLabels": [
                "Y-90-BC8 & Allogeneic Transplant"
              ],
              "otherNames": [
                "Cellcept",
                "MMF"
              ]
            },
            {
              "type": "PROCEDURE",
              "name": "Peripheral Blood Stem Cell Transplantation",
              "description": "Undergo allogeneic PBSC transplant",
              "armGroupLabels": [
                "Y-90-BC8 & Allogeneic Transplant"
              ],
              "otherNames": [
                "PBPC transplantation",
                "Peripheral Blood Progenitor Cell Transplantation",
                "Peripheral Stem Cell Support",
                "Peripheral Stem Cell Transplantation"
              ]
            },
            {
              "type": "OTHER",
              "name": "Pharmacological Study",
              "description": "Correlative studies",
              "armGroupLabels": [
                "Y-90-BC8 & Allogeneic Transplant"
              ]
            },
            {
              "type": "RADIATION",
              "name": "Total-Body Irradiation",
              "description": "Undergo TBI",
              "armGroupLabels": [
                "Y-90-BC8 & Allogeneic Transplant"
              ],
              "otherNames": [
                "TOTAL BODY IRRADIATION",
                "Whole-Body Irradiation"
              ]
            },
            {
              "type": "RADIATION",
              "name": "Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8",
              "description": "Given via central line (therapeutic dose)",
              "armGroupLabels": [
                "Y-90-BC8 & Allogeneic Transplant"
              ],
              "otherNames": [
                "90Y Anti-CD45 MoAb BC8"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "The MTD of Radiation Delivered Via 90Y-DOTA-BC8 When Combined With FLU and 2 Gy TBI as a Preparative Regimen for Patients Aged ≥ 18 With Advanced AML, ALL, and High-risk MDS.",
              "description": "The MTD will be defined as the dose that is associated with a true DLT rate of 25%. The highest dose achieved was 28 Gy but none of the patients experienced a DLT. Thus, the MTD was not reached.",
              "timeFrame": "Within the first 30 days following transplant"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "Achievement of Remission",
              "description": "Number of participants who are in complete remission (CR) 4 weeks after transplant. CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:\n\n1. Normal bone marrow with blasts \\<5% with normal cellularity, normal megakaryopoiesis, \\> 15% erythropoiesis and \\> 25% granulocytopoiesis\n2. Normalization of blood counts (no blasts, platelets \\> 100000/mm3, granulocytes \\>1500/mm3)\n3. No extramedullary disease.",
              "timeFrame": "4 weeks after transplant"
            },
            {
              "measure": "Disease-free Survival",
              "description": "Number of study participants who are alive and remains in complete remission after transplant.",
              "timeFrame": "100 days after transplant"
            },
            {
              "measure": "Duration of Remission",
              "description": "Median time to relapse after achieving complete remission (CR). CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:\n\n1. Normal bone marrow with blasts \\<5% with normal cellularity, normal megakaryopoiesis, \\> 15% erythropoiesis and \\> 25% granulocytopoiesis\n2. Normalization of blood counts (no blasts, platelets \\> 100000/mm3, granulocytes \\>1500/mm3)\n3. No extramedullary disease.\n\nRelapse Criteria:\n\n1. After CR: \\>5% blasts in the bone marrow and/or peripheral blood\n2. After partial remission (PR): increase of blasts cells in the marrow to \\>50% of those during PR\n3. Extramedullary disease confirmed cytologically or histologically.",
              "timeFrame": "1 year"
            },
            {
              "measure": "Estimation of Absorbed Radiation Doses to Normal Organs, Marrow and Tumor",
              "description": "The amount of energy absorbed per unit weight of the organ or tissue is called absorbed dose and is expressed in units of gray (Gy). One gray dose is equivalent to one joule radiation energy absorbed per kilogram of organ or tissue weight.",
              "timeFrame": "Approximately day -20 to day -12 prior to transplant"
            },
            {
              "measure": "Overall Survival",
              "description": "Number of participants who are still alive after transplant with or without disease.",
              "timeFrame": "Up to 5 years"
            },
            {
              "measure": "Rates of Acute GvHD",
              "description": "Number of participants who developed acute GVHD post-transplant, aGVHD stages:\n\nSkin: a maculopapular eruption involving \\< 25% BSA a maculopapular eruption involving 25 - 50% BSA generalized erythroderma generalized erythroderma with bullous formation and often with desquamation\n\nLiver:\n\nbilirubin 2.0 - 3.0 mg/100 mL bilirubin 3 - 5.9 mg/100 mL bilirubin 6 - 14.9 mg/100 mL bilirubin \\> 15 mg/100 mL\n\nGut:\n\nDiarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall.\n\naGVHD Grades Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death",
              "timeFrame": "Up to 84 days post-transplant"
            },
            {
              "measure": "Rates of Donor Chimerism",
              "description": "Number of participants who has 100% donor chimerism within 100 days after transplant",
              "timeFrame": "Up to 100 days post-transplant"
            },
            {
              "measure": "Rates of Engraftment",
              "description": "Average number of days to ANC \\>= 500 after transplant",
              "timeFrame": "Up to 84 days post-transplant"
            },
            {
              "measure": "Rates of Non-relapse Mortality",
              "description": "Transplant-related deaths within 100 days after transplant",
              "timeFrame": "Within the first 100 days following transplant"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have advanced AML, ALL or high-risk MDS meeting one of the following descriptions:\n\n  * AML or ALL beyond first remission (i.e., having relapsed at least one time after achieving remission in response to a treatment regimen)\n  * AML or ALL representing primary refractory disease (i.e., having failed to achieve remission at any time following one or more prior treatment regimens)\n  * AML evolved from myelodysplastic or myeloproliferative syndromes; or\n  * MDS expressed as refractory anemia with excess blasts (RAEB) or chronic myelomonocytic leukemia (CMML) by French-American-British (FAB) criteria\n* Patients not in remission must have CD45-expressing leukemic blasts; patients in remission do not require phenotyping and may have leukemia previously documented to be CD45 negative (because in remission patients, virtually all antibody binding is to non-malignant cells which make up \\>= 95% of nucleated cells in the marrow)\n* Patients should have a circulating blast count of less than 10,000/mm\\^3 (control with hydroxyurea or similar agent is allowed)\n* Patients must have an estimated creatinine clearance greater than 50/ml per minute (serum creatinine value must be within 28 days prior to registration)\n* Bilirubin \\< 2 times the upper limit of normal\n* Aspartate aminotransferase (AST) and alanine transaminase (ALT) \\< 2 times the upper limit of normal\n* Eastern Cooperative Oncology Group (ECOG) =\\< 2 or Karnofsky \\>= 70\n* Patients must have an expected survival of \\> 60 days and must be free of active infection\n* Patients must have an human leukocyte antigen (HLA)-identical sibling donor or an HLA-matched unrelated donor who meets standard Seattle Cancer Care Alliance (SCCA) and/or National Marrow Donor Program (NMDP) or other donor center criteria for PBSC or bone marrow donation, as follows:\n\n  * Related donor: related to the patient and genotypically or phenotypically identical for HLA-A, B, C, DRB1 and DQB1; phenotypic identity must be confirmed by high-resolution typing\n  * Unrelated donor:\n\n    * Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR mismatched for a single allele without antigen mismatching at HLA-A, B or C as defined by high resolution typing but otherwise matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing\n    * Doors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment; this determination is based on the standard practice of the individual institution; the recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain panel reactive antibody (PRA) screens to class I and class II antigens for all patients before hematopoietic cell transplant (HCT); if the PRA shows \\> 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained; the donor should be excluded if any of the cytotoxic cross match assays are positive; for those patients with and HLA class I allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained regardless of the PRA results; a positive anti-donor cytotoxic crossmatch is an absolute donor exclusion\n    * Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch; i.e., the patient is A\\*0101 and the donor is A\\*0102, and this type of mismatch is not allowed\n* DONOR: Donors must meet HLA matching criteria and standard SCCA and/or National Marrow Donor Program (NMDP) or other donor center criteria for PBSC or bone marrow donation\n\nExclusion Criteria:\n\n* Circulating human anti-mouse antibody (HAMA)\n* Prior radiation to maximally tolerated levels to any critical normal organ, or \\> 20 Gy prior radiation to large areas of the bone marrow (e.g., external radiation therapy to whole pelvis)\n* Patients may not have symptomatic coronary artery disease and may not be on cardiac medications for anti-arrhythmic or inotropic effects\n* Left ventricular ejection fraction \\< 35%\n* Corrected diffusion lung capacity of carbon monoxide (DLCO) \\< 35% or receiving supplemental continuous oxygen\n* Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease\n* Patients who are known to be seropositive for human immunodeficiency virus (HIV)\n* Perceived inability to tolerate diagnostic or therapeutic procedures\n* Active central nervous system (CNS) leukemia at time of treatment\n* Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin positive \\[HCG+\\]) or breast feeding\n* Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant\n* Inability to understand or give an informed consent",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "overallOfficials": [
            {
              "name": "Brenda Sandmaier",
              "affiliation": "Fred Hutch/University of Washington Cancer Consortium",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Fred Hutch/University of Washington Cancer Consortium",
              "city": "Seattle",
              "state": "Washington",
              "zip": "98109",
              "country": "United States",
              "geoPoint": {
                "lat": 47.60621,
                "lon": -122.33207
              }
            }
          ]
        },
        "referencesModule": {
          "references": [
            {
              "pmid": "31582553",
              "type": "DERIVED",
              "citation": "Vo P, Gooley TA, Rajendran JG, Fisher DR, Orozco JJ, Green DJ, Gopal AK, Haaf R, Nartea M, Storb R, Appelbaum FR, Press OW, Pagel JM, Sandmaier BM. Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia. Haematologica. 2020 Jun;105(6):1731-1737. doi: 10.3324/haematol.2019.229492. Epub 2019 Oct 3."
            }
          ]
        }
      },
      "resultsSection": {
        "participantFlowModule": {
          "recruitmentDetails": "This protocol is open to participants age 18 and above, of either gender and any race/ethnicity. The study is looking at the use of Y-90-DOTA-BC8 in conjunction with a standard reduced-intensity transplant regimen.",
          "groups": [
            {
              "id": "FG000",
              "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
              "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)"
            }
          ],
          "periods": [
            {
              "title": "Overall Study",
              "milestones": [
                {
                  "type": "STARTED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "16"
                    }
                  ]
                },
                {
                  "type": "COMPLETED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "15"
                    }
                  ]
                },
                {
                  "type": "NOT COMPLETED",
                  "achievements": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "1"
                    }
                  ]
                }
              ],
              "dropWithdraws": [
                {
                  "type": "HAMA + post dosimetry",
                  "reasons": [
                    {
                      "groupId": "FG000",
                      "numSubjects": "1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        "baselineCharacteristicsModule": {
          "groups": [
            {
              "id": "BG000",
              "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
              "description": "Study participants will receive an infusion of 0.5 mg/kg of ideal body weight of DOTA-BC8 trace labeled with \\~5-10 mCi of Indium-111 to evaluate biodistribution and calculate the radiation absorbed doses to major organs and the whole body. The subsequent therapy infusion of Yttrium-90-DOTA-BC8 will deliver an amount of Yttrium-90 calculated not to exceed the target dose to the critical normal organ receiving the highest radiation dose. The therapy dose will be administered on approximately day -12 of the preparative regimen, which will typically be approximately 1 to 2 weeks after the biodistribution dose."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "BG000",
                  "value": "16"
                }
              ]
            }
          ],
          "measures": [
            {
              "title": "Age, Categorical",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "categories": [
                    {
                      "title": "<=18 years",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Between 18 and 65 years",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "8"
                        }
                      ]
                    },
                    {
                      "title": ">=65 years",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "8"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Sex: Female, Male",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "categories": [
                    {
                      "title": "Female",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "8"
                        }
                      ]
                    },
                    {
                      "title": "Male",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "8"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ethnicity (NIH/OMB)",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "categories": [
                    {
                      "title": "Hispanic or Latino",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Not Hispanic or Latino",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "16"
                        }
                      ]
                    },
                    {
                      "title": "Unknown or Not Reported",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "title": "Race (NIH/OMB)",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "classes": [
                {
                  "categories": [
                    {
                      "title": "American Indian or Alaska Native",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Asian",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Native Hawaiian or Other Pacific Islander",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Black or African American",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "White",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "16"
                        }
                      ]
                    },
                    {
                      "title": "More than one race",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        }
                      ]
                    },
                    {
                      "title": "Unknown or Not Reported",
                      "measurements": [
                        {
                          "groupId": "BG000",
                          "value": "0"
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        "outcomeMeasuresModule": {
          "outcomeMeasures": [
            {
              "type": "PRIMARY",
              "title": "The MTD of Radiation Delivered Via 90Y-DOTA-BC8 When Combined With FLU and 2 Gy TBI as a Preparative Regimen for Patients Aged ≥ 18 With Advanced AML, ALL, and High-risk MDS.",
              "description": "The MTD will be defined as the dose that is associated with a true DLT rate of 25%. The highest dose achieved was 28 Gy but none of the patients experienced a DLT. Thus, the MTD was not reached.",
              "populationDescription": "Study participants who completed the study regimen.",
              "reportingStatus": "POSTED",
              "paramType": "NUMBER",
              "unitOfMeasure": "Gy",
              "timeFrame": "Within the first 30 days following transplant",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
                  "description": "Study participants will receive an infusion of 0.5 mg/kg of ideal body weight of DOTA-BC8 trace labeled with \\~5-10 mCi of Indium-111 to evaluate biodistribution and calculate the radiation absorbed doses to major organs and the whole body. The subsequent therapy infusion of Yttrium-90-DOTA-BC8 will deliver an amount of Yttrium-90 calculated not to exceed the target dose to the critical normal organ receiving the highest radiation dose. The therapy dose will be administered on approximately day -12 of the preparative regimen, which will typically be approximately 1 to 2 weeks after the biodistribution dose."
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "15"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "28"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Achievement of Remission",
              "description": "Number of participants who are in complete remission (CR) 4 weeks after transplant. CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:\n\n1. Normal bone marrow with blasts \\<5% with normal cellularity, normal megakaryopoiesis, \\> 15% erythropoiesis and \\> 25% granulocytopoiesis\n2. Normalization of blood counts (no blasts, platelets \\> 100000/mm3, granulocytes \\>1500/mm3)\n3. No extramedullary disease.",
              "populationDescription": "Study participants who completed the study regimen",
              "reportingStatus": "POSTED",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "timeFrame": "4 weeks after transplant",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
                  "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)"
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "15"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "13"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Disease-free Survival",
              "description": "Number of study participants who are alive and remains in complete remission after transplant.",
              "populationDescription": "Study participants who completed study regimen and in CR after transplant.",
              "reportingStatus": "POSTED",
              "paramType": "NUMBER",
              "unitOfMeasure": "participants",
              "timeFrame": "100 days after transplant",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
                  "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)"
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "15"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "7"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Duration of Remission",
              "description": "Median time to relapse after achieving complete remission (CR). CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:\n\n1. Normal bone marrow with blasts \\<5% with normal cellularity, normal megakaryopoiesis, \\> 15% erythropoiesis and \\> 25% granulocytopoiesis\n2. Normalization of blood counts (no blasts, platelets \\> 100000/mm3, granulocytes \\>1500/mm3)\n3. No extramedullary disease.\n\nRelapse Criteria:\n\n1. After CR: \\>5% blasts in the bone marrow and/or peripheral blood\n2. After partial remission (PR): increase of blasts cells in the marrow to \\>50% of those during PR\n3. Extramedullary disease confirmed cytologically or histologically.",
              "populationDescription": "Study participants who relapsed after achieving complete remission after transplant.",
              "reportingStatus": "POSTED",
              "paramType": "MEDIAN",
              "dispersionType": "Full Range",
              "unitOfMeasure": "days",
              "timeFrame": "1 year",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
                  "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)"
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "13"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "213",
                          "lowerLimit": "69",
                          "upperLimit": "351"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Estimation of Absorbed Radiation Doses to Normal Organs, Marrow and Tumor",
              "description": "The amount of energy absorbed per unit weight of the organ or tissue is called absorbed dose and is expressed in units of gray (Gy). One gray dose is equivalent to one joule radiation energy absorbed per kilogram of organ or tissue weight.",
              "populationDescription": "All study participants who completed the study regimen.",
              "reportingStatus": "POSTED",
              "paramType": "MEAN",
              "dispersionType": "Standard Deviation",
              "unitOfMeasure": "Gy",
              "timeFrame": "Approximately day -20 to day -12 prior to transplant",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
                  "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)"
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "15"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "title": "Average absorbed dose to the marrow",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "11.4",
                          "spread": "9.2"
                        }
                      ]
                    }
                  ]
                },
                {
                  "title": "Average absorbed dose to the liver",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "17.2",
                          "spread": "6.8"
                        }
                      ]
                    }
                  ]
                },
                {
                  "title": "Average abosorbed dose total body",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "3.1",
                          "spread": "5.7"
                        }
                      ]
                    }
                  ]
                },
                {
                  "title": "Average absorbed dose to the spleen",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "70",
                          "spread": "43"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Overall Survival",
              "description": "Number of participants who are still alive after transplant with or without disease.",
              "reportingStatus": "POSTED",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "timeFrame": "Up to 5 years",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
                  "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)"
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "15"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "7"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Rates of Acute GvHD",
              "description": "Number of participants who developed acute GVHD post-transplant, aGVHD stages:\n\nSkin: a maculopapular eruption involving \\< 25% BSA a maculopapular eruption involving 25 - 50% BSA generalized erythroderma generalized erythroderma with bullous formation and often with desquamation\n\nLiver:\n\nbilirubin 2.0 - 3.0 mg/100 mL bilirubin 3 - 5.9 mg/100 mL bilirubin 6 - 14.9 mg/100 mL bilirubin \\> 15 mg/100 mL\n\nGut:\n\nDiarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall.\n\naGVHD Grades Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death",
              "populationDescription": "Overall number of participants analyzed is 14 because one patient died prior to d+84 after transplant.",
              "reportingStatus": "POSTED",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "timeFrame": "Up to 84 days post-transplant",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
                  "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)"
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "14"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "title": "Grade 0 acute GVHD",
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "4"
                        }
                      ]
                    },
                    {
                      "title": "Grade I acute GVHD",
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "1"
                        }
                      ]
                    },
                    {
                      "title": "Grade II acute GVHD",
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "6"
                        }
                      ]
                    },
                    {
                      "title": "Grade III acute GVHD",
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "2"
                        }
                      ]
                    },
                    {
                      "title": "Grade IV acute GVHD",
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "1"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Rates of Donor Chimerism",
              "description": "Number of participants who has 100% donor chimerism within 100 days after transplant",
              "populationDescription": "Overall number of participants analyzed is 14 because one patient died prior to d+84 after transplant.",
              "reportingStatus": "POSTED",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "timeFrame": "Up to 100 days post-transplant",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
                  "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)"
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "14"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "14"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Rates of Engraftment",
              "description": "Average number of days to ANC \\>= 500 after transplant",
              "populationDescription": "Study participants with an ANC \\<= to 500 after transplant",
              "reportingStatus": "POSTED",
              "paramType": "MEAN",
              "dispersionType": "Standard Deviation",
              "unitOfMeasure": "days",
              "timeFrame": "Up to 84 days post-transplant",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
                  "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)"
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "14"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "16",
                          "spread": "6.0"
                        }
                      ]
                    }
                  ]
                }
              ]
            },
            {
              "type": "SECONDARY",
              "title": "Rates of Non-relapse Mortality",
              "description": "Transplant-related deaths within 100 days after transplant",
              "reportingStatus": "POSTED",
              "paramType": "COUNT_OF_PARTICIPANTS",
              "unitOfMeasure": "Participants",
              "timeFrame": "Within the first 100 days following transplant",
              "groups": [
                {
                  "id": "OG000",
                  "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
                  "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)"
                }
              ],
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "15"
                    }
                  ]
                }
              ],
              "classes": [
                {
                  "title": "Severe refractory GVHD",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "1"
                        }
                      ]
                    }
                  ]
                },
                {
                  "title": "Bacterial infection",
                  "categories": [
                    {
                      "measurements": [
                        {
                          "groupId": "OG000",
                          "value": "1"
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          ]
        },
        "adverseEventsModule": {
          "frequencyThreshold": "5",
          "timeFrame": "Adverse events (AEs) will be monitored and recorded in study-specific case report forms (CRFs) from the time of first exposure to an investigational agent (i.e., the start of the Indium-111-DOTA-BC8 infusion) through day +100 after transplant or through discharge prior to that date from the SCCA system to the care of the patient's primary physician.",
          "description": "Non-hematologic adverse events of ≥ grade 3, possibly related events of grade 2 that have not previously been observed with components of the study regimen, and all serious adverse events will be captured in protocol-specific case report forms. Beyond day +100, disease progression, development of secondary malignancies, and survival only will be collected.",
          "eventGroups": [
            {
              "id": "EG000",
              "title": "Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)",
              "description": "PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0. TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.",
              "deathsNumAffected": 5,
              "deathsNumAtRisk": 15,
              "seriousNumAffected": 9,
              "seriousNumAtRisk": 15,
              "otherNumAffected": 11,
              "otherNumAtRisk": 15
            }
          ],
          "seriousEvents": [
            {
              "term": "Febrile neutropenia",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 7,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Vomiting",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Creatinine increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Anorexia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Atrial fibrillation",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Oral pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Abdominal pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Fever",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Skin infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "notes": "Cellulitis",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hypokalemia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Bone pain",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Headache",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hypoxia",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Rash maculo-papular",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hematoma",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hypertension",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            }
          ],
          "otherEvents": [
            {
              "term": "Febrile neutropenia",
              "organSystem": "Blood and lymphatic system disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Chest pain - cardiac",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Heart failure",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Pericarditis",
              "organSystem": "Cardiac disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Abdominal pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 3,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Constipation",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 3,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Diarrhea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 6,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Dry mouth",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Dyspepsia",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Mucositis, oral",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Nausea",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 9,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Stomach pain",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Vomiting",
              "organSystem": "Gastrointestinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 5,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Chills",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Edema limbs",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Edema trunk",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Fatigue",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 6,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Fever",
              "organSystem": "General disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Allergic reaction",
              "organSystem": "Immune system disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 6,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Coag negative staph infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "CMV reactivation",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Lung infection",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Sepsis",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Sinusitis",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Upper respiratory infection - Rhinovirus",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Upper respiratory infection - Rhinorrea",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Upper respiratory infection - Metapneumovirus",
              "organSystem": "Infections and infestations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Blood bilirubin increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 3,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Creatinine increased",
              "organSystem": "Investigations",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Anorexia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hyperglycemia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hypokalemia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hypomagnesemia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hyponatremia",
              "organSystem": "Metabolism and nutrition disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Arthralgia",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Back pain",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Muscle weakness, lower limb",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Muscle weakness, trunk",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Myalgia",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 5,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Neck pain",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Pain in extremity",
              "organSystem": "Musculoskeletal and connective tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Dizziness",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Dysgeusia",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Headache",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 4,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Peripheral sensory neuropathy",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Tremor",
              "organSystem": "Nervous system disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Depression",
              "organSystem": "Psychiatric disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hallucinations",
              "organSystem": "Psychiatric disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Insomnia",
              "organSystem": "Psychiatric disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hematuria",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Urinary frequency",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Urinary tract pain",
              "organSystem": "Renal and urinary disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Cough",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 3,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Epistaxis",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hypoxia",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Postnasal drip",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Sinus disorder",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Sore throat",
              "organSystem": "Respiratory, thoracic and mediastinal disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Pruritis",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Rash acneiform",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Rash maculo-papular",
              "organSystem": "Skin and subcutaneous tissue disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 6,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hematoma",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 1,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hypertension",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            },
            {
              "term": "Hypotension",
              "organSystem": "Vascular disorders",
              "sourceVocabulary": "CTCAE) Version 4.0",
              "assessmentType": "SYSTEMATIC_ASSESSMENT",
              "stats": [
                {
                  "groupId": "EG000",
                  "numAffected": 2,
                  "numAtRisk": 15
                }
              ]
            }
          ]
        },
        "moreInfoModule": {
          "limitationsAndCaveats": {
            "description": "The highest dose achieved was 28 Gy but none of the patients experienced a DLT. Thus, the MTD was not reached."
          },
          "certainAgreement": {
            "piSponsorEmployee": true
          },
          "pointOfContact": {
            "title": "Brenda Sandmaier, MD",
            "organization": "Fred Hutchinson Cancer Research Center",
            "email": "bsandmai@fredhtuch.org",
            "phone": "(206) 667-4961"
          }
        }
      },
      "documentSection": {
        "largeDocumentModule": {
          "largeDocs": [
            {
              "typeAbbrev": "Prot_SAP",
              "hasProtocol": true,
              "hasSap": true,
              "hasIcf": false,
              "label": "Study Protocol and Statistical Analysis Plan",
              "date": "2016-07-08",
              "uploadDate": "2018-10-12T03:42",
              "filename": "Prot_SAP_000.pdf",
              "size": 1590628
            }
          ]
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000007938",
              "term": "Leukemia"
            },
            {
              "id": "D000007951",
              "term": "Leukemia, Myeloid"
            },
            {
              "id": "D000015470",
              "term": "Leukemia, Myeloid, Acute"
            },
            {
              "id": "D000011289",
              "term": "Preleukemia"
            },
            {
              "id": "D000054198",
              "term": "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            },
            {
              "id": "D000007945",
              "term": "Leukemia, Lymphoid"
            },
            {
              "id": "D000015477",
              "term": "Leukemia, Myelomonocytic, Chronic"
            },
            {
              "id": "D000054429",
              "term": "Leukemia, Myelomonocytic, Juvenile"
            },
            {
              "id": "D000009190",
              "term": "Myelodysplastic Syndromes"
            },
            {
              "id": "D000000753",
              "term": "Anemia, Refractory"
            },
            {
              "id": "D000000754",
              "term": "Anemia, Refractory, with Excess of Blasts"
            },
            {
              "id": "D000012008",
              "term": "Recurrence"
            }
          ],
          "ancestors": [
            {
              "id": "D000010335",
              "term": "Pathologic Processes"
            },
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000020969",
              "term": "Disease Attributes"
            },
            {
              "id": "D000001855",
              "term": "Bone Marrow Diseases"
            },
            {
              "id": "D000006402",
              "term": "Hematologic Diseases"
            },
            {
              "id": "D000011230",
              "term": "Precancerous Conditions"
            },
            {
              "id": "D000008232",
              "term": "Lymphoproliferative Disorders"
            },
            {
              "id": "D000008206",
              "term": "Lymphatic Diseases"
            },
            {
              "id": "D000007160",
              "term": "Immunoproliferative Disorders"
            },
            {
              "id": "D000007154",
              "term": "Immune System Diseases"
            },
            {
              "id": "D000054437",
              "term": "Myelodysplastic-Myeloproliferative Diseases"
            },
            {
              "id": "D000002908",
              "term": "Chronic Disease"
            },
            {
              "id": "D000000740",
              "term": "Anemia"
            }
          ],
          "browseLeaves": [
            {
              "id": "M3760",
              "name": "Anemia",
              "relevance": "LOW"
            },
            {
              "id": "M16045",
              "name": "Syndrome",
              "relevance": "LOW"
            },
            {
              "id": "M17817",
              "name": "Leukemia, Myeloid, Acute",
              "asFound": "Acute Myeloid Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "M10635",
              "name": "Leukemia",
              "asFound": "Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "M10641",
              "name": "Leukemia, Lymphoid",
              "asFound": "Lymphoblastic Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "M14540",
              "name": "Recurrence",
              "asFound": "Recurrent",
              "relevance": "HIGH"
            },
            {
              "id": "M10645",
              "name": "Leukemia, Myeloid",
              "asFound": "Myeloid Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "M27275",
              "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
              "asFound": "Acute Lymphoblastic Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "M11997",
              "name": "Neoplasm Metastasis",
              "relevance": "LOW"
            },
            {
              "id": "M3773",
              "name": "Anemia, Refractory",
              "asFound": "Refractory anemia",
              "relevance": "HIGH"
            },
            {
              "id": "M11835",
              "name": "Myelodysplastic Syndromes",
              "asFound": "Myelodysplastic Syndrome",
              "relevance": "HIGH"
            },
            {
              "id": "M13854",
              "name": "Preleukemia",
              "asFound": "Myelodysplastic Syndrome",
              "relevance": "HIGH"
            },
            {
              "id": "M17822",
              "name": "Leukemia, Myelomonocytic, Chronic",
              "asFound": "Chronic Myelomonocytic Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "M27396",
              "name": "Leukemia, Myelomonocytic, Juvenile",
              "asFound": "Chronic Myelomonocytic Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "M3774",
              "name": "Anemia, Refractory, with Excess of Blasts",
              "asFound": "Refractory anemia with excess blasts",
              "relevance": "HIGH"
            },
            {
              "id": "M10910",
              "name": "Lymphoma",
              "relevance": "LOW"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M22390",
              "name": "Disease Attributes",
              "relevance": "LOW"
            },
            {
              "id": "M4824",
              "name": "Bone Marrow Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M9180",
              "name": "Hematologic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M13801",
              "name": "Precancerous Conditions",
              "relevance": "LOW"
            },
            {
              "id": "M10915",
              "name": "Lymphoproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M10893",
              "name": "Lymphatic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M9896",
              "name": "Immunoproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M9890",
              "name": "Immune System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M11839",
              "name": "Myeloproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M27397",
              "name": "Myelodysplastic-Myeloproliferative Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M5837",
              "name": "Chronic Disease",
              "relevance": "LOW"
            },
            {
              "id": "T3995",
              "name": "Myeloid Leukemia",
              "asFound": "Myeloid Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "T182",
              "name": "Acute Myeloid Leukemia",
              "asFound": "Acute Myeloid Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "T175",
              "name": "Acute Lymphoblastic Leukemia",
              "asFound": "Acute Lymphoblastic Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "T3533",
              "name": "Lymphoblastic Lymphoma",
              "asFound": "Acute Lymphoblastic Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "T1303",
              "name": "Chronic Graft Versus Host Disease",
              "relevance": "LOW"
            },
            {
              "id": "T3993",
              "name": "Myelodysplastic Syndromes",
              "asFound": "Myelodysplastic Syndrome",
              "relevance": "HIGH"
            },
            {
              "id": "T188",
              "name": "Acute Non Lymphoblastic Leukemia",
              "asFound": "Acute Myeloid Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "T170",
              "name": "Acute Graft Versus Host Disease",
              "relevance": "LOW"
            },
            {
              "id": "T1310",
              "name": "Chronic Myelomonocytic Leukemia",
              "asFound": "Chronic Myelomonocytic Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "T3174",
              "name": "Juvenile Myelomonocytic Leukemia",
              "asFound": "Chronic Myelomonocytic Leukemia",
              "relevance": "HIGH"
            },
            {
              "id": "T3991",
              "name": "Myelodysplastic Syndrome With Excess Blasts",
              "asFound": "Refractory anemia with excess blasts",
              "relevance": "HIGH"
            },
            {
              "id": "T3543",
              "name": "Lymphosarcoma",
              "relevance": "LOW"
            },
            {
              "id": "T1311",
              "name": "Chronic Myeloproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "T3994",
              "name": "Myelodysplastic/myeloproliferative Disease",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC15",
              "name": "Blood and Lymph Conditions"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "BC23",
              "name": "Symptoms and General Pathology"
            },
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC20",
              "name": "Immune System Diseases"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        },
        "interventionBrowseModule": {
          "meshes": [
            {
              "id": "D000016572",
              "term": "Cyclosporine"
            },
            {
              "id": "D000009173",
              "term": "Mycophenolic Acid"
            },
            {
              "id": "D000074322",
              "term": "Antineoplastic Agents, Immunological"
            },
            {
              "id": "C000024352",
              "term": "Fludarabine"
            },
            {
              "id": "C000042382",
              "term": "Fludarabine phosphate"
            },
            {
              "id": "D000000906",
              "term": "Antibodies"
            },
            {
              "id": "D000007136",
              "term": "Immunoglobulins"
            },
            {
              "id": "D000000911",
              "term": "Antibodies, Monoclonal"
            },
            {
              "id": "D000003524",
              "term": "Cyclosporins"
            }
          ],
          "ancestors": [
            {
              "id": "D000007155",
              "term": "Immunologic Factors"
            },
            {
              "id": "D000045505",
              "term": "Physiological Effects of Drugs"
            },
            {
              "id": "D000000970",
              "term": "Antineoplastic Agents"
            },
            {
              "id": "D000000964",
              "term": "Antimetabolites, Antineoplastic"
            },
            {
              "id": "D000000963",
              "term": "Antimetabolites"
            },
            {
              "id": "D000045504",
              "term": "Molecular Mechanisms of Pharmacological Action"
            },
            {
              "id": "D000007166",
              "term": "Immunosuppressive Agents"
            },
            {
              "id": "D000004791",
              "term": "Enzyme Inhibitors"
            },
            {
              "id": "D000000935",
              "term": "Antifungal Agents"
            },
            {
              "id": "D000000890",
              "term": "Anti-Infective Agents"
            },
            {
              "id": "D000003879",
              "term": "Dermatologic Agents"
            },
            {
              "id": "D000018501",
              "term": "Antirheumatic Agents"
            },
            {
              "id": "D000065095",
              "term": "Calcineurin Inhibitors"
            },
            {
              "id": "D000000903",
              "term": "Antibiotics, Antineoplastic"
            },
            {
              "id": "D000000904",
              "term": "Antibiotics, Antitubercular"
            },
            {
              "id": "D000000995",
              "term": "Antitubercular Agents"
            },
            {
              "id": "D000000900",
              "term": "Anti-Bacterial Agents"
            }
          ],
          "browseLeaves": [
            {
              "id": "M3915",
              "name": "Antibodies",
              "asFound": "Use",
              "relevance": "HIGH"
            },
            {
              "id": "M9874",
              "name": "Immunoglobulins",
              "asFound": "Use",
              "relevance": "HIGH"
            },
            {
              "id": "M3920",
              "name": "Antibodies, Monoclonal",
              "asFound": "Risk",
              "relevance": "HIGH"
            },
            {
              "id": "M283197",
              "name": "Fludarabine",
              "asFound": "Surgical",
              "relevance": "HIGH"
            },
            {
              "id": "M225453",
              "name": "Fludarabine phosphate",
              "asFound": "Grams",
              "relevance": "HIGH"
            },
            {
              "id": "M11818",
              "name": "Mycophenolic Acid",
              "asFound": "People",
              "relevance": "HIGH"
            },
            {
              "id": "M18651",
              "name": "Cyclosporine",
              "asFound": "Refractory",
              "relevance": "HIGH"
            },
            {
              "id": "M6420",
              "name": "Cyclosporins",
              "asFound": "Refractory",
              "relevance": "HIGH"
            },
            {
              "id": "M1346",
              "name": "Antineoplastic Agents, Immunological",
              "asFound": "Risk",
              "relevance": "HIGH"
            },
            {
              "id": "M18807",
              "name": "Immunoglobulins, Intravenous",
              "relevance": "LOW"
            },
            {
              "id": "M9891",
              "name": "Immunologic Factors",
              "relevance": "LOW"
            },
            {
              "id": "M3971",
              "name": "Antimetabolites",
              "relevance": "LOW"
            },
            {
              "id": "M9902",
              "name": "Immunosuppressive Agents",
              "relevance": "LOW"
            },
            {
              "id": "M7641",
              "name": "Enzyme Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M3944",
              "name": "Antifungal Agents",
              "relevance": "LOW"
            },
            {
              "id": "M5942",
              "name": "Clotrimazole",
              "relevance": "LOW"
            },
            {
              "id": "M11486",
              "name": "Miconazole",
              "relevance": "LOW"
            },
            {
              "id": "M3904",
              "name": "Anti-Infective Agents",
              "relevance": "LOW"
            },
            {
              "id": "M6764",
              "name": "Dermatologic Agents",
              "relevance": "LOW"
            },
            {
              "id": "M20294",
              "name": "Antirheumatic Agents",
              "relevance": "LOW"
            },
            {
              "id": "M30142",
              "name": "Calcineurin Inhibitors",
              "relevance": "LOW"
            },
            {
              "id": "M3912",
              "name": "Anti-Bacterial Agents",
              "relevance": "LOW"
            },
            {
              "id": "M3914",
              "name": "Antibiotics, Antitubercular",
              "relevance": "LOW"
            },
            {
              "id": "M4001",
              "name": "Antitubercular Agents",
              "relevance": "LOW"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "All",
              "name": "All Drugs and Chemicals"
            },
            {
              "abbrev": "ANeo",
              "name": "Antineoplastic Agents"
            },
            {
              "abbrev": "Infe",
              "name": "Anti-Infective Agents"
            },
            {
              "abbrev": "ARhu",
              "name": "Antirheumatic Agents"
            },
            {
              "abbrev": "Derm",
              "name": "Dermatologic Agents"
            }
          ]
        }
      },
      "hasResults": true
    },
    {
      "protocolSection": {
        "identificationModule": {
          "nctId": "NCT04684472",
          "orgStudyIdInfo": {
            "id": "MCART-003"
          },
          "organization": {
            "fullName": "Sichuan University",
            "class": "OTHER"
          },
          "briefTitle": "Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies",
          "officialTitle": "Phase I, Open Label, Study of CXCR4 Modified CD19 CAR-T Therapy in Patients With Relapsed or Refractory CD19+ B-cell Malignancies"
        },
        "statusModule": {
          "statusVerifiedDate": "2022-09",
          "overallStatus": "RECRUITING",
          "expandedAccessInfo": {
            "hasExpandedAccess": false
          },
          "startDateStruct": {
            "date": "2021-03-17",
            "type": "ACTUAL"
          },
          "primaryCompletionDateStruct": {
            "date": "2023-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2024-01-01",
            "type": "ESTIMATED"
          },
          "studyFirstSubmitDate": "2020-12-21",
          "studyFirstSubmitQcDate": "2020-12-21",
          "studyFirstPostDateStruct": {
            "date": "2020-12-24",
            "type": "ACTUAL"
          },
          "lastUpdateSubmitDate": "2022-09-22",
          "lastUpdatePostDateStruct": {
            "date": "2022-09-26",
            "type": "ACTUAL"
          }
        },
        "sponsorCollaboratorsModule": {
          "responsibleParty": {
            "type": "SPONSOR_INVESTIGATOR",
            "investigatorFullName": "Liqun Zou",
            "investigatorTitle": "Professor of Department of Medical Oncology",
            "investigatorAffiliation": "Sichuan University"
          },
          "leadSponsor": {
            "name": "Liqun Zou",
            "class": "OTHER"
          }
        },
        "oversightModule": {
          "isFdaRegulatedDrug": false,
          "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
          "briefSummary": "This study aims to evaluate the safety and tolerance of modified CD19 CAR T cells in treating refractory/relapsed B-cell malignancies. CAR-T cells will be investigated as a single agent both in relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) and up to 60% of patients with B-cell non-Hodgkin's lymphoma (NHL)."
        },
        "conditionsModule": {
          "conditions": [
            "Refractory B-Cell Non-Hodgkin Lymphoma",
            "Refractory Leukemia"
          ],
          "keywords": [
            "Modified CD19 CAR-T"
          ]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "phases": [
            "PHASE1"
          ],
          "designInfo": {
            "allocation": "NA",
            "interventionModel": "SINGLE_GROUP",
            "primaryPurpose": "TREATMENT",
            "maskingInfo": {
              "masking": "NONE"
            }
          },
          "enrollmentInfo": {
            "count": 18,
            "type": "ESTIMATED"
          }
        },
        "armsInterventionsModule": {
          "armGroups": [
            {
              "label": "Modified anti-CD19 CAR T cell therapy",
              "type": "EXPERIMENTAL",
              "description": "CAR T cell therapy",
              "interventionNames": [
                "Biological: Modified anti-CD19 CAR T cells"
              ]
            }
          ],
          "interventions": [
            {
              "type": "BIOLOGICAL",
              "name": "Modified anti-CD19 CAR T cells",
              "description": "intravenous infusion",
              "armGroupLabels": [
                "Modified anti-CD19 CAR T cell therapy"
              ]
            }
          ]
        },
        "outcomesModule": {
          "primaryOutcomes": [
            {
              "measure": "Incidence of treatment-emergent adverse events [Safety and Tolerability]",
              "description": "Adverse events assessed according to NCI-CTCAE v5.0 criteria",
              "timeFrame": "Up to 5 years after modified CD19 CAR-T cells infusion"
            },
            {
              "measure": "Dose-limiting toxicity (DLT)",
              "description": "Adverse events assessed according to NCI-CTCAE v5.0 criteria",
              "timeFrame": "Baseline up to 28 days after modified CD19 CAR-T cells infusion"
            }
          ],
          "secondaryOutcomes": [
            {
              "measure": "B-cell malignancies, Overall response rate(ORR)",
              "description": "Assessment of ORR(ORR=CR+PR)",
              "timeFrame": "3 months, 6 months"
            },
            {
              "measure": "B-cell malignancies, Overall survival",
              "description": "From the first infusion of modified CD19 CAR-T cells to death or the last visit",
              "timeFrame": "Up to 2 years after modified CD19 CAR-T cells infusion"
            },
            {
              "measure": "B-cell malignancies, progression-free survival（PFS）",
              "description": "From the first infusion of modified CD19 CAR-T cells to the occurrence of any event, including death, relapse, disease progression, and the last visit",
              "timeFrame": "Up to 2 years after modified CD19 CAR-T cells infusion"
            },
            {
              "measure": "B-cell malignancies, disease control rate (DCR)",
              "description": "Assessment of DCR(DCR=CR+PR+SD)",
              "timeFrame": "Month 6,12,18 and 24"
            }
          ]
        },
        "eligibilityModule": {
          "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female aged 18-70 years;\n2. Estimated survival time ≥ 12 weeks;\n3. Histologically confirmed diagnosis of CD19+ B-ALL or CD19+ B-NHL(meeting one of the following conditions):\n\n   1. Ineffectively or relapses after 2 or more remedial treatments\n   2. Relapse after auto-HSCT or unsuitable for auto-HSCT;\n4. At least one assessable tumor lesion;\n5. ECOG performance status 0 to 2;\n6. Creatinine clearance rate≥ 60 ml/min, ALT and AST ≤ 2.5 times of upper limit of normal, total bilirubin ≤ 1.5 times of upper limit of normal;\n7. Male and female of reproductive potential must agree to use birth control during the study and for at least 30 days post study;\n8. Patients or their legal guardians volunteer to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Patients with other uncontrolled malignancies;\n2. Previously treated with any CAR-T cell product or other genetically-modified T cell therapy;\n3. Patients with HIV infection, hepatitis B (HBsAg positive) or hepatitis C（anti-HCV positive);\n4. Patients with central nervous system involvement by lymphoma ,malignant cells in cerebrospinal fluid or history of brain metastasis;\n5. Patients with atrial or ventricular involvement by B-cell malignancies;\n6. Patients with tumor mass require urgent treatment, such as ileus or vascular compression;\n7. Patients with severe disease or other uncontrolled diseases that were not suitable for this trial, such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage, grade 2-3 hypertension;\n8. Unstable pulmonary embolism, deep venous embolism, or other major arterial/venous thromboembolism events occurred within 30 days prior to randomization. If patients receive anticoagulant therapy, the treatment dose must be stable prior to randomization;\n9. Any situations that the investigators believes were not suitable for this trial;\n10. Long-term use of immunosuppressive agents after organ transplantation, except for the patients recently or currently receiving inhaled steroids;\n11. Pregnant(or lactation) women;\n12. Patients with severe active infections(excluding simple urinary tract infection and bacterial pharyngitis)within 30 days prior to randomization",
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years",
          "stdAges": [
            "ADULT",
            "OLDER_ADULT"
          ]
        },
        "contactsLocationsModule": {
          "centralContacts": [
            {
              "name": "pei shu, MD",
              "role": "CONTACT",
              "phone": "+86(028)85423525",
              "email": "peishu1991@sina.com"
            },
            {
              "name": "fuchun guo, MD",
              "role": "CONTACT",
              "phone": "+86(028)85423525",
              "email": "FCguo0797@wchscu.cn"
            }
          ],
          "overallOfficials": [
            {
              "name": "liqun zou, phd",
              "affiliation": "Sichuan University",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "locations": [
            {
              "facility": "Sichuan University",
              "status": "RECRUITING",
              "city": "Chengdu",
              "state": "Sichuan",
              "country": "China",
              "contacts": [
                {
                  "name": "weiming li",
                  "role": "CONTACT"
                }
              ],
              "geoPoint": {
                "lat": 30.66667,
                "lon": 104.06667
              }
            }
          ]
        },
        "ipdSharingStatementModule": {
          "ipdSharing": "NO"
        }
      },
      "derivedSection": {
        "miscInfoModule": {
          "versionHolder": "2024-01-18",
          "modelPredictions": {
            "bmiLimits": {
              "minBmi": 0,
              "maxBmi": 101
            }
          }
        },
        "conditionBrowseModule": {
          "meshes": [
            {
              "id": "D000016393",
              "term": "Lymphoma, B-Cell"
            }
          ],
          "ancestors": [
            {
              "id": "D000009369",
              "term": "Neoplasms"
            },
            {
              "id": "D000008228",
              "term": "Lymphoma, Non-Hodgkin"
            },
            {
              "id": "D000008223",
              "term": "Lymphoma"
            },
            {
              "id": "D000009370",
              "term": "Neoplasms by Histologic Type"
            },
            {
              "id": "D000008232",
              "term": "Lymphoproliferative Disorders"
            },
            {
              "id": "D000008206",
              "term": "Lymphatic Diseases"
            },
            {
              "id": "D000007160",
              "term": "Immunoproliferative Disorders"
            },
            {
              "id": "D000007154",
              "term": "Immune System Diseases"
            }
          ],
          "browseLeaves": [
            {
              "id": "M10910",
              "name": "Lymphoma",
              "relevance": "LOW"
            },
            {
              "id": "M10635",
              "name": "Leukemia",
              "relevance": "LOW"
            },
            {
              "id": "M18518",
              "name": "Lymphoma, B-Cell",
              "asFound": "B-Cell Non-Hodgkin Lymphoma",
              "relevance": "HIGH"
            },
            {
              "id": "M10912",
              "name": "Lymphoma, Non-Hodgkin",
              "relevance": "LOW"
            },
            {
              "id": "M12005",
              "name": "Neoplasms by Histologic Type",
              "relevance": "LOW"
            },
            {
              "id": "M10915",
              "name": "Lymphoproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M10893",
              "name": "Lymphatic Diseases",
              "relevance": "LOW"
            },
            {
              "id": "M9896",
              "name": "Immunoproliferative Disorders",
              "relevance": "LOW"
            },
            {
              "id": "M9890",
              "name": "Immune System Diseases",
              "relevance": "LOW"
            },
            {
              "id": "T3543",
              "name": "Lymphosarcoma",
              "relevance": "LOW"
            },
            {
              "id": "T640",
              "name": "B-cell Lymphoma",
              "asFound": "B-Cell Non-Hodgkin Lymphoma",
              "relevance": "HIGH"
            }
          ],
          "browseBranches": [
            {
              "abbrev": "BC04",
              "name": "Neoplasms"
            },
            {
              "abbrev": "BC15",
              "name": "Blood and Lymph Conditions"
            },
            {
              "abbrev": "BC20",
              "name": "Immune System Diseases"
            },
            {
              "abbrev": "All",
              "name": "All Conditions"
            },
            {
              "abbrev": "Rare",
              "name": "Rare Diseases"
            }
          ]
        }
      },
      "hasResults": false
    }
  ],
  "nextPageToken": "NF0g5JuDkQ"
}